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Abstract 
 
The Role of the Human Placenta in Regulating Fetal Exposure to Maternal Hormones and 
Implications for Child Neurobehavioral Outcomes 
 
Morgan Reiss Firestein 
 
Prenatal exposure to sex hormones has profound effects on neurodevelopment with 
lifelong implications for mental health. Fetal exposure to aberrant levels of sex hormones alters 
sexual dimorphism (i.e. degree of feminization or masculinization; sex differences in brain and 
behavior) and may contribute to the differential susceptibility of males and females to psychiatric 
risk and neurodevelopmental disorders, including autism. During fetal development, the in-utero 
environment is regulated by the placenta, a maternal-fetal endocrine structure that serves as a 
“gate-keeper” between the maternal and fetal circulatory systems. The placenta expresses high 
levels of aromatase, an enzyme that converts testosterone to estrogen, and it has been proposed 
that placental aromatase precludes the transfer of maternal testosterone to the fetus. However, 
this view does not account for individual differences in placental aromatase expression or 
maternal hormone levels that may account for altered neurobehavioral outcomes. Retinoic acid-
related orphan receptor-alpha (RORA) has been identified as a transcription factor that regulates 
aromatase and as an autism candidate gene – yet the role of RORA in the placenta as a regulator 
of the prenatal hormonal environment has yet to be determined. The research presented in this 
thesis aimed to evaluate 1) the relationship between maternal and neonatal hormone 
concentrations, 2) whether placental aromatase/RORA influences the relationship between 
maternal and neonatal hormones concentrations, 3) the relationship between maternal sex 
hormones during pregnancy and neurobehavioral outcomes in the offspring, and 4) the 
relationship between placental aromatase/RORA and neurobehavioral outcomes in the offspring. 
Chapters 1 and 2 of this thesis provide a review of the literature pertaining to the sources of and 
neurodevelopmental consequences of fetal exposure to hormones and the methods used to 
address our research questions. Chapters 3, 4, and 5 of this thesis used in vivo and in vitro 
methods to investigate the role of placental aromatase and RORA in regulating fetal exposure to 
maternal hormones. Results from these studies indicate that maternal testosterone is a strong 
predictor of neonatal testosterone levels at birth and that aromatase and RORA expression in the 
human placenta subtly influence the relationship between maternal and neonatal testosterone and 
estradiol in a sex-dependent manner. Results from our studies using an in vitro approach call into 
question the widely proposed role of placental aromatase in converting maternal testosterone 
intro estradiol. Chapters 6 and 7 of this thesis aimed to determine whether variability in maternal 
testosterone and placental aromatase/RORA expression was associated with increased 
neurodevelopmental risk as a result of elevated fetal hormone exposure. For the first time in the 
literature, we report a direct association between elevated maternal testosterone and poorer 
childhood neurodevelopmental outcome in a sex-dependent manner. We also report that the 
effects of placental aromatase and RORA expression on childhood outcomes vary depending on 
the neurobehavioral domain being assessed. Taken together, these studies support the notion that 
fetal exposure to sex hormones, especially those of maternal origin, can affect neonatal hormone 
production as well as long-term child neurobehavior. The specific mechanisms by which the 
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Chapter 1: Introduction 
 
Prenatal exposure to sex hormones such as androgens and estrogens has profound effects 
on mammalian brain development and function with lifelong implications for social behavior. 
The etiology of many psychiatric conditions, including autism, are known to have a genetic 
component, however, risk for psychiatric outcomes cannot be entirely accounted for by genomic 
factors (Lichtenstein, Carlström, Råstam, Gillberg, & Anckarsäter, 2010). Given robust sex 
differences in the prevalence and presentation of many psychiatric conditions, studying how 
prenatal hormones influence the developing brain may offer insight into non-genomic etiological 
mechanisms. It is well established that sexual differentiation in the brain begins during the early 
prenatal period and is significantly influenced by fetal exposure to the primary sex hormones, 
androgens and estrogens. The effects of these hormones extend far beyond differences in 
physical development and contribute prenatal programming of variation in behavioral, social, 
and cognitive development. Fetal exposure to aberrantly high levels of sex hormones has the 
potential to alter sexual dimorphism and may contribute to the etiology of neurodevelopmental 
disorders, including autism. It has been suggested that the fetus is the primary contributor of in-
utero sex hormones given the assumption that the placenta acts as a fetal barrier against maternal 
hormones. However, the actual mechanism by which the placenta protects the fetus from 
maternal hormones and the implications of individual differences in the permeability of this 
barrier has not been empirically examined. In this chapter, I will review previous research that 
has explored the relationship between fetal hormone exposure and neurobehavioral outcomes 
and the potential mechanisms by which maternal hormones may affect neurobehavioral 
development in the offspring. In subsequent chapters, I will present original data that contributes 
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to our understanding of the complex regulatory functions of the human placenta in shaping fetal 
exposure to sex hormones and child neurobehavioral development.  
 
1.1 Current methods for measuring fetal exposure to sex hormones 
Several methods, ranging from minimally invasive to highly invasive, have been 
developed to measure the effects of fetal hormone exposure during the formative prenatal period. 
 
1.1.1 Amniocentesis 
In an effort to quantify fetal exposure to androgens during mid-gestation, samples of 
amniotic fluid can be retrieved through amniocentesis and analyzed for hormone levels. This is 
considered to be an indirect measure of circulating fetal testosterone because testosterone that is 
produced by the fetus initially enters the amniotic fluid by diffusing through the fetus’s skin and 
later through fetal urination (J. D. Robinson, Judd, Young, Jones, & Yen, 1977). Using this 
approach, several studies have found that amniotic fluid from male pregnancies is higher in 
testosterone compared to amniotic fluid from female pregnancies, whereas amniotic fluid from 
female pregnancies tends to be higher in estrogen (Judd, Robinson, Young, & Jones, 1976; 
Nagamani, McDonough, Ellegood, & Mahesh, 1979; J. D. Robinson et al., 1977; Rodeck, Gill, 
Rosenberg, & Collins, 1985). However, these reported sex differences in hormone 
concentrations are not robust enough to reliably predict fetal sex. The inability to predict fetal 
sex based on hormone concentrations may be due to the considerable overlap in average 
amniotic fluid hormone levels between the two sexes (Chapman et al., 2006; Dawood & Saxena, 
1977; J. A. Finegan, Bartleman, & Wong, 1989a; Judd et al., 1976; Rodeck et al., 1985; van de 
Beek, Thijssen, Cohen-Kettenis, van Goozen, & Buitelaar, 2004a). Additionally, direct 
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measurements of hormone concentrations in fetal blood across the prenatal period reveal that the 
observed sex difference may be specific to certain gestational time points (J. A. Finegan et al., 
1989a; Martin, 1985; Rebecca Troisi, Potischman, Roberts, Siiteri, et al., 2003).  In a cross-
sectional study, testosterone levels in cord blood of aborted fetuses between 12-22 weeks’ 
gestation differed between males and females, whereas no sex differences were found in 
umbilical cord blood of full-term males and females (Abramovich & Rowe, 1973a).  
Perhaps one of the greatest limitations of amniocentesis is the reliance on a convenience 
sample of high-risk pregnancies. Amniocentesis is a highly invasive and an uncommon medical 
procedure that is exclusively conducted for pregnancies that are complicated by a known or 
suspected risk factor for maternal or neonatal morbidities. For example, advanced maternal age, 
which is itself associated with changes in maternal steroidogenesis, may warrant amniocentesis. 
Therefore, data collected via amniocentesis may not be an accurate reflection of typical 
development.  
 
1.1.2 Anogenital distance 
Measuring an individual’s anogenital distance (AGD) - the distance from the anus to the 
genital tubercle - provides an indirect physical marker of gonadal development as a result of 
testosterone activity (Thankamony, Pasterski, Ong, Acerini, & Hughes, 2015). AGD cannot be 
reliably predicted by umbilical cord blood testosterone, but it may be affected by the testosterone 
surge earlier in mid-gestation (Jain et al., 2018). Based on early fetal imaging, differences in 
AGD between male and female fetuses have been observed as early as 11-13 weeks gestational 
age (GA) and remain equally sexually dimorphic by birth (Salazar-Martinez, Romano-Riquer, 
Yanez-Marquez, Longnecker, & Hernandez-Avila, 2004; Sathyanarayana, Beard, Zhou, & 
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Grady, 2010; Thankamony, Ong, Dunger, Acerini, & Hughes, 2009). In addition to the effects of 
endogenous androgens, exposure to synthetic endocrine disruptors in phthalate-based products 
has been associated with decreased AGD (Bornehag et al., 2015; Schwartz et al., 2019; Swan et 
al., 2006). Longer AGD predicts more male-typical play behavior in 2-4 year old children (V. 
Pasterski et al., 2015). In a condition known as hypospadias, the opening of the urethra is 
positioned on the ventral side of the penis as a result of insufficient fusion of the urethral folds 
during early-to-mid gestation (Butwicka et al., 2015). In a large population study, male patients 
with hypospadias were significantly more likely to be diagnosed with autism spectrum disorder, 
ADHD, intellectual disability, and behavioral/emotional disorders (Butwicka et al., 2015), 
suggesting that sex hormones may play an underlying role in the etiology of both physical and 
psychiatric conditions. 
  
1.1.3 2D:4D digit ratio 
Another commonly used indirect marker of fetal androgen exposure is the 2D:4D ratio. 
This value represents the ratio of the second-to-fourth fingers and there is a large body of 
evidence to support the notion that the ratio is sexually differentiated in children and in adults 
(McIntyre, 2006). Though not confirmed, it has been speculated that this sex difference may 
arise from sex differences in androgen and estrogen levels during prenatal development as sex 
steroids influence growth plates through receptor binding (Abu, Horner, Kusec, Triffitt, & 
Compston, 1997). Lower 2D:4D digit ratios are considered to be more “male-typical” and are 
associated with higher systemizing - the desire and ability to understand or construct rule-based 
systems and patterns – and lower empathizing – the ability to understand the emotional state of 
others and to use this information to appropriately take the perspective of another individual 
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(Auyeung et al., 2006; Wakabayashi & Nakazawa, 2010). With regard to neurodevelopmental 
outcomes, children diagnosed with autism have lower 2D:4D digit ratios, which is consistent the 
finding that these children are exposed to higher levels of testosterone as measured by amniotic 
fluid (S. Lutchmaya, Baron-Cohen, Raggatt, Knickmeyer, & Manning, 2004; John T. Manning, 
Baron-Cohen, Wheelwright, & Fink, 2010). 
 
1.1.4 Studies in clinical settings 
Finally, studying special populations that are affected by health conditions that alter 
endocrine production, synthesis, and uptake provides an indirect method for assessing the effects 
of prenatal exposure to hormones. Conditions of this type include congenital adrenal hyperplasia 
(CAH), preeclampsia and pregnancy-related hypertension, and polycystic ovary syndrome 
(PCOS). 
 
1.1.4.1 Congenital adrenal hyperplasia  
Congenital adrenal hyperplasia (CAH) is an inherited, autosomal recessive condition that 
is most commonly due to a 21-hydroxylase deficiency and causes overstimulation of the adrenal 
glands (Manson, 2008). Due to the 21-hydroxylase defect, the body is unable to produce 
sufficient levels of cortisol. The adrenal glands respond to this insufficiency by over-stimulating 
the adrenal glands, which causes elevated levels of testosterone to be secreted (Melissa Hines, 
2010; Speiser, 2001). CAH typically arises during the prenatal period and most females with 
CAH are postnatally treated with medications to normalize their hormones, it is presumed that 
the behavioral effects are caused by prenatal testosterone exposure. However, treatments 
involving hormonal interventions may contribute to some of the observed differences in 
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postnatal neurobehavior. Generally, children with CAH have lower 2D:4D ratios that controls, 
which has been attributed to the high androgen excess experienced by children diagnosed with 
CAH (Brown, Hines, Fane, & Breedlove, 2002a). Several studies have found evidence that 
females with CAH engage in more male-typical play behavior including toy preference and 
aggression and show less interest in marriage and motherhood compared to women without CAH 
(Berenbaum, Duck, & Bryk, 2000; Dittmann, Kappes, & Kappes, 1992; Ehrhardt & Meyer-
Bahlburg, 1981; M. Hines et al., 2003; V. L. Pasterski et al., 2005; Puts, McDaniel, Jordan, & 
Breedlove, 2007). With regard to neurodevelopmental outcomes, females with CAH score higher 
on the social skills and imagination subscales of the Autism Spectrum Quotient, a self-
assessment designed to measure autism-related traits in individuals of normal intelligence (S. 
Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001; R. Knickmeyer et al., 2006). 
Therefore, the elevated androgenic activity associated with CAH may increase risk for autism, 
especially in females. In most reports, males with CAH do not seem to differ as dramatically 
from typical males, presumably because feedback mechanisms reduce testosterone production by 
the testes (Melissa Hines, 2010; Manson, 2008). Some data suggest that boys with CAH have 
lower (more masculinized) 2D:4D ratios, but engage in less rough and tumble play and perform 
more poorly on mental rotation tasks compared to boys without CAH (Brown, Hines, Fane, & 
Breedlove, 2002b; M. Hines et al., 2003; M. Hines & Kaufman, 1994). These contradictory 
effects observed in males could reflect specific timing effects of androgen exposure. A lower 
2D:4D ratio has been associated with high prenatal testosterone, pointing to the effects of 
androgen exposure during the prenatal period, though the postnatal effects of hormonal treatment 
for CAH, which reduces adrenal androgen production may have more profound consequences 




1.1.4.2 Polycystic ovary syndrome 
Polycystic ovary syndrome (PCOS) is an endocrine condition that affects approximately 
5-10% of women and is characterized by ovulatory dysfunction, polycystic ovaries, infertility, 
and notably, hyperandrogenism (Kosidou et al., 2015; Nisenblat & Norman, 2009; Palomba et 
al., 2012; Sir-Petermann et al., 2002, p.). Hyperandrogenism is one of the defining features of 
PCOS and therefore, it is a very useful model for studying the effects of fetal exposure to excess 
androgens. During pregnancy, circulating testosterone levels are higher and continue to rise 
throughout gestation among women with PCOS (Palomba et al., 2012; Sir-Petermann et al., 
2002, p.). Placental exposure to elevated androgens has been associated with increased 
expression of hypoxia and inflammatory markers, as well as expression of genes involved in 
growth regulation (Kelley et al., 2019). Therefore, high androgenic activity in utero has the 
potential to both directly and indirectly impact the developing fetal brain. 
 
1.1.4.3 Preeclampsia/pregnancy-related hypertension 
Preeclampsia is a pregnancy-related condition that is characterized by hypertension and 
proteinuria after the 20th week of pregnancy and is also associated with maternal 
hyperandrogenism (Acromite, Mantzoros, Leach, Hurwitz, & Dorey, 1999; Perez-Sepulveda et 
al., 2015a). In fact, women with PCOS are at increased risk for preeclampsia, potentially 
implicating testosterone as a causal risk factor (Kamalanathan, Sahoo, & Sathyapalan, 2013; S. 
Kumar, Gordon, Abbott, & Mishra, 2018). Preeclampsia is usually not diagnosed until the 2nd or 
3rd trimester, and due to research limitations, most studies of the hyperandrogenism in 
preeclampsia are conducted during the 3rd trimester near delivery. Several studies report that 
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women with preeclampsia have significantly higher maternal testosterone in the 3rd trimester 
(Acromite et al., 1999; S. Kumar et al., 2018; Salamalekis, Bakas, Vitoratos, Eleptheriadis, & 
Creatsas, 2006; R. Troisi, 2003). In normotensive pregnancies, maternal testosterone often does 
not differ by fetal sex. Mothers with preeclampsia have higher testosterone regardless of fetal 
sex, but preeclamptic mothers carrying a male fetus have higher testosterone compared to 
preeclamptic mothers carrying a female fetus ([normotensive females = normotensive males] < 
preeclamptic females < preeclamptic males) (Steier, Ulstein, & Myking, 2002). Contradicting 
data regarding maternal estradiol in preeclampsia have been reported, with some reports of 
elevated estradiol and others reporting up to a 50% reduction in estradiol compared to 
normotensive pregnancies (Hertig et al., 2010; Perez-Sepulveda et al., 2015a).  
With increasing prevalence in the United States, preeclampsia and pregnancy-related 
hypertension increase risk for maternal seizures, preterm delivery, and low birth weight, 
potentially due to suboptimal trophoblast invasion of the maternal decidua and dysfunction of the 
maternal spiral arteries (Ananth, Keyes, & Wapner, 2013; S. Kumar et al., 2018; Perez-
Sepulveda et al., 2015a).  
To date, much of what is known about the influence of androgens on the developing brain 
has been pieced together using evidence from all of these approaches. Depending on the 
specificity of timing, magnitude, and mechanism, certain methods may be more preferable than 
others. Knickmeyer & Baron-Cohen provide a comprehensive review of the pros and cons of 
each approach (R. C. Knickmeyer & Baron-Cohen, 2006). 
 
1.2 In-utero synthesis and action of sex steroid hormones  
1.2.1 Fetal steroidogenesis 
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Throughout the life span, sex steroids serve as lipophilic chemical messengers that 
readily enter the cytoplasm and are able to induce rapid genomic changes. Steroid hormones 
carry out particularly critical functions during pregnancy, promoting implantation of the embryo, 
sustaining continued embryonic and fetal growth, and driving the organization of numerous brain 
regions involved in homeostatic regulation, sexually differentiated behavior, and long-term 
neurobehavior. During pregnancy, steroid hormones are produced by the mother, the fetus, and 
the placenta, though steroid synthesis by each compartment is not necessarily independent of the 
other two.  
For the first five weeks of human gestation, fetal gonads are undifferentiated in 
appearance and function. However, by the 6th week of pregnancy, the presence of the testis-
determine factor (TDF) and the sex-determining region Y (SRY) gene, which is located 
exclusively on the Y-chromosome, prompts the development of testes in males. The formation of 
the testes continues into the 8th week of gestation as Leydig cells begin to develop and by the 12th 
week, these cells are stimulated by placental human chorionic gonadotropin (hCG) to release 
testosterone (Abramovich & Rowe, 1973a; Auyeung, Lombardo, & Baron-Cohen, 2013; 
Clements, Reyes, Winter, & Faiman, 1976; Reyes, Boroditsky, Winter, & Faiman, 1974; Reyes, 
Winter, & Faiman, 1973). This initial surge of testosterone marks the start of a 10-week period 
during which males produce significantly higher quantities of testosterone compared to females 
(Auyeung et al., 2013; J. A. Finegan et al., 1989a; Melissa Hines, 2010). By the third trimester, 
however, this divergence in testosterone production minimizes and levels are comparable 
between the sexes (McIntyre, 2006; van de Beek et al., 2004a).  
 
1.2.2 Maternal steroidogenesis 
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Over the course of pregnancy, a mild increase in maternal circulating testosterone has 
been previously reported (Kerlan, Nahoul, Martelot, & Bercovici, 1994). Some studies have 
found that mothers carrying a male fetus tend to have higher levels of plasma testosterone during 
pregnancy (Maccoby, Doering, Jacklin, & Kraemer, 1979; Meulenberg & Hofman, 1991), most 
researchers do not find an effect of fetal sex on maternal testosterone, especially during the 
second and third trimesters (Dawood & Saxena, 1977; Nabi, Aziz, Amin, & Khan, 2014; Rodeck 
et al., 1985). At birth, mothers who deliver a male infant have lower estriol levels (Rebecca 
Troisi, Potischman, Roberts, Siiteri, et al., 2003). Many research groups have found no 
correlation between maternal plasma testosterone levels and testosterone levels in amniotic fluid 
(Dawood & Saxena, 1977; Rodeck et al., 1985; R. Troisi, 2003). Maternal testosterone during 
pregnancy correlates with neonatal testosterone levels, though varying degrees of association 
have been found and differences may relate to the sex of the offspring (Gitau, Adams, Fisk, & 
Glover, 2005; J. A. Harris, Vernon, & Boomsma, 1998).  
 
1.2.3 Placental steroidogenesis 
1.2.3.1 Structure of the human placenta 
 The human placenta serves as the primary interface between mother and fetus throughout 
pregnancy and appropriate placental structure and function are critical for the health of the 
pregnancy (Figure 1.1). During the early phases of post-implantation cell division, the totipotent 
morula forms a blastocyst, which contains two primary layers; the trophoblast and the inner cell 
mass (ICM) (Figure 1.2) (Boss, Chamley, & James, 2018). Ultimately, the trophoblast cells will 
form the placenta and the cells of the ICM will form the embryo. It is important to take this 
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Figure 1.2 Formation of the blastocyst 
Early in cell division, the blastocyst forms, which contains the trophoblast cells and 
the inner cell mass (ICM).  
 
 Within the first 8 days post-conception, the developing placenta embeds into the maternal 
decidua (Boss et al., 2018). Through this process, there is minimal integration of maternal and 
embryonic cells. As the placenta continues to develop, three distinct regions of the placenta form 
(Figure 1.3). The chorionic plate contains fetal blood vessels, which feed into the arteries and 
vein of the umbilical cord. The placenta embeds into the maternal decidua of the uterus and 
forms the basal plate, or the “maternal side,” of the placenta. Finally, the intervillous space forms 
as mononuclear cytotrophoblast cells fuse together to form multinucleated syncytiotrophoblast 
cells (Rejniak, Kliman, & Fauci, 2004). The intervillous space is composed of chorionic villi, 
which contain fetal blood vessels and therefore, are responsible for carrying out many of the 
primary functions of the placenta, especially those involved in maternal-fetal exchanges (Gude, 





Figure 1.3 Structure of the human placenta 
Three primary regions of the human placenta include the chorionic plate, the chorionic 
villi, which are important for the exchange of nutrients and waste between mother and 
fetus, and the basal plate, which contains the spiral arteries and embeds into the maternal 
decidua. 
 
1.2.3.2 Placental synthesis and enzymatic regulation of androgens and estrogens 
The placenta is the primary source of estrogen during pregnancy, which is indicated by 
higher levels of estrogen in the retroplacental space than in the maternal peripheral vein or 
umbilical vein/arteries (Kaludjerovic & Ward, 2012; Tulchinsky, 1973). Placental synthesis of 
estrogen is dependent on both the maternal and fetal compartments (Figure 1.4). The fetal zone 
of the adrenal cortex begins to express P450c17 by the 10th week of gestation and is responsible 
for the synthesis of dehydroespiandrosterone (DHEA) and dehydroespiandrosterone suflate 
(DHEA-S) from free cholesterol and other androgen precursors that are transferred from the 
maternal to fetal circulation via the placenta (Kaludjerovic & Ward, 2012). The fetal adrenal 
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gland also expresses the 3-hydroxysteroid dehydrogenase (3-HSD) enzyme that converts 
DHEA into androstenedione, the precursor for testosterone. As will be discussed in greater detail 
later in this chapter, the placenta is then able to aromatize the bioavailable testosterone to 
estradiol (Kaludjerovic & Ward, 2012). A positive feedback mechanism is likely, given that 
maternal testosterone, estrogen, and aromatase in syncytotrophoblast cells of the human placenta 
all increase across gestation (Grumbach & Auchus, 1999; Kitawaki et al., 1992; Schock et al., 
2016). 
 
Figure 1.4 Maternal, fetal, and placental involvement in in-utero estradiol 
synthesis 
Placental synthesis of estrogen is dependent on a complex pathway involving the 
maternal, fetal, and placental compartments. Free cholesterol and other androgen 
precursors are transferred from the maternal to fetal circulation via the placenta. The fetal 
zone of the adrenal cortex synthesizes DHEA and DHEA-S from the free cholesterol The 
3-HSD enzyme in the fetal adrenal cortex then converts DHEA into androstenedione, 








1.3 Prenatal exposure to sex hormones and fetal programming 
1.3.1 Organizational and activational effects of testosterone 
From the first trimester of pregnancy through adulthood, the effects of testosterone can be 
categorized as either organizational or activational (Figure 1.5). Activational effects, such as 
those observed during puberty, are often brief and dependent on the presence of a hormone 
molecule. Organizational effects, in contrast, typically occur during critical periods of brain 
development and plasticity when hormone-dependent neural systems are being established 
(Arnold & Gorski, 1984; Auyeung et al., 2013; Cohen-Bendahan, van de Beek, & Berenbaum, 
2005; Melissa Hines, Constantinescu, & Spencer, 2015; Sakai, Baker, Jacklin, & Shulman, 
1991). In rats, free testosterone that is not bound to sex hormone-binding globulin (SHBG) 
circulates through the bloodstream and has the capacity to affect a cell by binding to an androgen 
receptor and forming a steroid-receptor complex that can alter protein synthesis and gene 
expression (Breedlove, 1994). Both males and females express androgen receptors, however, sex 
differences in the level of circulating bioavailable testosterone can affect receptor binding. 
Importantly, some of the first brain regions to express androgen receptors are those that are 
involved in sexually dimorphic behaviors. For example, analyses of first-trimester post-mortem 
brain tissue identified neuronal cells that express androgen receptors in areas of the brain that are 
involved in sexual behavior including the medial preoptic area (MPOA) within the hypothalamus 
and the spinal nucleus of the bulbocavernosus (SNB) (Arnold & Gorski, 1984; Breedlove, 1994). 
Throughout the prenatal period, the activational and organizational effects of sex hormones work 
in concert to shape and stimulate these steroid-sensitive brain regions, suggesting the potential 




Figure 1.5 Organizational and activational pathways for estrogen and 
androgen action 
In males, the SRY gene on the Y-chromosome induces testicular production of 
testosterone which is aromatized into estradiol. Estradiol organizes regions of the brain 
that, during the activational period, will be sensitive to androgens and drive sex 
differences in behavior. 
 
1.3.2 Aromatization of in-utero testosterone: indirect effects of prenatal androgens on 
neurobehavioral outcomes 
The multiplicity of mechanisms – direct and indirect - by which testosterone can affect a 
cell makes it extremely difficult to identify whether the cause of masculinization is due to 
testosterone or its downstream metabolites. While estradiol is often thought to be the “feminine 
hormone” and testosterone the “masculine hormone,” several studies indicate that estradiol may 
be important for both female and male-typical behaviors.  
Testosterone can act on the brain directly by binding to androgen receptors or indirectly 
through aromatization into estradiol. Aromatase is an enzyme in the p450 gene family that is 
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encoded by the CYP19A1 gene. Aromatase is primarily responsible for converting testosterone 
into estradiol and is found in human brain tissue, skin, adipose tissue, ovaries, testes, and 
placenta tissue. 
Similar behavioral phenotypes can be triggered either through direct administration of 
estradiol or through aromatization of testosterone into estradiol. For example, female rats that are 
treated with high doses of estrogen display masculinized behaviors similar to those observed in 
females who are treated with testosterone, which suggests that the effects of the testosterone 
were the result of increased levels of estradiol via aromatization (Goy & McEwen, 1980). As 
another example, male rats with reduced androgen receptors, but intact gonadal testosterone 
production, display normal differentiation and development within the central nervous system 
(MacLusky & Naftolin, 1981). Further, male and female rhesus monkeys that are given an 
androgen receptor antagonist actually demonstrated masculinization of several sexually 
dimorphic behaviors (Herman, Jones, Mann, & Wallen, 2000). Even though the testosterone 
could not bind directly to a receptor, the animals continued to produce sufficient levels of 
testosterone for aromatization and synthesis of estradiol, which we now recognize as a critical 
determinant of sexual differentiation within the brain.  
Given the fact that females produce more endogenous estradiol than males, it seems 
paradoxical that estradiol would be responsible for masculinization. In response to this apparent 
paradox, a hypothesis of female protection was proposed. Females produce high levels of alpha-
fetoprotein, which binds to estradiol and prevents it from activating estrogen receptors 
(MacLusky & Naftolin, 1981). Therefore, females may produce more estradiol than males, but 
they have less bioavailable estradiol in the presence of alpha-fetoprotein, protecting them from 
the masculinizing effects of estrogens (Bakker et al., 2006). 
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1.3.3 Effects of fetal androgen exposure on physical and neurobehavioral outcomes 
The extent to which prenatal exposure to sex hormones influences behavior and cognition 
has been illustrated in numerous human and animal based studies. Foundational work in this area 
involved manipulating pre- and postnatal exposure to both endogenous and exogenous sex 
hormones. By manipulating testosterone availability and metabolism, sex-dependent variation in 
behavior can either be exaggerated or muted. Across species, it has been shown that exposing 
developing females to testosterone during the prenatal period results in the masculinization of 
sexually dimorphic social behaviors. For example, female monkeys who are treated with 
testosterone display male-typical play compared to females who gestate under normal hormonal 
conditions (Goy & McEwen, 1980; Thornton, Zehr, & Loose, 2009). In contrast, males who are 
exposed to androgen receptor antagonists show reduced male-typical play behavior. Effects like 
these tend to be dose-dependent; individuals who are prenatally exposed to higher levels of 
testosterone exhibit more masculinized behaviors than those who are exposed to lower levels of 
testosterone (Cohen-Bendahan et al., 2005; Tapp, Maybery, & Whitehouse, 2011). 
The effects of experimentally manipulated hormone exposure compliment findings that 
have come from observational studies in humans. As part of the Cambridge Child Development 
Study, Baron-Cohen and his colleagues have further established the influence of pre- and early 
postnatal testosterone exposure on cognition and social behavior in humans. Variability in 
testosterone exposure has been associated with sexually dimorphic cognitive styles that can be 
measured by the Empathizing Quotient (EQ) and Systemizing Quotient (SQ). Baron-Cohen and 
others have demonstrated quite reliably that females score higher than males on the EQ and 
males score higher than females on the SQ. Weak correlations have been found between 2D:4D 
digit ratio and the EQ in adulthood (Wakabayashi & Nakazawa, 2010), but these findings point 
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to a potential relationship between early hormone exposure and higher-order cognition later in 
life. This supposition has been further supported by a study that found that 6-9 year olds’ ability 
to accurately assign an emotion to images of the eye region of a face (Eyes-C) was negatively 
correlated with testosterone in amniotic fluid. Performance on the child version of the EQ (EQ-
C) was also negatively correlated with amniotic fluid testosterone levels, but only among boys 
(Chapman et al., 2006). However, other behaviors that are related to empathy, like the use of 
affective state terms, are not associated with lower prenatal testosterone (R. C. Knickmeyer & 
Baron-Cohen, 2006). It is not well understood how early exposure to hormones directly 
influences affective development, but brain regions that have been implicated in empathy and 
emotion recognition and regulation, like the amygdala, the fusiform gyrus, right temporo-parietal 
junction, and the medial prefrontal cortex, have sexually dimorphic structural and functional 
properties and have the potential to be shaped by sex hormones (Auyeung et al., 2013; Canli, 
Desmond, Zhao, & Gabrieli, 2002; Goldstein et al., 2001). 
The sex difference in “empathizing” is preceded by an earlier sex difference in preference 
for social stimuli, which remarkably can be observed within the first postnatal day. In 1975, 
Goren et al. studied preferential looking towards social stimuli in neonates between 3-27 minutes 
post-partum. The experimenters presented the neonates with paddles that had four different 
patterns: a face, a moderately scrambled face, a scrambled face, and a blank paddle. They found 
that the newborns turned their heads to a greater degree to look at the face-like paddle compared 
to any of the other paddles (Goren, Sarty, & Wu, 1975). To determine whether social-preference 
measured through preferential looking could illuminate emerging sex differences during the 
neonatal period, a subsequent study gave neonates the choice to look at a human face or a 
mechanical mobile (Connellan, Baron-Cohen, Wheelwright, Batki, & Ahluwalia, 2000). They 
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found that within the first 24 hours after birth, males spent significantly more time looking at the 
mobile than females, and females spent more time looking at the face than the mobile. The early 
emergence of sex differences in preferential looking toward social stimuli suggests that some 
sexual dimorphisms may arise independent of social learning and social experience and may 
instead be due to prenatal influences.  
The sex differences observed during the neonatal period extend into the first years of 
childhood and is prominent in behaviors including eye contact, communicative skills, and play 
behavior. By 12 months of age, the duration and number of instances of eye contact are predicted 
by lower testosterone in amniotic fluid during mid-pregnancy, especially in boys (Svetlana 
Lutchmaya, Baron-Cohen, & Raggatt, 2002). Girls are also precocious in their use of language, 
including the type of words they use and their vocabulary sizes. Toddlers with more restricted 
vocabularies, which is more common among boys, tend to have higher levels of testosterone in 
their amniotic fluid, again suggesting a prenatal influence (Svetlana Lutchmaya, Baron-Cohen, & 
Raggatt, 2001). By 12 months of age, children also have sex-typed play behavior patterns with 
distinct preferences in toys (Servin, Bohlin, & Berlin, 1999; Snow, Jacklin, & Maccoby, 1983) 
and playmates (M. Hines & Kaufman, 1994) and there is evidence that prenatal testosterone is 
associated with male-typical play behavior (Auyeung, Baron-Cohen, et al., 2009; Beek, Goozen, 
Buitelaar, & Cohen-Kettenis, 2007; R. C. Knickmeyer et al., 2005). 
 
1.3.3.1 Fetal programming by prenatal maternal androgens 
One study found that mothers with high plasma testosterone levels between 5-36 weeks 
of gestation give birth to girls who engage in more male-typical play behavior (Melissa Hines, 
Golombok, Rust, Johnston, Golding, & Avon Longitudinal Study of Parents and Children Study 
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Team, 2002), but a more recent study found no association between maternal testosterone and 
sex-typed behavior in their daughters (van de Beek et al., 2004a). Pregnant rhesus monkeys that 
are treated with exogenous testosterone propionate throughout pregnancy, a manipulation 
intended to mimic the effects of a high androgenic in utero environment, give birth to 
masculinized offspring (Goy & McEwen, 1980). Hines et al. (2002) measured testosterone levels 
in maternal plasma during pregnancy (range: 5-35 weeks, mean: 16 weeks) and administered the 
Preschool Activities Inventory (PSAI) at 3.5 years of age. They found a positive linear 
relationship between maternal testosterone levels and masculine play behavior in the female 
children (Melissa Hines, Golombok, Rust, Johnston, Golding, & Avon Longitudinal Study of 
Parents and Children Study Team, 2002). In order to understand why this effect was only seen in 
the female children, an important distinction must be made. If testosterone levels in the fetus and 
infant determine the masculinity of play behavior then the Hines et al. (2002) study suggests that 
either maternal testosterone has a direct impact on fetal exposure to testosterone (e.g. it crosses 
the placenta and enters the fetal cavity or it triggers a release of testosterone from the fetus’ 
adrenal gland) or it has an indirect impact on fetal testosterone (e.g. through genetic heritability 
or environmental factors). Unfortunately, these indirect factors are difficult to assess. Firstly, it 
would be important to know whether mothers with the highest testosterone levels during 
pregnancy also had the highest levels of testosterone when they are not pregnant. It is possible 
that the mothers with high testosterone during pregnancy also had high levels throughout the first 
3 years of their children’s lives. If this were the case, it would be difficult to exclude the 
possibility that these mothers engaged in more masculine play behavior with their children and 
therefore encouraged their children - including their daughters - to play in masculine ways 
(Cohen-Bendahan et al., 2005). Additionally, it has been estimated that up to 40-60% of the 
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variability in testosterone levels may be heritable (J. A. Harris et al., 1998; Kuijper et al., 2007). 
That is to say, an individual’s testosterone levels may be partly influenced by genetic factors that 
are passed down from the biological parents. For reasons that are unknown, the heritability of 
testosterone levels seems to be higher in females (J. A. Harris et al., 1998), so it is possible that 
mothers pass down more genetic factors that regulate testosterone levels to their daughters than 
their sons. Finally, since males produce higher levels of testosterone than females, maternal 
testosterone may not cause a significant increase in the cumulative level of testosterone exposure 
in males or male fetuses may be better equipped to metabolize the additional testosterone.  
 
1.3.3.2 Fetal programming by androgens of co-twin siblings 
Rodent litters gestate within a uterine horn, a structure that provides each fetal pup with 
an individual amniotic sac and placenta that can exchange nutrients and waste products with the 
maternal circulatory system via the umbilical artery. Fetal sacs are arranged side by side in a “U” 
shape and several researchers have found effects of littermate position on the development of 
sexually dimorphic characteristics (Ryan & Vandenbergh, 2002). Females who gestate between 
two males (2M) show more aggressive behavior, more masculine sexual behaviors such as 
mounting (Clemens, 1974; Houtsmuller & Slob, 1990), increased body weight (Kinsley et al., 
1986), and they have a longer (male-like) AGD (Kinsley et al., 1986; McDermott, Gandelman, & 
Reinisch, 1978; Quadagno et al., 1987). Further, 2M females seem to show greater sensitivity to 
testosterone, requiring a lower dose to induce aggressive behavior (Gandelman, Saal, & 
Reinisch, 1977). It is hypothesized that testosterone from one fetus may transfer either via the 
mother’s circulation or through diffusion across the fetal membranes. It has been reported that 
2M mice have higher levels of testosterone in neonatal plasma and amniotic fluid compared to 
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females who gestated next to one male or two females (Ryan & Vandenbergh, 2002; Saal & 
Bronson, 1980; Vom Saal et al., 1990). Importantly, the effects of uterine position on behavior 
and AGD were diminished if the pups were exposed daily to an anti-androgen between prenatal 
day 10 through parturition (Clemens, 1974). This has been taken as strong evidence for the 
organizational effects of testosterone during prenatal development since the use of a prenatal 
anti-androgen ameliorates the masculinizing effects. However, the effects of the anti-androgen 
may not be limited to the prenatal period. Since both sexes responded to the anti-androgen with 
reduced male-typical behaviors and were reared together, it is possible that the females’ behavior 
was affected by changes in the male littermates’ postnatal behavior. It has been proposed that 
testosterone from one fetus may reach a neighboring fetus via maternal circulation (E. M. Miller, 
1994). However, several studies have failed to find differences in maternal testosterone levels 
between women carrying a female and male fetus, which suggests that the transfer of 
testosterone between mother and fetus may be unidirectional (Melissa Hines, Golombok, Rust, 
Johnston, Golding, & Team, 2002; van de Beek et al., 2004a).  
Many human studies have investigated the physical, behavioral, and cognitive differences 
between females with a male co-twin (Fm) and a female co-twin (Ff) and the results have been 
comprehensively reviewed elsewhere (Cohen-Bendahan et al., 2005, p.; Tapp et al., 2011). In 
summary, Fm girls have larger teeth than Ff girls, however, they do not differ on other 
phenotypic characteristics including birth weight, height, BMI, and waist circumference 
(Dempsey, Townsend, & Richards, 1999; Tapp et al., 2011). It is unclear whether 2D:4D digit 
ratio is affected in females with a male twin. Mixed results have been found among studies 
measuring differences in sensation-seeking, temperament, aggression, toy preference, and 
disordered eating, and these differences seem to vary depending on the age of the participants. 
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Perception and cognition is more reliably influenced by the sex of a child’s co-twin. For 
example, otoacoustic emissions are produced by the inner ear and are more common in girls. Ff 
girls produce significantly more otoacoustic emissions than Fm girls (McFadden, 1993). 
Additionally, girls demonstrate a larger expressive vocabulary by toddlerhood and Fm girls show 
a reduced expressive vocabulary compared to Ff girls (Galsworthy, Dionne, Dale, & Plomin, 
2000). Additionally, Fm girls demonstrate masculine cerebral lateralization (i.e. right-ear 
superiority) when both ears are simultaneously stimulated during a dichotic listening task 
(Cohen-Bendahan, Buitelaar, van Goozen, & Cohen-Kettenis, 2004). The Mental Rotation Test 
is a visuospatial task that requires the participant to match a target image with an identical image 
that has been rotated. Males across multiple age groups outperform females on this task and, as 
hypothesized, males with a male twin outperform males with a female twin (Vuoksimaa et al., 
2010). Interestingly, it has been reported that Ff and Fm twins have comparable levels of 
circulating testosterone when measured postnatally (Cohen-Bendahan et al., 2004, 2005). This 
finding supports the notion that organizational events that contribute to neural development 
during the prenatal period may be more sensitive to testosterone exposure than are the 
activational events, such as a release of testosterone from the adrenal gland during childhood.  
Caution is recommended when drawing conclusions about the prenatal influences of sex 
hormones synthesized by a co-twin because the socialization patterns of female-male twins are 
undoubtedly different than those of female-female twins. Adoption studies involving twins 
reared apart would help elucidate whether these effects are due to prenatal transfer of 
testosterone between twins, postnatal interactions between twins, or a combination of both pre- 




1.4 Fetal testosterone exposure and autism spectrum disorder 
In light of the rising prevalence of autism spectrum disorder (ASD) and the effectiveness 
of early interventions in improving quality of life and functioning of affected individuals 
(Fernell, Eriksson, & Gillberg, 2013; S. L. Harris & Handleman, 2000), it is critically important 
to identify biological markers of ASD risk that emerge early in development. In determining 
autism risk, sibling studies can provide important information about subsequent pregnancies, as 
children with affected siblings are more likely to have autism, themselves (Constantino et al., 
2010). However, for first-time parents, a diagnosis often relies on behavioral observation during 
childhood or retrospective examination of a child’s behavior (Nadel & Poss, 2006). Baranek 
(1999) retrospectively assessed early home videos of 9-12 year old children with autism, 
developmental disabilities, and typical development and found that specific behaviors were able 
to predict a differential diagnosis in 93.75% of the cases, suggesting that observable behavioral 
differences are present at a young age. In a recent longitudinal study, children with autism 
demonstrated atypical eye gaze patterns by 6 months of age, providing the earliest behavior-
based screening technique yet (Jones & Klin, 2013).   
ASD is a pervasive neurodevelopmental disorder that is typically diagnosed during early 
childhood and is characterized by impairments in social functioning and restricted and repetitive 
behaviors and interests. Notably, there is a strong male bias of 4:1 with many more boys being 
diagnosed with the disorder than girls. Although the etiology of ASD is not well understood, one 
potential risk factor for ASD is aberrant in utero exposure to sex hormones. Atypical 
steroidogenic activity during prenatal development may disrupt the normal process of sexual 
differentiation and alter hormone-sensitive brain regions that contribute to sensory processing, 
emotional regulation, cognition, and social behavior, and may account for the increased ASD 
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risk in males (Auyeung, Baron-Cohen, et al., 2009; Cohen-Bendahan et al., 2004; J.-A. K. 
Finegan, Alison, & Sitarenios, 1992). 
It has been proposed that the elevated circulating testosterone levels in the male fetus 
may create increased vulnerability in males (Beek et al., 2007; van de Beek et al., 2004a). Given 
the trajectory of testosterone production by the fetus, it is likely that the effects of testosterone 
will be most robust during early to mid-gestation. Indeed, it has been shown that by birth, 
androgens in cord blood (testosterone, androstenedione, and dehydroepiandrosterone) are not 
associated with autism phenotypes in early childhood (Park et al., 2017). 
In typical development, higher prenatal exposure to fetal testosterone in males may shape 
the fetal brain and program behavioral patterns of enhanced male-typical behaviors and 
suppressed female-typical behaviors. The Extreme Male Brain Theory of Autism purports that in 
the case of ASD, the developing fetus may carry genetic or environmental predispositions that 
exacerbate susceptibility to the effects of prenatal testosterone exposure, resulting in behaviors 
and physiological patterns that fall on the male end of the sex distribution (Chapman et al., 2006; 
Teatero & Netley, 2013).  
There are several characteristics of ASD that are compatible with the Extreme Male 
Brain Theory. Boys tend to develop social skills more slowly than girls and children with ASD 
demonstrate significantly delayed social development and these behaviors are associated with 
greater prenatal exposure to testosterone. For example, individuals with ASD and Asperger’s 
syndrome perform more poorly on empathy tasks and reading the mind in the eyes tasks than 
typical males and typical females (Simon Baron-Cohen, 2010). The 2D:4D digit ratio is 
negatively correlated with the testosterone-estrogen ratio in the amniotic fluid, is lower in males 
than in females, and is lowest in individuals with ASD (S. Lutchmaya et al., 2004; J. T. Manning 
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& Robinson, 2003; John T. Manning et al., 2010). Most directly, higher levels of testosterone in 
amniotic fluid have been measured from children who display autistic traits later in childhood 
(Auyeung, Baron-Cohen, et al., 2009; R. C. Knickmeyer & Baron-Cohen, 2006). Baron-Cohen 
and his colleagues have recently explored how other hormones and hormone precursors along 
the delta-4 steroid pathway may contribute to the onset of autistic traits (S. Baron-Cohen et al., 
2015a). In a large study of 345 males (217 cases, 128 controls), a principal component analysis 
(PCA) of the delta-4 steroids and cortisol in amniotic fluid samples revealed that the combination 
of hormones best predicted an ASD diagnosis. Among cases and controls, all of the hormones 
positively correlated with one another. The PCA revealed that the model in which the delta-4 
hormones and cortisol loaded equally, best explained a significant amount of variance within the 
sample (49.47%). This principal component was the only factor that differed between the control 
and ASD groups.  
Research investigating the effects of prenatal testosterone has almost exclusively focused 
on the role of testosterone that is produced by the fetus. However, another potential mechanism 
of sexually-dimorphic susceptibility to ASD is aberrant in utero exposure to maternal sex 
hormones. Pregnant mice that are treated with testosterone during pregnancy give birth to 
offspring with increased density of dendritic spines, a morphological characteristic of autistic 
brains (Hatanaka et al., 2015; Tang et al., 2014; Penzes et al., 2011). This work suggests that 
increased maternal testosterone during prenatal development may negatively affect 
synaptogenesis and synaptic pruning in a clinically relevant way. The placenta is a maternal-fetal 
endocrine structure that serves as a critical interface between the maternal and fetal circulatory 
systems during pregnancy and has been put forth as a “gate-keeper” that regulates the amount of 
testosterone that is transferred between the mother and her fetus. The syncytiotrophoblast cells of 
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the placenta express high levels of aromatase (CYP19A1) and placental aromatase is thought to 
modulate fetal exposure to maternal testosterone (Gore, Martien, Gagnidze, & Pfaff, 2014; 
Sarachana, Xu, Wu, & Hu, 2011a; Siiteri & MacDonald, 1966). However, there is no empirical 
evidence to support this assumption and further, the effects of reduced aromatase activity in the 
placenta on fetal hormone exposure and neurodevelopment have not been evaluated. Studies 
using postmortem brain tissue have indicated that aromatase protein and mRNA expression are 
significantly lower in the frontal gyrus and prefrontal cortex of individuals with ASD compared 
to neurotypical controls (Crider, Thakkar, Ahmed, & Pillai, 2014a; Sarachana et al., 2011a).  
Retinoic acid-related orphan receptor-alpha (RORA) is a transcription factor that 
upregulates aromatase in neuroblastoma cells. In vitro studies suggest that there are regulatory 
feedback loops between the sex hormones, RORA, and aromatase expression. Specifically, 
neuroblastoma cells that were treated with estrogen showed increased RORA expression, whereas 
cells that were treated with testosterone expressed significantly lower levels of RORA (Sarachana 
et al., 2011a). Aromatase and RORA are positively correlated in brain tissue, but the regulatory 
function of RORA in the placenta has not been empirically addressed. We therefore propose that 
RORA should be considered as a potential contributor to the hormonal “gate-keeping” function 
of the placenta. Like aromatase, RORA expression and protein levels are reduced and RORA 
methylation is increased in the frontal gyrus, prefrontal cortex, and cerebellum in postmortem 
tissue from individuals with ASD and it is now recognized as an ASD candidate gene (Nguyen, 
Rauch, Pfeifer, & Hu, 2010; Sarachana et al., 2011a). RORA also carries out critical functions in 
the cerebellum and RORA deficient mice known as the “staggerer” mutant mouse have defective 
Purkinje cells and severe motor deficits (Dussault, Fawcett, Matthyssen, Bader, & Giguère, 
1998). Importantly, the placenta is fetal tissue that develops from the trophoblast layer of the 
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blastocyst. Therefore, the placenta is genetically identical to the fetus and the altered patterns of 
aromatase and RORA expression in the brain may generalize to atypical patterns of expression in 
the placenta. If aromatase and RORA are reduced in the placentas of children with ASD, this 
could allow for greater transfer of maternal testosterone to the fetus. 
In animal models, exogenous testosterone administration to pregnant mothers exerts 
dose-dependent increases in testosterone and masculine behavior in the offspring, whereas 
prenatal administration of androgen inhibitors feminizes behavior in offspring (Goy & McEwen, 
1980; Melissa Hines, 2006a). For example, Veiga-Lopez et al. (2011) treated pregnant sheep 
with testosterone proprionate from day 30 to 90 of gestation (term age is 147 days) and measured 
fetal hormone levels in the early, mid, and late gestational time points (Veiga-Lopez et al., 2011, 
p.). They found that male and female offspring had increased levels of both testosterone and 
estradiol, particularly during the mid-gestation period. Since they found that testosterone-treated 
males and females had higher estradiol compared to their respective controls, the authors 
concluded that the placenta is the primary source of aromatization, rather than the fetal gonads. 
However, more direct measurements of this proposed aromatase mechanism in the placenta have 
not been previously explored. 
In humans, an increase in maternal testosterone from the 25th to 75th percentile during 
mid-pregnancy is associated with significantly lower birth weight (S M Carlsen, 2006). There are 
also clinical conditions associated with ASD risk that support the hypothesis that elevated 
maternal testosterone paired with reduced aromatase/RORA expression in the placenta may 
contribute to ASD etiology. In addition to the maternal and neonatal morbidities associated with 
preeclampsia and severe pregnancy-related hypertension, there is also increased risk for autism 
and atypical neurobehavioral outcomes in the offspring (Maher et al., 2018; M. Robinson et al., 
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2009; Walker CK et al., 2015). A meta-analysis of 11 studies with adjusted estimates of autism 
risk reports a pooled adjusted odds ratio of 1.35, indicating a moderate increase in autism risk 
among children born to mothers with pregnancy-related hypertensive disorders (Maher et al., 
2018). For unknown reasons, women with preeclampsia have elevated testosterone by the second 
and third trimesters, though some reports indicate that changes in androgen levels may be sex-
specific (Sven Magnus Carlsen, Romundstad, & Jacobsen, 2005; Steier et al., 2002; R. Troisi, 
2003; Tuutti et al., 2011). In addition to the elevated steroidogenic activity, differences in 
placenta aromatase activity have been observed in preeclamptic pregnancies. In one study, 
aromatase mRNA and protein levels were reduced in placenta samples obtained from 
preeclamptic pregnancies and in vivo analyses revealed that aromatase was reduced in JEG-3 
trophoblast cell lines under conditions of hypoxia (Perez-Sepulveda et al., 2015a). This finding 
was further supported by a rabbit model for preeclampsia in which partial ligation of the spiral 
arteries led to decreased placental aromatase activity (Perez-Sepulveda et al., 2015a). Another 
study detected a specific defect in the aromatase gene in placentas from preeclamptic 
pregnancies at 24-29 weeks’ gestation (Berkane et al., 2018).  Finally, lower levels of aromatase 
mRNA and protein were seen in placentas from preeclamptic pregnancies, though the effect was 
sex-dependent such that affected males had lower placental aromatase than control males, but 
affected females had higher placental aromatase than control females (Sathishkumar et al., 
2012a). The researchers of this study also found higher aromatase levels in male placentas 
compared to female placentas, though this has not been reported widely. This sex-specific 
finding suggests placental modulation of exposure to maternal testosterone is dependent on fetal 
sex, which could further contribute to the sex bias in ASD. Three studies have reported an 
association between maternal PCOS and neurodevelopmental disorders in the offspring. Two 
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large population-based matched case-control analyses found that the odds of having a child with 
autism were up to 60% higher among women with PCOS compared to the healthy controls 
(Cherskov et al., 2018; Kosidou et al., 2015). In a smaller sample, it was reported that daughters 
of women with PCOS demonstrate more autism-related behaviors on the Autism Spectrum 
Quotient, score lower in the Empathizing Quotient, and higher on the Systemizing Quotient 
(Palomba et al., 2012). As is the case in preeclampsia, aromatase activity is reduced in placentas 
from pregnancies that are affected by maternal PCOS (Maliqueo et al., 2013). This pattern of 
results further supports the notion that increased maternal testosterone during pregnancy may 
influence autism risk in the fetus. While it is unlikely that these conditions have a direct effect on 
ASD etiology, they serve as a biological indication of abnormal hormone activity, which may 
affect fetal brain development and neuropsychiatric outcome.  
 
1.5 Proposed studies to evaluate hypothesized model of neurodevelopmental risk 
   The placenta is routinely accessible to clinicians at delivery and could potentially be used 
to create a genetic profile that could identify newborns who are at high risk for developing ASD 
and other adverse neuropsychiatric outcomes. The studies described in subsequent chapters 
evaluate a proposed risk model presented in Figure 1.6. This model is based on the hypothesis 
that increased cord blood testosterone and subsequent risk for adverse neurodevelopmental 
outcomes will be predicted by the combined effects of exposure to high maternal testosterone 
and low placental aromatase/RORA. To assess whether placental aromatase (CYP19A1) and 
RORA could serve as a robust indicator for neurodevelopmental risk, we investigated whether 
CYP19A1 and RORA expression in the placenta mediates the transfer of maternal testosterone to 
the fetus using in vivo and in vitro methodological approaches. Through conducting long-term 
 
 32 
follow-up of the children enrolled in the in vivo studies, we also sought to determine whether 
variation in fetal exposure to maternal testosterone and placental aromatase/RORA expression 
was associated with adverse neurodevelopmental outcomes. 
 
 
Figure 1.6 Proposed relationship between placental aromatase and RORA, 
maternal testosterone, fetal testosterone exposure, and childhood 
neurodevelopmental outcome 
Risk is defined as likelihood that a child will have high fetal/neonatal testosterone and 
will demonstrate poor neurodevelopmental outcome. Individuals in the ”low risk” 
category are exposed to low maternal testosterone and high placental aromatase/RORA. 
Individuals in the ”moderate risk” category are exposed to low maternal testosterone and 
low placental aromatase/RORA or high maternal testosterone and high placental 
aromatase/RORA. Individuals in the ”high risk” category are exposed to high maternal 







Chapter 2: General methods and approach 
 
2.1 Biological samples 
2.1.1 Placenta tissue collection procedures 
For all studies presented here, we specifically collected regions of tissue containing 
chorionic villi and avoided collecting tissue from either the basal plate or the chorionic plate. 
To evaluate mRNA levels in placenta tissue, two primary considerations were taken into 
account for all studies presented here. Firstly, in order to avoid significant degradation of the 
RNA, placentas were collected no more than 60 minutes after delivery, though in most cases, the 
placenta was collected and processed within 30 minutes after delivery. Secondly, to aid in the 
stabilization of the RNA, placenta samples used in the studies described in Chapter 4, Chapter 
6, and Chapter 7 were placed in RNAlater stabilization solution (Invitrogen). Protocols varied 
slightly for each study, but typically, whole placentas (including placental membranes and the 
umbilical cord) were collected immediately after birth and were either processed immediately or 
were stored at 4C for up to 30 minutes prior to processing. Placentas were placed on a sterile 
hospital pad with the chorionic plate facing up. Using a punch biopsy or a scalpel, tissue was 
dissected from the region between the cord insertion and the edge of the placenta (Figure 2.1). In 
all protocols, tissue samples were immediately rinsed in cold PBS or saline and excess liquid was 
removed using sterile gauze. In protocols that required RNAlater, tissue samples were placed in 
2ml of RNAlater and stored at 4C for 48 hours before being stored at -80°C. In other protocols, 






Figure 2.1 Locations for collection of placenta and umbilical cord samples 
A punch biopsy was used to collect a sample of placental tissue from the chorionic villi. 




2.1.2 Maternal plasma collection procedures 
Whole blood was collected by venipuncture into EDTA-coated collection tubes. 
Collection tubes were repeatedly inverted to distribute the anticoagulant. The protocols used in 
Chapter 4, Chapter 6, and Chapter 7 required centrifugation at 1500g for 10 minutes at 4°C, 
whereas samples collected under the protocol for Chapter 3 were centrifuged for 15 minutes at 
2,500 rpm at 4°C. Plasma was extracted and transferred to 2ml collection tubes and stored at -




2.1.3 Umbilical cord plasma collection 
After delivery and umbilical cord clamping, study staff transported the whole placenta in 
a closed container to a laboratory for further processing. Whole umbilical cord blood was 
obtained by venipuncture of the umbilical cord or vessels on the surface of the chorionic plate 
using a sterile syringe and was collected into an EDTA-coated collection tube (Figure 2.1). The 
collection tubes were repeatedly inverted to distribute the anticoagulant. The protocols used in 
Chapter 4, Chapter 6, and Chapter 7 required centrifugation at 1500g for 10 minutes at 4°C, 
whereas samples collected under the protocol for Chapter 3 were centrifuged for 15 minutes at 
2,500 rpm at 4°C. Plasma was extracted and transferred to 2ml collection tubes and stored at -
80°C until further processing.  
 
2.1.4 Placenta tissue processing for gene expression analyses 
2.1.4.1 RNA and DNA extraction 
 While procedures varied slightly across studies, our general approach was to prepare 30 
mg sections of placental tissue for RNA and DNA extraction. Tissue was homogenized in 700μl 
lysis buffer RLTplus (Qiagen) with 1% β-mercaptoethanol using a tissue homogenizer (Omni) 
for 15 seconds. RNA and DNA were simultaneously extracted using the Qiagen All Prep 
DNA/RNA Mini Kit and the Qiagen RNase-Free DNase I Kit from batches of up to 24 samples 
per extraction. RNA and DNA concentration yields were measured using a spectrophotometer 
(Nanodrop). When applicable, RNA samples were normalized to a concentration of 100 ng/ul. 
For each sample, 10 ul of cDNA were generated from RNA and nuclease-free water using the 





2.1.4.2 Primer design and validation 
 Primers were designed to span or be located on separate exons with single melt peaks, an 
efficiency of 2, and a linear slope of -3.322 in a standard curve. Using a serial dilution protocol, 
primers were validated using mammalian cDNA. The forward and reverse sequences of each 
primer, as well as the efficiency and linear slope values obtained during validation are included 
in Table 2.1. 
 





Forward primer Reverse primer 
CYP19A1 1588 GCGCAAAGCCTTAGAAGATG CAAAGCCAAATGGCTGAAAG 
RORA 6095 TCATGGCTGCAAGAAAAGGT GAGGAAAATGAAGTCGCACAA 
YWHAZ 7534 GACGTCCCTCAAAACTTGCT GCCAGTTTGGCCTTCTGAAC 
 
2.1.4.3 Gene expression 
Relative gene expression was measured using real-time quantitative PCR (RT-qPCR) on 
a 96-well 7500 Fast qPCR machine (Applied Biosystems) using Fast SYBR Green Master Mix. 
The 2-ΔΔCt method is a widely used formula to calculate the relative gene expression in relation to 
a reference gene in samples based on data acquired through RT-qPCR. Using the 2-ΔΔCt method, 
we calculated relative gene expression of CYP19A1 (forward: 
GCGCAAAGCCTTAGAAGATG, reverse: CAAAGCCAAATGGCTGAAAG) and RORA 
(forward: TCATGGCTGCAAGAAAAGGT, reverse: GAGGAAAATGAAGTCGCACAA) 
using YWHAZ (forward: GACGTCCCTCAAAACTTGCT, reverse: 
GCCAGTTTGGCCTTCTGAAC) as a control gene with high expression stability in human 




2.1.5 Radioimmunoassay of maternal and umbilical cord plasma 
2.1.5.1 Radioimmunoassay of estradiol in maternal and umbilical cord plasma 
Estradiol radioimmunoassays were conducted using commercially available kits and 
performed as indicated by the supplier (MP Biomedicals; Solon, OH).  For all assays, samples 
were run in duplicate and values were averaged.  Due to the relatively high levels of estradiol in 
maternal and umbilical cord plasma, all estradiol samples were diluted in assay buffer and the 
raw values multiplied by the dilution factor. For the estradiol assays, the intra-assay coefficient 
of variations (CV) and lower limits of detectability (LLD) were calculated and are presented for 
each study in Table 2.2. 
 
Table 2.2 CV and LLD values for testosterone and estradiol radioimmunoassays 
  Testosterone Assay Estradiol Assay 
Study Sample Type CV (%) LLD (ng/ml) CV (%) LLD (pg/ml) 
Chapter 3 Maternal & Cord Plasma 3.3, 10.6 0.1 – 0.09 4.6, 4.5 9.57, 9.43 
Chapter 4 Maternal Plasma 11.15 0.09 13.72 9.07 
 Cord Plasma 16.48 0.10 8.51 8.12 
Chapter 5 Culture Medium - - 9.8 11.05 
Chapter 6 Culture Medium - - 12.9, 12.5 9.37, 8.38 
Chapter 7 Maternal Plasma 11.15 0.09 13.72 9.07 
 Cord Plasma 16.48 0.10 8.51 8.12 
Chapter 8 Maternal Plasma 11.15 0.09 13.72 9.07 
 Cord Plasma 16.48 0.10 8.51 8.12 
Note: When more than two assays were performed, the average CVs and LLDs across all 
assays are provided. 
 
 
2.1.5.2 Radioimmunoassay of testosterone in maternal and umbilical cord plasma 
Testosterone radioimmunoassays were conducted using commercially available kits and 
performed as indicated by the supplier (MP Biomedicals; Solon, OH).  For all assays, samples 
were run in duplicate and values were averaged. For the testosterone assays, the intra-assay CVs 




2.2 Neurobehavioral measures 
2.2.1 nuMOM2b study participants 
Between 2010-2013, 8 participating clinical centers across the United States enrolled 
10,037 nulliparous women with singleton pregnancies into the Nulliparous Pregnancy Outcomes 
Study: Monitoring Mothers-to-be (nuMoM2b) study (Haas et al., 2015). Nulliparous pregnant 
women were screened for eligibility during the 1st trimester. Eligible women were between 60-
136 weeks of gestation based on an ultrasound crown-rump length measurement. Pregnant 
women were excluded if they had a prior pregnancy lasting 20 weeks’ gestation or more, were 
younger than 13 years of age, had a history of 3 or more spontaneous abortions, or if a likely 
fatal fetal malformation was identified during screening.  
Approximately 1,000 of the nuMoM2b study participants were enrolled at Columbia 
University Medical Center. Of these 1,000 participants, 661 met criteria to be included in the 
secondary analyses presented here. Mothers were eligible to participate in the secondary analyses 
if they participated in the original nuMoM2b study, delivered at the Columbia University 
Medical Center site, were fluent in English or Spanish, and were ≥ 18 years old at the time of 
enrollment in the nuMoM2b study. As part of the nuMoM2b study, participants were provided a 
sample of maternal plasma during the second trimester, a sample of cord blood plasma at birth, 
and a sample of frozen placenta tissue at birth. To participate in this secondary analysis, 
participants must have provided written consent to the future use of their biological samples and 
written consent to be re-contacted by study staff. 
 
2.2.2 Qualtrics online survey 
 Qualtrics (Qualtrics, Provo, UT) is an online survey platform. With fully customizable 
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features, it allows researchers to design surveys that can be distributed securely to study 
participants. Participants from the nuMoM2b study sample were contacted by study staff and 
were asked to complete a brief survey administered through Qualtrics for a $25 compensation to 
a specified retail company. Participants who agreed to complete the survey were sent a link to 
the survey by email. To ensure the confidentiality of study participants’ information and data, 
they were prompted to enter their de-identified study ID (e.g. 1234567X) as their response to the 
first item on the survey. All responses were recorded on the Qualtrics platform and were securely 
exported as comma separated values files. 
 
2.2.3 Behavioral assessment System for Children (3rd Ed.) (BASC-3) 
The BASC-3 Parent Rating Scales (Preschool), is a validated parent-report questionnaire 
that is designed to assess a child's neurobehavioral development between the ages of 2 years 0 
months and 21 years 11 months (Altmann, Reynolds, Kamphaus, & Vannest, 2017). The BASC-
3 provides cutoffs that address diagnostic criteria from the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) and can be used to identify children who should be evaluated further. 
The BASC-3 provides clinical, adaptive, content, composite, and probability index scales. The 
clinical scales assess the following neurobehavioral domains: aggression, anxiety, attention 
problems, atypicality, conduct problems, depression, hyperactivity, learning problems, 
somatization, and withdrawal. The adaptive scales assess activities of daily living, adaptability, 
functional communication, leadership, social skills, and study skills. The content scales assess 
anger control, bullying, developmental social disorders, emotional self-control, executive 
functioning, negative emotionality, and resiliency. Finally, the clinical probability indexes 
measure attention-deficit/hyperactivity disorder (ADHD) probability, emotional behavior 
 
 40 
disorder probability, autism probability, functional impairment, and general clinical probability. 
In an effort to reduce participant fatigue and increase completion of the entire survey, we 
customized the Qualtrics survey to only included items pertaining to the hyperactivity, 
developmental social disorders, and general clinical probability scales. The hyperactivity scale 
measures the child’s tendency to be overly active, rush through tasks, and act without thinking. 
The developmental social disorders scales measure the child’s tendency to demonstrate 
behaviors associated with deficits in and restricted expression of social skills, communication, 
interests, and activities. Finally, the general clinical probability index can be used to identify 
children who are at risk for presenting with a clinical disorder. Parent responses to each item 
were entered using the online Q-Global scoring system. For each child, Q-Global generated t-
scores and percentile scores based on four normalized sample groups (general combined, general 
gender-specific, clinical combined, clinical gender-specific) for each scale. Higher t-scores or 
percentile scores on all scales indicate more problem behaviors. 
 
2.2.4 Social Communication Questionnaire (SCQ) 
The SCQ lifetime version is a parent-report questionnaire to evaluate autism-related 
behaviors in children 4 years (or mental age of 2 years) and older (Allen, Silove, Williams, & 
Hutchins, 2007). The SCQ contains 40 yes-or-no items that are intended to determine whether 
the child has ever demonstrated behaviors associated with autism spectrum disorder. The SCQ 
parallels the Autism Diagnostic Interview Revised (ADI-R) and robust agreement with the ADI-
R in identifying children with autism has been demonstrated. The SCQ provides both a 
continuous score (0-40) where a higher scores indicates more autism-related behaviors and a 
binary risk score. The developers of the SCQ suggest a risk cutoff score of 15, however, it has 
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since been shown that a cutoff score of 10 may have greater sensitivity, especially when 
assessing children 7.5 years of age and older (Barnard‐Brak, Brewer, Chesnut, Richman, & 
Schaeffer, 2016). 
 
2.2.5 Children’s Empathizing Quotient (EQ-C) 
The EQ-C is a parent-report questionnaire that was adapted from the adult version of the 
Empathizing Quotient questionnaire (EQ) and is designed to assess trends in sex-typical 
empathizing behavior in children (Auyeung, Wheelwright, et al., 2009). The EQ-C includes 55 
items that pertain to the child’s real-life situations, experiences, and interests. Of the 55 items, 27 
measure the child’s empathizing behaviors and 28 measure the child’s systemizing behaviors. In 
an effort to reduce participant fatigue and increase completion of the entire survey, we asked 
parents to only complete the 27 items from the EQ-C scale. Parents can respond to each item by 
selecting one of the following choices: ‘slightly agree,’ ‘definitely agree,’ ‘slightly disagree,’ or 
‘definitely disagree.’ A response of ‘slightly agree’ is scored as 1, ‘definitely agree’ as 2, and 
both ‘slightly disagree’ or ‘definitely disagree’ as 0 on items 1, 6, 14, 18, 26, 28, 30, 31, 37, 42, 
43, 45, 48, and 52. A response of ‘slightly disagree’ is scored as 1, ‘definitely disagree’ as 2, and 
both ‘slightly agree’ or ‘definitely agree’ as 0 on items 2, 4, 7, 9, 13, 17, 20, 23, 33, 36, 40, 53, 
and 55. Responses to each item were reverse scored when appropriate and summated to generate 







Chapter 3: Sex hormones in maternal and umbilical cord plasma 
during the perinatal period in relation to placental expression 
of aromatase and RORA 
 
3.1 Introduction 
It has been widely observed that males have a greater propensity for neurodevelopmental 
disorders including autism spectrum disorder (ASD) (Young & Pfaff, 2014). While clinical and 
scientific evidence support the supposition that this sex bias is due to differences in presentation 
between males and females (e.g. females may mask or compensate for their maladaptive 
behaviors more than males), it also is possible that specific biological processes during the 
prenatal period predispose the male fetus to greater risk for ASD, partially driving the observed 
sex bias. The question of whether prenatal exposure to androgens contributes to the etiology of 
ASD and related disorders has been one of particular interest. 
Exposure to sex hormones during critical period of brain development during gestation has 
the potential to alter organization and subsequent activation of hormone-sensitive brain regions 
involved in sensory processing, emotional regulation, social behavior, and other domains affected 
in individuals with ASD (Goy & McEwen, 1980; Liu, Portnoy, & Raine, 2012). Elevated amniotic 
fluid levels of testosterone and several key hormones (cortisol, progesterone, 17α-hydroxy-
progesterone, androstenedione) assessed during pregnancy are associated with a broad range of 
autism-related traits in early childhood including altered play behavior, reduced eye contact and 
vocabulary size, poorer emotion recognition, poorer quality of social relationships, restricted 
interests and sex-dependent cognitive styles  (Auyeung, Wheelwright, et al., 2009; S. Baron-Cohen 
et al., 2015a; Chapman et al., 2006; Goy & McEwen, 1980; R. Knickmeyer et al., 2006; Svetlana 
Lutchmaya et al., 2001, 2002; McIntyre, 2006; Thankamony et al., 2015). Importantly, the effect 
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of androgens on neurobehavioral development is restricted to the prenatal period, as cord blood 
androgen levels are not associated with increased autism risk (Park et al., 2017). 
 Testosterone measured in amniotic fluid is thought to be of fetal origin because the 
placenta is able to convert maternal testosterone into estradiol via aromatization. However, the 
assumption that placental aromatase serves as a fetal barrier against maternal testosterone 
assumes that the permeability of the aromatase barrier is consistent across individuals. As 
discussed in Chapter 1, differences in aromatase activity and activity of its transcriptional 
regulator, RORA have been reported in postmortem brain tissue of individuals with autism and 
several gestational-related health conditions have been associated with changes in aromatase in 
placenta tissue (Berkane et al., 2018; Maliqueo et al., 2013; Perez-Sepulveda et al., 2015a; 
Sarachana et al., 2011a; Sathishkumar et al., 2012a). However, the potential effects of 
perturbations in placental aromatase or RORA activity on fetal exposure to maternal androgens 
and the implications this may have for neurodevelopmental outcomes have not been evaluated 
extensively.  
As an initial step in investigating the combined effects of maternal androgens and 
placental regulation of steroidogenesis on neonatal hormone concentrations, we measured the 
relationship between maternal testosterone in the 3rd trimester, expression of aromatase and 
RORA in the placenta at birth, and neonatal estrogen and testosterone levels in umbilical cord 
blood at birth in a sample of healthy, uncomplicated pregnancies. We specifically hypothesized 
that the relationship between maternal testosterone and cord blood testosterone levels would be 






Twenty-nine pregnant women were enrolled in the study upon admission to the labor and 
delivery unit of Sloane Hospital for Women at New York Presbyterian Hospital of Columbia 
University Medical Center. All procedures were reviewed and approved by the Columbia 
University Medical Center Institutional Review Board and participants provided informed 
written consent prior to all study procedures. Eligible mothers were fluent in English, 18 years 
old, in at least the 37th week of their pregnancy, and admitted to the unit for an elective cesarean 
section. We restricted our enrollment to non-laboring patients who were admitted for delivery by 
an elective cesarean section in order to avoid the hormonal fluctuations that occur during labor, 
including increased fetal estradiol, decreased fetal testosterone, and decreased maternal estradiol 
(Adamcová et al., 2018; Hickey, Hart, & Keelan, 2014; Keelan et al., 2012; Mathur, Landgrebe, 
Moody, Powell, & Williamson, 1980). Further, elective cesarean deliveries are scheduled during 
a narrow time frame, which limited variability in the diurnal effects on hormone levels. We 
excluded women who had been diagnosed with polycystic ovary syndrome (PCOS), congenital 
adrenal hyperplasia (CAH), or preeclampsia during the current pregnancy because these 
conditions can alter circulating levels of testosterone and estrogen. Six mother-infant pairs were 
removed from the analyses presented here; two delivered vaginally, two provided blood samples 
that had insufficient yields, and two had advanced maternal age of >45 years, which was more 
than two standard deviations above the average maternal age of our sample. Therefore, all 
analyses presented include samples from 23 women and 25 infants (21 single and 2 twin 
pregnancies).  
 
3.2.2 Maternal plasma collection 
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Patients who were admitted for an elective cesarean delivery were brought to a surgical 
waiting room to prepare for their procedure. All maternal blood samples were collected between 
7:00am and 1:00pm, with an average collection time of 9:30am. On average, maternal blood was 
collected 2.5 hours prior to delivery. While placing an intravenous line as part of standard care, a 
member of the nursing staff collected approximately 1ml of blood from participating mothers. 
Blood was collected directly into an EDTA-treated collection tube, which was inverted several 
times to distribute the anticoagulant, and kept on wet ice for approximately 10 minutes until 
centrifugation. Detailed methods are described elsewhere (see Chapter 2).  
 
3.2.3 Umbilical cord plasma collection 
After the placenta was delivered, the umbilical cord was clamped and study staff 
transported the whole placenta in a closed container to a laboratory for further processing. 
Deliveries and cord blood collection occurred between 8:45am and 4:00pm, with an average 
delivery time of 11:45am. Approximately 1ml of umbilical cord blood was collected from the 
umbilical arteries and vein using a sterile syringe and injected into an EDTA-treated collection 
tube. Detailed methods are described elsewhere (see Chapter 2). 
 
3.2.4 Placenta tissue collection 
Immediately after the placenta was delivered, the umbilical cord was clamped and study 
staff transported the whole placenta in a closed container to a laboratory for further processing. 
Detailed methods are described elsewhere (see Chapter 2). 
 
3.2.5 Sex hormone radioimmunoassay of maternal and umbilical cord plasma 
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Testosterone and estradiol radioimmunoassays were conducted using commercially 
available kits and standard procedures, described in Chapter 2, were followed. For the 
testosterone assays, the intra-assay coefficient of variations (CV) and lower limits of 
detectability (LLD) were 3.3% and 10.6% and 0.1 ng/ml and 0.09 ng/ml, respectively (see Table 
2.2, Chapter 2). For the estradiol assays, the intra-assay CVs and LLDs were 4.6% and 4.5% 
and 9.57 pg/ml and 9.43 pg/ml, respectively (see Table 2.2, Chapter 2). We performed a square 
root transformation of the umbilical cord testosterone as the data were not normally distributed.   
 
3.2.6 Aromatase (CYP19A1) and RORA gene expression assays in placenta tissue 
30 mg sections of placental tissue were dissected in a temperature-regulated cryostat and 
standard RNA/DNA extraction procedures, described in Chapter 2, were conducted. Since this 
study does not involve a control group, we calculated the 2-ΔΔCt by averaging across the entire 
sample (Schmittgen & Livak, 2008). We repeated the calculations using female infants as the 
reference group and found no effect on relative gene expression values. We performed a square 
root transformation of CYP19A1 and RORA expression as the data were not normally distributed.   
 
3.3 Results 
3.3.1 Sample characteristics 
Demographic and medical information for infants and their mothers were extracted directly 
from patient medical records and are provided in Table 3.1. The average maternal age at 
delivery was 35.84 years (range 28-42 years). Fifty-two percent (n=12) self-identified as white, 
twenty-two percent (n=5) as black or African American, four percent (n=1) as American 
Indian/Native Alaskan, and race could not be identified for twenty-two percent (n=5) of the 
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participants. Fifty-two percent (n=12) of the participants self-identified as not Hispanic or 
Latino, seventeen percent (n=4) identified as Hispanic or Latino, and information on ethnicity 
was not available for thirty-one percent (n=7) of the participants. Twenty-six percent of the 
participants were pregnant for the first time. The majority (56%) of the participants elected to 
deliver via cesarean section due to a previous cesarean delivery. Other reasons for delivery 
included fetal malpresentation or a pre-existing maternal medical complication. Ten female 
infants and fifteen male infants were born to the twenty-five mothers and are included in the 
analyses presented here. All infants were at least 37 weeks gestational age and the average 
gestational age at delivery was 38.4 weeks. The effects of several demographic and pregnancy-
related variables on maternal and cord blood hormone concentrations and placental aromatase 
















Table 3.1 Study sample characteristics 
Characteristics 
n=25 mothers, 27 infants 
Mean SD 
Gestational age at delivery (weeks) 38.70 1.07 
Birth weight (grams) 3239.40 480.56 
Maternal age (years) 35.84 3.52 
 % n 
Reason for delivery   
Prior Cesarean section 56 14 
Malpresenting fetus 24 6 
Maternal health condition 16 4 
Unknown 4 1 
Primipara Pregnancy 24 6 
1-Minute Apgar Score   
7 11.5 3 
8 29.6 8 
9 59.5 16 
Infant Sex   
Female 44.5 12 
Male 15.5 15 
Maternal Race   
American Indian/Native Alaskan 4 1 
Black or African American 20 5 
White 60 15 
Unknown 16 4 
Maternal Ethnicity   
Hispanic/Latino 16 4 
Not Hispanic/Latino 56 14 
Unknown 28 7 
 
 
3.3.2 Sex differences in maternal and neonatal hormone concentrations 
Means and standard deviations of maternal and cord blood testosterone and estradiol 
levels are presented in Table 3.2. When comparing mothers carrying a male fetus to mothers 
carrying a female fetus, no differences were found in maternal plasma estradiol or testosterone 
levels (Figure 3.1Figure 3.1 Sex differences in second trimester maternal hormone levels).  
Analyses of cord blood hormones revealed a significant sex difference in estradiol; 
female infants had significantly higher levels of estradiol in umbilical cord blood at birth 
compared to male infants (p = 0.02) (Figure 3.2). We did not find a significant sex difference in 
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umbilical cord blood testosterone levels; however, males had a higher testosterone to estradiol 
ratio than females (p = 0.02).  
 
 
Table 3.2 Mean values of cord blood and maternal blood testosterone and estradiol 
 Females (n=10) Males (n=15)  
 Mean (SD) Mean (SD) p-value 
Umbilical Cord Plasma    
Testosterone (ng/ml) 1.35 (.59) 1.06 (.79) >.05 
Estradiol (ng/ml) 3.87 (1.24) 2.5 (1.50) .03 
Maternal Plasma    
Testosterone (ng/ml) 1.05 (.58) .96 (.44) >.05 
Estradiol (ng/ml) 10.13 (3.51) 8.33 (2.94) >.05 




Figure 3.1 Sex differences in second trimester maternal hormone levels 
There were no significant sex differences in maternal estradiol or testosterone. (A) No 
sex difference in maternal estradiol. (B) No sex difference in maternal testosterone. 
Horizontal lines represent the mean. # significance at p <0.1; * significance at p > 0.05; 








Figure 3.2 Sex differences in cord blood hormone levels 
(A) Cord blood estradiol was significantly higher in females compared to males. (B) No sex 
difference in cord blood testosterone. Horizontal lines represent the mean. # significance at p 
<0.1; * significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 0.001, 
**** significance at p < 0.0001. 
 
3.3.3 Relationships between maternal and neonatal hormone concentrations in relation to 
fetal sex 
Maternal testosterone and estradiol levels were not significantly correlated with one 
another, regardless of infant sex (Figure 3.3). 
In males and females, testosterone and estradiol levels in cord blood at birth were highly 





Figure 3.3 Relationship between maternal testosterone and estradiol 
There is not a significant correlation between maternal testosterone (after square root 
transformation) and maternal estradiol during the second trimester. The solid black line 
represents the regression line. The gray shading represents the 95% confidence bands of 
the best-fit line. 
 
 
Figure 3.4 Relationship between cord blood testosterone and cord blood 
estradiol 
There is a positive correlation between cord blood testosterone (after square root 
transformation) and cord blood estradiol at birth. The solid black line represents the 





Comparing hormone levels across maternal and fetal measures, we found that maternal 
testosterone was positively correlated with cord blood estradiol (r(25) = 0.468, p = 0.018), but 
not cord blood testosterone (r(25) = 0.364, p= 0.07) (Figure 3.5). However, after performing a 
median split, a t-test with Welch’s correction revealed that cord blood testosterone was 
moderately higher in children born to women with testosterone levels above the sample median 
(p = 0.009, Figure 3.5). Maternal estradiol levels were positively correlated with both 
testosterone and estradiol levels in umbilical cord blood (r(25) = 0.437, p = 0.028; r(25) = 0.453, 





Figure 3.5 Relationships between maternal and cord blood hormone levels 
(A) Positive correlation between maternal testosterone and cord blood estradiol. (B) No 
relationship between maternal testosterone and cord blood testosterone (after square root 
transformation). (C) Cord blood testosterone is significantly higher in infants born to 
mothers with above the median level of second trimester circulating testosterone. (D) 
Positive correlation between maternal estradiol and cord blood estradiol. (E) Positive 
correlation between maternal estradiol and cord blood testosterone. The solid black line 
represents the regression line. The gray shading represents the 95% confidence bands of 




3.3.4 Aromatase (CYP19A1) and RORA mRNA expression in placenta tissue 
Expression of CYP19A1 was slightly higher in placentas of males compared to females (p 
= 0.06), but no significant sex differences were observed in RORA mRNA levels (Figure 3.6). In 
the overall sample and within each sex, there was a strong positive correlation between placental 
CYP19A1 and RORA mRNA expression (r(25) = 0.709, p= 0.000) (Figure 3.7).  
 
 
Figure 3.6 Sex differences in placental aromatase and RORA expression 
levels 
(A) Trending higher level of aromatase mRNA in female compared to male placentas (B) 
No sex difference in placental RORA mRNA. Horizontal lines represent the mean. # 
significance at p <0.1; * significance at p > 0.05; ** significance at p < 0.01, *** 





Figure 3.7 Correlation between placental aromatase and RORA 
Placental aromatase mRNA and RORA mRNA levels are significantly positively 
correlated. The solid black line represents the regression line. The gray shading 
represents the 95% confidence bands of the best-fit line. 
 
3.3.5 Placental RORA mediates the relationship between maternal and fetal hormones  
We first sought to determine the relationships between maternal and cord blood hormone 
levels and levels of CYP19A1 and RORA mRNA (Figure 3.8, Figure 3.9). CYP19A1 was 
significantly negatively correlated with cord blood estradiol levels (p = 0.02, r = -0.454) and this 
effect remained significant after controlling for infant weight at birth. RORA was weakly 
negatively correlated with cord blood estradiol levels (p = 0.06, r = -0.369), though this effect 
was non-significant after controlling for infant weight at birth.  
We categorized each infant into one of four groups based on maternal testosterone levels 
and placenta RORA and CYP19A1 mRNA levels. For each infant, we determined whether the 
maternal testosterone concentration was above or below the median value in our sample. 
Similarly, we determined whether the placental mRNA levels of RORA and CYP19A1 were 
above or below the median mRNA value for that gene in our sample. Based on our theoretical 
framework, we hypothesized that infants were most likely to have above median levels of 
testosterone in their cord blood sample if their mothers had above median maternal testosterone 
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levels and below median RORA or CYP19A1 mRNA levels. Infants in this category were 
expected to have the highest cord blood testosterone because their mothers had above median 
testosterone levels and thus, higher levels of bioavailable testosterone. Further, their placentas 
expressed below median levels of RORA and/or CYP19A1 mRNA and therefore, there was less 
potential for aromatization of maternal testosterone into estradiol. 
 
 
Figure 3.8 Relationships between placental aromatase expression and 
maternal and cord blood hormones 
(A) Placental aromatase mRNA is significantly negatively correlated with cord blood 
estradiol (B) No relationship between placental aromatase mRNA and cord blood 
testosterone (after square root transformation). (C) No relationship between aromatase 
mRNA and maternal estradiol (D) No relationship between placental aromatase mRNA 
and maternal testosterone. The solid black line represents the regression line. The gray 





Figure 3.9 Relationships between placental RORA expression and maternal 
and cord blood hormones 
(A) Placental RORA mRNA is almost significantly negatively correlated with cord blood 
estradiol (B) No relationship between placental RORA mRNA and cord blood 
testosterone (after square root transformation). (C) No relationship between RORA 
mRNA and maternal estradiol (D) No relationship between placental RORA mRNA and 
maternal testosterone. The solid black line represents the regression line. The gray 
shading represents the 95% confidence bands of the best-fit line.. 
 
We found that none of the infants in the low maternal testosterone/low CYP19A1 group 
had cord testosterone levels that exceeded the median value (Figure 3.10). Moreover, only three 
of the twelve infants (25%) whose mothers had low testosterone had above the median level of 
umbilical cord testosterone at birth. In contrast, ten of the thirteen infants (77%) whose mothers 
had high testosterone had above the median level of umbilical cord testosterone. Infants were 
most likely to have above the median level of cord blood testosterone if their mothers had high 
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testosterone and their placentas expressed below the median level of CYP19A1 mRNA. 
Two of the six infants in the low maternal testosterone/low RORA group had cord 
testosterone levels that exceeded the median value (Figure 3.11). Only three of the twelve 
infants whose mothers had low testosterone had above the median level of umbilical cord 
testosterone at birth. In contrast, ten of the thirteen infants (77%) whose mothers had high 
testosterone had above the median level of umbilical cord testosterone. None of the infants 
whose mothers had high testosterone and whose placentas expressed lower levels of RORA had 
cord blood testosterone levels below the median value in the sample. 
 
 
Figure 3.10 Cord blood testosterone by maternal testosterone/placental 
aromatase group 






Figure 3.11 Cord blood testosterone by maternal testosterone/placental 
RORA group 




This is the first study to empirically evaluate the potential regulatory role of placental 
aromatase in the relationship between maternal and fetal hormone levels. Further, this is the first 
study to measure RORA mRNA expression in the placenta. 
In our sample, cord blood estradiol levels were higher in female neonates compared to 
males, but sex difference in cord blood testosterone levels were not detected. Though the cause is 
not well-understood, there is significant inconsistency in the literature regarding sex differences 
in sex hormones measured in umbilical cord blood at birth (Hollier, Keelan, Hickey, Maybery, & 
Whitehouse, 2014). It has been widely reported that testosterone levels are higher in cord blood 
from male neonates (Herruzo et al., 1993; Keelan et al., 2012; Maccoby et al., 1979). Although 
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we did not find a sex difference in testosterone in this small sample, we did find that males had a 
higher testosterone to estradiol ratio in cord blood. Consistent with our finding, it has been 
reported that females have higher estradiol in cord blood compared to males (Anderson et al., 
2010). It has been reported that males have higher cord blood estradiol (Simmons, France, 
Keelan, Song, & Knox, 1994; van de Beek et al., 2004a), but the predominant finding is that 
there is not a sex difference in cord blood estradiol levels (Herruzo et al., 1993; Hill et al., 2014; 
Maccoby et al., 1979; Rebecca Troisi, Potischman, Roberts, Harger, et al., 2003; Rebecca Troisi, 
Potischman, Roberts, Siiteri, et al., 2003).  
We used several approaches to assess whether placental aromatase or RORA mediates the 
relationship between maternal and fetal hormones. Firstly, we measured the correlations between 
maternal and fetal testosterone and estradiol. We found that maternal testosterone was 
significantly positively correlated with cord estradiol, but not with cord testosterone. In support 
of our hypothesis that aromatase acts as a fetal barrier against maternal testosterone, the non-
significant relationship between maternal and fetal testosterone levels in concert with the highly 
significant association between maternal testosterone and fetal estradiol levels may reflect the 
aromatization of maternal testosterone into estradiol prior to reaching the fetus.  
We also categorized infants into one of four profiles based on a median split of maternal 
testosterone and a median split of RORA and CYP19A1 expression, respectively. Consistent with 
our hypothesis, we found that 77% of the infants in our “high risk” group whose mothers had 
above the median maternal testosterone levels and whose placentas expressed below the median 
levels of CYP19A1 or RORA had higher (above the sample median) testosterone levels in 
umbilical cord blood. 
Sathishkumar et al. (2012) found that aromatase expression is higher in male placentas 
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compared to female placentas. In our sample, we also found higher aromatase mRNA expression 
in male placentas, though the sex difference did not meet robust statistical significance. Three 
important differences in study design could explain our weaker sex difference in aromatase 
mRNA expression. Firstly, we exclusively enrolled women who were admitted for an elective 
cesarean section and who, therefore, were not in labor. Sathishkumar et al. did not specify the 
participants’ mode of delivery, so it is possible that the reported increased aromatase in males 
was related to decreased testosterone levels due to labor. Given the consistent finding that 
maternal testosterone decreases with advancing maternal age (Rebecca Troisi, Potischman, 
Roberts, Siiteri, et al., 2003), it is important to note that the mean maternal age of the participants 
in the study by Sathishkumar et al. is more than 10 years lower than the mean maternal age in 
our sample. Finally, Sathishkumar et al. calculated the relative aromatase mRNA levels against 
the housekeeping gene, GAPDH, which has been shown to have poorer expression stability than 
YWHAZ (Meller, Vadachkoria, Luthy, & Williams, 2005). 
A previous analysis of aromatase and RORA activity in post-mortem brain tissue revealed 
a significant positive correlation between the two genes (Hu et al., 2015). Additionally, they 
transfected isolated neuroblastoma cells with a plasmid vector in order to enhance the RORA 
transcript level in the cells. They found that the increase in RORA transcription was followed by 
an increase in aromatase transcription, suggesting that aromatase is a transcriptional target of 
RORA. In our study, we found a similar highly significant positive correlation between 
aromatase and RORA mRNA expression in human placenta tissue. This parallel finding supports 
the notion that the transcriptional regulatory relationship between RORA and aromatase is 
conserved across tissue types. 
Hu et al. (2015) reported that RORA mRNA expression was differentially regulated by 
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estradiol and dihydrotestosterone (DHT), such that RORA expression increased in neuroblastoma 
cells treated with estradiol and decreased in cells treated with DHT. In our analysis, we found 
that neither testosterone nor estradiol in the maternal circulation was associated with RORA 
expression. Surprisingly, cord blood estradiol levels were moderately negatively correlated with 
RORA expression in the placenta and cord blood testosterone levels were not associated with 
RORA expression. The lack of association between maternal/cord blood testosterone and RORA 
expression may indicate that androgen regulation of RORA is specific to DHT, which is 
enzymatically derived from testosterone through 5α-reductase, but is a far more potent agonist of 
the androgen receptor. It is interesting, however, that cord blood estradiol levels are negatively 
associated with RORA expression in the placenta in light of the finding that in vitro estradiol 
treatment increases RORA expression in neuroblastoma cells. Our study was limited by our 
ability to collect the cord blood and placental samples at only one time point. If we consider our 
data as a snapshot of a larger feedback cycle, it is possible that our measurements are reflecting a 
period of time in which RORA expression is low, allowing for increased transfer of maternal 
testosterone across the placenta. Through fetal aromatization, increased exposure to testosterone 
may result in elevated estradiol levels. This scenario could partially explain the negative 
correlational relationship between cord blood estradiol and placental RORA expression. 
There are several important limitations to the study presented here. Firstly, the sample 
size is very small, which makes it difficult to fully assess the complexities of the maternal-fetal-
placental system, which are undoubtedly under the influence of numerous obstetric, 
physiological, and psychosocial factors. Regarding the biological samples, we were limited in 
that we could not differentiate between venous and arterial blood in the umbilical cord. While 
most studies reporting sex hormone levels in umbilical cord blood collapse across the two 
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sources, it may be valuable to study them independently. Additionally, our radioimmunoassay 
protocol measured total testosterone and estradiol, rather than selectively measuring either the 
free or bound hormone. It would be valuable to also measure the levels of specific proteins, such 
as sex hormone binding globulin, to evaluate whether there are differences in free vs. bound 
hormone levels. A final limitation of the current study is that our analyses are primarily 
dependent on correlative relationships between variables, and given the probable complexities of 
the system, correlational studies may not be sufficient to fully understand the time course and 

















Chapter 4: The role of placental aromatase in regulating fetal 




  It has been widely postulated that the unique endocrine functions of the placenta regulate 
fetal exposure to maternal sex steroid hormones throughout pregnancy. While the placenta, itself, 
is a highly steroidogenic organ, specific enzymatic processes in the placenta are also thought to 
protect the fetus from sex hormones, specifically those of maternal origin. Aromatase 
(CYP19A1) is a highly expressed enzyme in the syncytiotrophoblast cells of the human placenta 
and is responsible for the conversion of bioavailable testosterone into estradiol. It is suggested 
that placental aromatization of maternal testosterone protects the fetus from exposure to high 
levels of maternal testosterone that would otherwise enter the fetal circulation (Edman, 
Toofanian, MacDonald, & Gant, 1981; Illingworth, Johnstone, Steel, & Seth, 1992; Kallak et al., 
2017; Kragie, 2002; Makieva, Saunders, & Norman, 2014). Elevated steroidogenic activity in 
amniotic fluid has been associated with autism-related behaviors in childhood, as well as several 
sub-clinical behavioral and physiological differences (Auyeung, Taylor, Hackett, & Baron-
Cohen, 2010; S. Baron-Cohen et al., 2015a; Simon Baron-Cohen et al., 2019; R. C. Knickmeyer 
& Baron-Cohen, 2006; S. Lutchmaya et al., 2004; Svetlana Lutchmaya et al., 2001). Non-
significant correlations between second trimester maternal testosterone and amniotic fluid 
testosterone has led many researchers to conclude that the mother does not contribute to the 
testosterone measured in amniotic fluid (van de Beek et al., 2004a). However, cord blood 
testosterone levels were also not significantly correlated with testosterone levels in amniotic 
fluid, pointing to a complex pathway of androgen transport and/or synthesis that may be 
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regulated by the placenta (van de Beek et al., 2004a). Therefore, this study aimed to further 
investigate whether the extent to which maternal testosterone contributes fetal androgen 
exposure is dependent on placental hormone regulation. In the previous chapter (Chapter 3), we 
found that maternal testosterone collected at birth was positively correlated with cord blood 
estradiol, but not testosterone. We interpreted this finding as an indication that placental 
aromatase actively converted maternal testosterone into estradiol, explaining the lack of 
association between maternal and neonatal testosterone levels. Moreover, we found that infants 
were more likely to have above the median level of cord blood testosterone if their mothers had 
above the median level of testosterone in the 3rd trimester and their placentas expressed below 
the median level of aromatase or RORA (see Chapter 3). These results were intriguing, but were 
limited by several methodological factors. The analyses presented in this chapter address many 
of those limitations. In Chapter 3, we collected maternal testosterone just prior to delivery. 
Given the previous literature, we are particularly interested in studying the influence of maternal 
testosterone during the second trimester – the period during which fetal steroidogenesis is 
highest and during which previous studies have collected amniotic fluid samples. In this chapter, 
we were able to analyze hormone concentrations in maternal blood samples collected during the 
second trimester between 16-21 weeks’ gestation. Our sample size was very small in Chapter 3, 
whereas this chapter includes data from a sample of 661 pregnancies that were enrolled as part of 
the Nulliparous-Mothers-to-be study (nuMoM2b). Unlike the participants recruited for Chapter 
3, these study participants were recruited in the first trimester of pregnancy and therefore, 
include vaginal and Cesarean-section deliveries, laboring and non-laboring deliveries, and a wide 
range of gestational ages at the time of delivery. Additionally, as part of the nuMoM2b study, 
detailed demographic and medical information was available. Therefore, we were able to 
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perform more in-depth analyses of the relationships between maternal and neonatal hormone 
concentrations and placental gene expression while taking into account numerous variables of 




Between 2010-2013, 8 participating clinical centers across the United States enrolled 
10,037 nulliparous women with singleton pregnancies into the Nulliparous Pregnancy Outcomes 
Study: Monitoring Mothers-to-be (nuMoM2b) study (Haas et al., 2015). To participate in the 
nuMoM2b study, nulliparous pregnant women were screened for eligibility during the 1st 
trimester. Eligible women were between 60-136 weeks of gestation based on an ultrasound 
crown-rump length measurement. Pregnant women were excluded if they had a prior pregnancy 
lasting 20 weeks’ gestation or more, were younger than 13 years of age, had a history of 3 or 
more spontaneous abortions, or if a likely fatal fetal malformation was identified during 
screening.  
Approximately 1,000 of the nuMoM2b study participants were enrolled at Columbia 
University Medical Center. Of these 1,000 participants, 661 met inclusion criteria to be included 
in the secondary analyses presented here. Mothers were eligible to participate in the secondary 
analyses if they participated in the original nuMoM2b study, delivered at the Columbia 
University Medical Center site, were fluent in English or Spanish, and were ≥ 18 years old at the 
time of enrollment in the nuMoM2b study. As part of the nuMoM2b study, participants were 
asked to provide a sample of maternal plasma during the second trimester, a sample of cord 
blood plasma at birth, and a sample of frozen placenta tissue at birth. Participants must have 
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provided all three of these samples in order to be included in these secondary analyses. Finally, 
to be included in the analyses presented here, mothers had to have provided written consent to 
the future use of their biological samples and written consent to be re-contacted by study staff. 
Data was requested for the 661 eligible infants. Upon receiving the data, one pregnancy was 
deemed ineligible due to intrauterine fetal demise. A complete consort diagram is presented in 
Figure 4.1. 
 
4.2.2 Maternal plasma collection 
Maternal plasma was collected between 160-216 weeks gestational age. Whole blood was 
collected by venipuncture into an EDTA-coated collection tube. Detailed methods are described 
elsewhere (see Chapter 2). 
 
4.2.3 Umbilical cord plasma collection 
Cord blood plasma was collected and processed within 30 minutes of the delivery of the 
placenta. At the time of delivery, the umbilical cord was clamped and study staff transported the 
whole placenta in a closed container to a laboratory for further processing. Detailed methods are 





Figure 4.1 Consort diagram 
*Eligible mothers participated in nuMoM2b study, delivered at Columbia University 
Medical Center site, were fluent in English or Spanish, were ≥ 18 years old at the time of 
enrollment in the nuMoM2b study, provided maternal plasma during the second 
trimester, provided cord blood plasma at birth, provided placenta tissue at birth, provided 





4.2.4 Placenta tissue collection 
After delivery, whole placentas were stored on ice and brought to the laboratory for 
further processing. Efforts were made to obtain placenta tissue within 30 minutes of delivery, but 
in some cases, placentas were stored on ice or in refrigerators at 4°C for up to 72 hours prior to 
processing. Placentas were rinsed in normal saline to remove blood clots and placed on a sterile 
hospital chuck with the fetal side of the placenta facing up. Using a punch biopsy or a scalpel, a 
piece of tissue (0.7 x 0.7 x 1cm or 8 mm x 1cm punch biopsy) was carefully dissected from the 
midpoint between the cord insertion and the edge of the placenta (Figure 4.2). The first 258 
samples (39%) were flash frozen in liquid nitrogen and stored at -80°C. The subsequent 401 
samples (61%) were stabilized in RNAlater (Invitrogen) for 48 hours and then stored at -80°C. 
Detailed methods are described elsewhere (see Chapter 2). 
 
 
Figure 4.2 Locations for collection of placenta and umbilical cord samples 




4.2.5 Sex hormone radioimmunoassay of maternal and umbilical cord plasma 
Total testosterone and estradiol radioimmunoassays were conducted using commercially 
available kits and standard procedures, described in Chapter 2, were followed. For the 
testosterone assays of the maternal plasma samples, the average intra-assay coefficient of 
variations (CV) and average lower limits of detectability (LLD) were 11.15% and 0.09 ng/ml, 
respectively (see Table 2.2, Chapter 2). For estradiol assays of the maternal plasma samples, the 
average intra-assay CVs and average LLDs were 13.72% and 9.07 pg/ml, respectively (see 
Table 2.2, Chapter 2). For the testosterone assays of the umbilical cord plasma samples, the 
average intra-assay coefficient of variations (CV) and average lower limits of detectability 
(LLD) were 16.48% and 0.10 ng/ml, respectively (see Table 2.2, Chapter 2). For estradiol 
assays of the umbilical cord plasma samples, the average intra-assay CVs and average LLDs 
were 8.51% and 8.12 pg/ml, respectively (see Table 2.2, Chapter 2). Samples that were below 
detection (e.g. <0.08) were assigned the value of the lowest level of detectability. 
 
4.2.6 Aromatase (CYP19A1) and RORA gene expression assays in placenta tissue 
30 mg sections of placental tissue were dissected and homogenized in 700μl lysis buffer 
RLTplus (Qiagen) with 1% β-mercaptoethanol using a tissue homogenizer (Omni) for 15 
seconds. RNA and DNA were extracted using the Qiagen All Prep DNA/RNA Mini Kit. cDNA 
was generated using the SuperScript III Reverse Transcriptase kit (ThermoFisher). Relative gene 
expression was measured using real-time quantitative PCR (RT-qPCR) on a 96-well 7500 Fast 
qPCR machine (Applied Biosystems) using Fast SYBR Green Master Mix. We calculated 
relative gene expression of CYP19A1 (forward: GCGCAAAGCCTTAGAAGATG, reverse: 
CAAAGCCAAATGGCTGAAAG) and RORA (forward: TCATGGCTGCAAGAAAAGGT, 
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reverse: GAGGAAAATGAAGTCGCACAA) using YWHAZ (forward: 
GACGTCCCTCAAAACTTGCT, reverse: GCCAGTTTGGCCTTCTGAAC) as a control gene. 
Due to variability in placenta collection, we excluded 251 samples with RNA concentrations 
<100ng/ul as measured by a spectrophotometer. As an additional quality control measure, we 
excluded samples with Ct values that were equal to or greater than 35. Thus, we had high quality 
gene expression data for 353 subjects. Maternal age was significantly higher in participants 
whose placentas were included compared to those that were excluded, but there were no other 
differences in maternal, paternal, or infant demographic and health variables. Since this study 
does not involve a control group, we calculated the 2-ΔΔCt using females as the reference group. 
We excluded samples from analyses that were identified as outliers using Grubbs’ test for 
outliers (Grubbs, 1969). 
 
4.2.7 Statistical analyses 
 Statistical analyses were conducted using R and SPSS software. Maternal testosterone, 
cord blood testosterone, placental aromatase expression, and placental RORA expression values 
were positively skewed and 1-minute Apgar scores, neonatal head circumference, and infant 
gestational age were negatively skewed, so they were square root transformed prior to statistical 
analysis. We examined several covariates relating to parental characteristics, the course of the 
pregnancy, and neonatal outcomes. Variables that were a priori identified as potential covariates 
included maternal age at delivery, paternal age at delivery, maternal education, paternal 
education, annual family income, infant gestational age at birth, infant birth weight, 1-minute 
Apgar scores, and neonatal head circumference. Specifically, analyses of bivariate correlations 
between continuous covariates and the primary dependent and independent variables, which 
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included the maternal hormone variables, cord blood hormone variables, and placental gene 
expression variables, were conducted. We also performed Welch’s two sample t-tests to 
determine whether any of our variables of interests differed by mode of delivery, labor onset, and 
sex of the infant. Candidate covariates were included in the adjusted linear models if they were 
associated with both the dependent and independent variables at a significance level of 0.1.  
 
4.3 Results 
4.3.1 Sample characteristics 
 Demographic and medical information for infants and their mothers were provided by the 
NuMoM2b data management center and are provided in Table 4.1. The average maternal age at 
delivery was 28.26 years (range 17.00 – 43.00 years) and the average paternal age at delivery 
was 30.75 years (range 17.00 – 64.00 years, median 31.00 years). Detailed information regarding 
participants’ race was unavailable. 60.7% of the mothers self-identified as being Hispanic/Latino 
and 56.8% of the fathers self-identified as being Hispanic/Latino. The primary reasons for 
delivery, in order of prevalence, were: labor onset (n = 337), rupture of membranes (n = 77), post 
due-date (n = 62), a maternal condition (n = 52), convenience (n = 49), oligohydramnios (n = 
43), abnormal fetal testing (n = 22), a fetal condition (n = 8), intrauterine growth restriction (n = 
6), abruptio placenta (n = 2), unknown reasons (n = 2), and polyhydramnios (n = 1). 34.4% of the 
infants were delivered by Cesarean section (C-section). The majority of C-section deliveries 
were unscheduled and urgent (n = 127), followed by unscheduled and non-urgent (n = 60) and 
scheduled (n = 39). In three cases, details regarding the C-section delivery were unavailable. The 
average gestational age at delivery was 39.3 weeks (range 25.3 – 42.1 weeks, median 39.5 
weeks), with an average birth weight of 3287 grams (range 610 – 4855 grams, median 3305 
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grams). In this study sample, there were 313 female infants and 347 male infants. We performed 
statistical analyses to determine whether maternal and cord blood hormone concentrations and 
placental gene expression was affected by any demographic and pregnancy-related variables 
including infant sex, labor onset, and mode of delivery. The results of these analyses are 























Table 4.1 Study sample characteristics 
 
Characteristics 
Total n = 661 
Mean SD 
Gestational age at delivery (weeks) 39.3 1.76 
Birth weight (grams) 3287.40 516.98 
Infant head circumference (cm) 33.97 1.70 
Maternal age (years) 28.26 6.03 
Paternal age (years) 30.75 7.28 
 % n 
Infant sex (male) 52 347 
Cesarean section 34.4 228 
Laboring delivery 91.2 603 
Reason for delivery   
Abnormal fetal testing 3.3 22 
Placental abruption 0.3 2 
Convenience 7.4 49 
Fetal health condition 1.2 8 
Intrauterine growth restriction (IUGR) 0.9 6 
Labor onset 50.1 337 
Maternal health condition 7.8 52 
Oligohydramnios 6.5 43 
Rupture of membranes 11.6 77 
Polyhydramnios 0.15 1 
Post due-date 9.4 62 
Unknown 0.6 2 
Maternal hypertensive disorder 14.9 99 
Maternal diabetes   
None 95.0 628 
Before pregnancy 0.7 5 
During pregnancy 3.9 26 
Unknown 0.3 2 
Maternal Education   
No high school degree 6 43 
High school degree 13.7 91 
Some college, no degree 21.4 142 
College degree 21.5 142 
Graduate/professional degree 36.4 241 
Refused 0.3 2 
Maternal ethnicity (Hispanic/Latino) 60.7 401 
Paternal ethnicity (Hispanic/Latino) 56.8 376 
Annual household income   
< $50,000 22.2 147 
$50,000 - $99,999 15.4 102 
$100,000 - $199,999 18.1 120 
 $200,000 12.4 82 





4.3.2 Sex hormone concentrations in maternal and cord blood plasma 
 The overall and sex-stratified descriptive statistics for testosterone and estradiol measured 
in maternal and cord blood are presented in Table 4.2. The mean cord blood testosterone levels 
in the overall sample, in females, and in males were 1.74 ng/ml, 1.79 ng/ml, and 1.69 ng/ml, 
respectively. The mean cord blood estradiol levels in the overall sample, in females, and in males 
were 6511 pg/ml, 6694 pg/ml, and 6344 pg/ml, respectively. The mean maternal testosterone 
levels in the overall sample, in females, and in males were 0.62 ng/ml, 0.63 ng/ml, and 0.62 
ng/ml, respectively. The mean maternal estradiol levels in the overall sample, in females, and in 
males were 3917 pg/ml, 3978 pg/ml, and 3862 pg/ml, respectively. 
 
Table 4.2 Descriptive statistics of cord blood and maternal blood testosterone and estradiol measurements 
 
4.3.3 Correlations between maternal and infant steroid hormones 
 Maternal testosterone and maternal estradiol levels in the overall sample and within each 
sex were significantly positively correlated, though the effect was greater among women 
carrying a male fetus (overall: r(637) = 0.342, p < 0.0001, males: r(333) = 0.398, p < 0.0001, 
females: r(302) = 0.284, p < 0.0001) (Figure 4.3A).  
 Umbilical cord blood testosterone was significantly positively correlated with umbilical 
cord blood estradiol in the overall sample and within each sex. (overall: r(656) = 0.535, p < 
 Overall  Females  Males 
 n Mean (SD)  n Mean (SD)  n Mean (SD) 
Cord Blood Plasma         
Testosterone (ng/ml) 659 1.74 (1.27)  312 1.79 (1.42)  347 1.69 (1.12) 
Estradiol (pg/ml) 659 6511 (3405)  313 6694 (3455)  346 6344 (3356) 
Maternal Plasma         
Testosterone (ng/ml) 657 0.62 (0.51)  311 0.63 (0.53)  346 0.62 (0.48) 
Estradiol (pg/ml) 642 3917 (1482)  306 3978 (1509)  336 3862 (1456) 
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0.0001, males: r(344) = 0.555, p < 0.0001, females: r(310) = 0.515, p < 0.0001) (Figure 4.3B).  
 
Figure 4.3 Relationships between testosterone and estradiol from maternal 
and cord blood samples 
(A) Maternal testosterone (square root transformed) is significantly positively correlated 
with maternal estradiol during the second trimester. (B) Cord blood testosterone (square 
root transformed) is significantly positively correlated with cord blood estradiol at birth. 
Solid black lines represents the regression line and dashed black lines represent the 95% 









We performed Pearson correlation tests to determine the relationship between maternal 
and infant hormone measures. Maternal testosterone during the second trimester was positively 
correlated with umbilical cord blood testosterone at birth in the overall sample and within each 
sex (overall: r(654) = 0.204, p < 0.0001, males: r(344) = 0.281, p < 0.0001, females: r(308) = 
0.132, p = 0.019) (Figure 4.4). After performing a stepwise linear regression that included 
parental age at delivery, gestational age at birth, neonatal head circumference, and 1-minute 
Apgar scores in the model, maternal testosterone and gestational age at birth were the only 
significant predictors of cord blood testosterone (Table 4.3). Maternal testosterone during the 
second trimester was moderately positively correlated with umbilical cord blood estradiol at birth 
in the overall sample and within each sex (overall: r(654) = 0.193, p < 0.0001, males: r(343) = 
0.231, p < 0.0001, females: r(309) = 0.154, p = 0.006) (Figure 4.4). Maternal estradiol during 
the second trimester was weakly positively correlated with umbilical cord blood testosterone at 
birth in the overall sample and in males, alone (overall: r(639) = 0.126, p = 0.001, males: r(334) 
= 0.153, p = 0.004, females: r(303) = 0.099, p = 0.082) (Figure 4.5). Maternal estradiol during 
the second trimester was weakly positively correlated with umbilical cord blood estradiol at birth 
in the overall sample and within each sex (overall: r(639) = 0.24, p < 0.0001, males: r(333) = 




Figure 4.4 Relationship between second trimester maternal blood and cord 
blood hormones 
(A) Maternal testosterone (square root transformed) is significantly positively correlated 
with cord blood testosterone (square root transformed). (B) Maternal testosterone (square 
root transformed) is significantly positively correlated with cord blood estradiol. Solid 
black lines represents the regression line and dashed black lines represent the 95% 
confidence bands of the best-fit line. 
 
Table 4.3 Stepwise linear regression model for maternal testosterone and cord blood testosterone 
  B SE B  t p 
Model 1 Sex (male) 0.03 0.04 0.04 0.88 0.38 
Maternal age -0.01 0.00 -0.11 -1.89 0.06 
Paternal age 0.00 0.00 0.04 0.63 0.53 
Head circumference 0.00 0.01 0.02 0.35 0.73 
1-minute Apgar -0.03 0.02 -0.07 -1.69 0.09 
Gestational age 1.6 0.10 0.14 2.86 0.00 
Maternal testosterone (ng/ml) 0.31 0.07 0.20 4.63 0.00 
       
Model 2 Maternal age -0.01 0.00 -0.11 -1.86 0.06 
 Paternal age 0.00 0.00 0.02 0.43 0.67 
 Maternal testosterone (ng/ml) 0.27 0.07 0.17 4.13 0.00 
Model 1: Covariates were associated with either the dependent or independent variables 





Figure 4.5 Relationships between second trimester maternal estradiol and 
cord blood hormones 
(A) Maternal estradiol is significantly positively correlated with cord blood testosterone 
(square root transformed). (B) Maternal estradiol is significantly positively correlated 
with cord blood estradiol. Solid black lines represents the regression line and dashed 
black lines represent the 95% confidence bands of the best-fit line. 
 
4.3.4 Placental expression of aromatase and RORA at birth 
The overall and sex-stratified descriptive statistics for aromatase and RORA expression in 
the placenta are presented in Table 4.4. The mean relative aromatase mRNA expression in the 
overall sample, in female placentas, and in male placentas was 1.63, 1.67, and 1.61, respectively. 
The mean relative RORA mRNA expression in the overall sample, in female placentas, and in 
male placentas was 1.53, 1.52, and 1.56, respectively. 
 
Table 4.4 Descriptive statistics of aromatase and RORA expression in the placenta 
 
In contrast to our finding from a previous study (Chapter 3), aromatase and RORA 
mRNA expression in the placenta were very weakly positively correlated in the overall sample 
 Overall  Females  Males 
 n Mean (SD)  n Mean (SD)  n Mean (SD) 
Aromatase mRNA 353 1.63 (1.88)  164 1.67 (1.87)  189 1.61 (1.90) 
         
RORA mRNA 353 1.53(1.76)  168 1.52 (1.75)  185 1.56 (1.76) 
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(r(309) = 0.10, p =0.08) (Figure 4.6).  
 
 
Figure 4.6 Correlation between relative aromatase and RORA mRNA in 
the human placenta 
No correlation between placental aromatase and RORA expression was found. Gene 
expression values have been square root transformed. Solid red lines represents the 
regression line and dashed red lines represent the 95% confidence bands of the best-fit 
line. 
 
4.3.5 The effects of maternal testosterone on cord blood hormones are partially moderated 
by placental aromatase and RORA expression 
 An unadjusted and adjusted linear regression indicated a significant effect of second 
trimester maternal testosterone on umbilical cord blood testosterone at birth (p < 0.000). To 
assess whether the effect of maternal testosterone on cord blood testosterone was dependent on 
placental aromatase expression, we included aromatase as a covariate in the model. In the overall 
sample, there was not a main effect of aromatase expression on cord blood testosterone, nor did 
it significantly impact the main effect of maternal testosterone on cord blood testosterone, though 
the adjusted R2 increased from 0.04 to 0.08. Only among male infants, the linear regression 
revealed a significant effect of maternal testosterone and a marginally significant effect of 
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placental aromatase (p = 0.06) on cord blood testosterone. We also performed a median split 
analysis of aromatase (low aromatase = below the sample median aromatase expression; high 
aromatase = equal to or above the sample median aromatase expression). There was not a main 
effect of high versus low aromatase on cord blood testosterone in the overall sample or within 
each sex. As a covariate in the model, there was not a significant interaction effect of the binary 
aromatase variable and maternal testosterone on cord blood testosterone. 
To determine whether the effect of maternal testosterone on cord blood testosterone was 
dependent on placental RORA expression, we similarly included RORA as a covariate in the 
model. There was not a main effect of RORA mRNA expression on cord blood testosterone 
including it in the model did not significantly impact the main effect of maternal testosterone on 
cord blood testosterone. The adjusted R2 increased from 0.04 to 0.08. We also performed a 
median split analysis of RORA expression (low RORA = below the sample median RORA 
expression; high RORA = equal to or above the sample median RORA expression) and included 
the binary RORA variable as an interaction term in the model. There was not a main effect of 
high versus low RORA expression on cord blood testosterone, nor was there a significant 
interaction effect of RORA expression and maternal testosterone on cord blood testosterone. 
Infants were categorized into four hormonal exposure groups based on maternal 
testosterone levels and aromatase expression in the placenta. For each infant, we determined 
whether the maternal testosterone value was below (low maternal testosterone) versus equal to or 
greater than (high maternal testosterone) the median value in our sample. Similarly, we 
determined whether the placental aromatase expression value was below (low aromatase) versus 
equal to or greater than (high aromatase) the median value in our sample. Based on our 
theoretical framework and the preliminary results presented in Chapter 3, we hypothesized that 
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cord blood testosterone concentrations would be highest among infants who were born to 
mothers who had high maternal testosterone and low placental aromatase expression. Thus, the 
four groups, in order from lowest to highest expected impact on cord blood testosterone were: 1) 
low maternal testosterone + high aromatase, 2) low maternal testosterone + low aromatase, 3) 
high maternal testosterone + high aromatase, 4) high maternal testosterone + low aromatase. We 
performed a one-way analysis of variance (ANOVA) using a two-sided 0.05 level of significance 
to determine whether the mean cord blood testosterone concentration differed across the four 
groups. The results are presented in Table 4.5.  
 
Table 4.5 One-way ANOVA of maternal testosterone and placental aromatase on cord blood hormones 

















 Mean  SD Mean  SD Mean  SD Mean  SD   












There was a statistically significant difference in cord blood testosterone between the 
maternal testosterone/aromatase groups as determined by the one-way ANOVA (F(3, 346) = 
5.15, p = 0.002). Tukey’s post-hoc test was applied to identify how the groups differed from one 
another. The post-hoc analysis revealed that the two low maternal testosterone groups (groups 1 
and 2) did not differ from one another, nor did the two high maternal testosterone groups (groups 
3 and 4) (Figure 4.7, Table 4.5). Cord blood testosterone was significantly lower in infants in 
the low maternal testosterone + high aromatase group (group 1) compared to infants in the high 
maternal testosterone + low aromatase group and in the high maternal testosterone + high 
aromatase group (group 3 and group 4) (p = 0.02 and p = 0.01, respectively) (Figure 4.7, Table 
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4.5). We found that this effect was sex-dependent such that the combined effect of maternal 




Figure 4.7 One-way ANOVA of the effect of maternal testosterone and 
placental aromatase on cord blood testosterone 
(A) Male infants with low maternal testosterone + high placental aromatase mRNA have 
lower cord blood testosterone compared to infants of mothers with high maternal 
testosterone. (B) There were no significant differences among female infants. Horizontal 
lines represent the mean. # significance at p <0.1; * significance at p > 0.05; ** 
significance at p < 0.01, *** significance at p < 0.001, **** significance at p < 0.0001. 
 
This procedure was repeated for RORA expression and again, we found that there was a 
statistically significant difference in cord blood testosterone between the groups as determined 
by the one-way ANOVA (F(3, 346) = 5.96, p = 0.001). Tukey’s post-hoc test was applied to 
identify how the groups differed from one another. The post-hoc analysis revealed that the two 
low maternal testosterone groups (groups 1 and 2) did not differ from one another, nor did the 
two high maternal testosterone groups (groups 3 and 4) (Figure 4.8, Table 4.6). Cord blood 
testosterone was significantly lower in infants in the low maternal testosterone + high RORA  
group (group 1) compared to both the high maternal testosterone + high RORA group (group 3) 
and the high maternal testosterone + low RORA group (group 4) (p = 0.002, p = 0.004, 
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respectively) (Figure 4.8, Table 4.6). Again, this effect was only observed in male infants.  
 
 
Figure 4.8 One-way ANOVA of the effect of maternal testosterone and 
placental RORA on cord blood testosterone 
(A) Male infants with low maternal testosterone + high placental RORA mRNA have lower 
cord blood testosterone compared to infants of mothers with high maternal testosterone. (B) 
There were no significant differences among female infants. Horizontal lines represent the 
mean. # significance at p <0.1; * significance at p > 0.05; ** significance at p < 0.01, *** 
significance at p < 0.001, **** significance at p < 0.0001. 
 
 
Table 4.6 One-way ANOVA of maternal testosterone and placental RORA on cord blood hormones 













 Mean  SD Mean  SD Mean  SD Mean  SD   
Testosterone 1.11  0.43 1.19  0.38 1.33  0.42 1.32  0.49 5.96 0.001 
Estradiol 5255  3123 6147  3026 7749  3672 6677  3352 8.81 0.000 
 
As a secondary analysis, we applied the same procedure to determine group differences 
in cord blood estradiol concentrations in relation to maternal testosterone and placental 
aromatase expression. There was a statistically significant difference in cord blood estradiol 
between the groups as determined by the one-way ANOVA (F(3, 346) = 5.24, p = 0.002). 
Tukey’s post-hoc test was applied to identify how the groups differed from one another. The 
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post-hoc analysis revealed that the two low maternal testosterone groups (groups 1 and 2) did not 
differ from one another, nor did the two high maternal testosterone groups (groups 3 and 4) 
(Figure 4.9, Table 4.5). Infants in both the low maternal testosterone + high aromatase group 
(group 1) and the low maternal testosterone + low aromatase group (group 2) were significantly 
different from infants in the high maternal testosterone + low aromatase group (group 4) (p = 
0.002 and p = 0.01, respectively) (Figure 4.9, Table 4.5). When we stratified the analysis by sex, 
these effects were only observed in male infants. 
 
 
Figure 4.9 One-way ANOVA of the effect of maternal testosterone and 
placental aromatase on cord blood estradiol 
(A) Male infants with low maternal testosterone + high placental aromatase mRNA have 
lower cord blood estradiol compared to infants of mothers with high maternal 
testosterone + low placental aromatase. (B) There were no significant differences among 
female infants. Horizontal lines represent the mean. # significance at p <0.1; * 
significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 0.001, **** 
significance at p < 0.0001. 
 
When evaluating the combined effect of maternal testosterone and RORA, there was a 
statistically significant difference in cord blood estradiol between the groups as determined by 
the one-way ANOVA (F(3, 347) = 8.81, p = 0.000). Tukey’s post-hoc test was applied to 
identify how the groups differed from one another. The post-hoc analysis revealed that the two 
low maternal testosterone groups (groups 1 and 2) were not significantly different from one 
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another and the two high maternal testosterone groups (groups 3 and 4) were not significantly 
different from one another (Figure 4.10, Table 4.6). Infants in the low maternal testosterone + 
high RORA group (group 1) had significantly lower estradiol levels compared to infants in both 
of the high maternal testosterone groups (group 3 and group 4) (p = 0.000 and p = 0.03, 
respectively) (Figure 4.10). Infants in the low maternal testosterone + low RORA group (group 
2) also had significantly lower estradiol levels compared to infants in the high maternal 
testosterone + high RORA group (group 3) (p = 0.01). Though present in both sexes, the effect 
was more robust among male infants. 
 
 
Figure 4.10 One-way ANOVA of the effect of maternal testosterone and 
placental RORA on cord blood estradiol 
(A) Male infants with low maternal testosterone + high placental RORA mRNA have 
lower cord blood estradiol compared to infants of mothers with high maternal 
testosterone. (B) Female infants with low maternal testosterone + high placental RORA 
mRNA and those with low maternal testosterone + low placental RORA mRNA have 
lower cord blood estradiol compared to infants of mothers with high maternal 
testosterone and high RORA mRNA . Horizontal lines represent the mean. # significance 
at p <0.1; * significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 
0.001, **** significance at p < 0.0001. 
 
4.4 Discussion 
This study presents data from a large sample of demographically and medically diverse 
nulliparous women. Here, we sought to replicate previous reports and to further elucidate the 
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relationship between maternal and fetal hormones with regard to placental hormone regulation. 
Few studies have prospectively recruited nulliparous women, making this population 
underrepresented in the literature. The study sample is also unique demographically; maternal 
ethnicity is highly diverse and the average maternal age is significantly higher than that of many 
other study samples. Our findings both support and contrast previously reported relationships 
between demographic and health characteristics, maternal and infant hormonal profiles, and 
placental expression of sex steroid-related genes. Fundamental differences between previous 
studies and the one presented here, in addition to important methodological limitations, may 
explain some of the unexpected discrepancies.  
An important consideration when interpreting the data from the nuMoM2b study sample 
is the significant time lapse between when the maternal blood samples were collected and when 
the cord blood and placenta samples were collected. Typically, the maternal blood sample was 
collected between 19 and 24 weeks before the cord blood and placenta samples were collected. It 
is well documented that maternal hormones fluctuate and change dramatically over the course of 
pregnancy (Kuijper, Ket, Caanen, & Lambalk, 2013). By the second trimester, the fetus is also 
independently able to produce and secrete endogenous testosterone. An analysis of fetal plasma 
testosterone between the 16th-20th week of gestation compared to samples collected at term 
suggests that testosterone levels in male fetuses peak during the second trimester and gradually 
decrease until birth (Abramovich & Rowe, 1973b; J. A. Finegan, Bartleman, & Wong, 1989b; 
Reyes et al., 1973; Shigeo et al., 1977). The placenta also remains a source of endogenous 
estradiol throughout the pregnancy and evidence suggests that aromatase activity in the placenta 
increases across gestation, reflected by a rise in relevant steroid hormone ratios (e.g. 
estradiol:testosterone, estrone:androstenedione) (Hill et al., 2010, 2014). Taken together, it is 
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clear that the hormonal milieu during pregnancy is complex and highly-dependent on timing. 
Given that we compared maternal hormone levels during the second trimester to neonatal 
hormone levels at term-age, it is difficult to draw definitive conclusions about the role of the 
placenta in regulating fetal exposure to maternal hormones at a specific time point during 
pregnancy.  
It is also important to carefully consider the source of the hormone measurement. In this 
study, umbilical cord blood was taken from both the umbilical vein and the umbilical arteries. 
Numerous studies have collapsed across venous and arterial blood samples and strong 
correlations between steroid hormones, including estradiol and testosterone, collected separately 
from the umbilical vein and arteries have been demonstrated (Hill et al., 2014). However, higher 
levels of estrogens are measured in blood from the umbilical vein compared to the umbilical 
arteries. Since cord blood was not sampled equally across the umbilical vein and arteries, it 
raises some concern about the interpretability of the data. Finally, due to methodological 
restrictions, we were unable to control for diurnal fluctuations in maternal testosterone and 
estradiol, which have been shown to decrease from morning to evening (Panico et al., 1990). 
 In this study, we exclusively measured total testosterone and total estradiol. This is an 
important limitation because steroid hormones are only able to exert classical or genomic actions 
in the unconjugated form. In humans, sex hormone-binding globulin (SHBG), a plasma 
glycoprotein, binds to androgens and estrogens with very high affinity, acting as a transporter 
and thus, rendering the steroid hormone biologically inactive. SHBG levels are detectable in fetal 
blood and amniotic fluid as early as the 13th week of gestation and correlate closely with 
testosterone levels (Hammond, 2011). SHBG levels continue to increase during mid to late 
gestation across both sexes. It has been purported that SHBG during fetal development may 
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protect females from exposure to high levels of testosterone. In rodents, alpha-fetoprotein (AFP) 
binds to estradiol and is believed to serve a similar protective function. The role of AFP in 
protecting females from high exposure to androgens has not been demonstrated in humans. 
Therefore, the function of SHBG may be redundant in non-human mammals, but it likely carries 
out critical neuroprotective effects in humans. The radioimmunoassay used in our study 
disregards the bioavailability of the measured testosterone and may have prevented us from 
detecting differences (e.g. between males and females) in the potential for steroid-mediated 
cellular and genomic changes and downstream effects. 
With regard to total hormone concentrations, we did not find a sex difference in 
testosterone or estradiol in the maternal blood or cord blood samples, which is consistent with 
some previous reports (Dawood & Saxena, 1977; McIntyre, 2006; Nabi et al., 2014; Rodeck et 
al., 1985; van de Beek et al., 2004a). All of the mothers in our study were first-time mothers, an 
obstetric variable that is often ignored in the literature. In multigravida, pregnancy-induced 
hormonal changes may result in long-term effects that carry over to subsequent pregnancies, 
amplifying sex differences in hormone levels. It would be interesting to determine whether sex 
differences in maternal and infant hormone levels are contingent on parity and the sex of any 
prior pregnancies. Contrary to previous studies, we found that labor did not affect cord blood 
estradiol or testosterone levels (Hickey et al., 2014; Keelan et al., 2012; Mathur et al., 1980). 
Again, this may be explained by the fact that this sample was exclusively comprised of 
nulliparous women. In this sample, the large majority (93%) received an anesthetic intervention, 
which could have affected hormonal activity during labor. 
We performed several bivariate correlations both between and within maternal and fetal 
hormone levels. In this sample, maternal estradiol was positively correlated with cord blood 
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estradiol, most likely due to the direct transfer of maternal estradiol across the placenta. Maternal 
estradiol was also correlated with cord blood testosterone. Though we cannot assess these 
explanations directly, it is possible that this relationship is a reflection of elevated fetal adrenal 
activity, which could result in increased placental estrogen production and increased flow of 
estrogen into the maternal circulation. 
We found a highly significant positive correlation between cord blood testosterone and 
estradiol. The conversion of radiolabeled testosterone to estrogen was demonstrated in fetal 
ovaries, liver, and brain and placental aromatase is highly expressed by early to mid-gestation, so 
this relationship likely reflects fetal and/or placental aromatase activity (Doody & Carr, 1989). 
Maternal testosterone was positively correlated with cord blood testosterone. This is 
likely explained by either 1) direct transfer of maternal testosterone to the fetus via the placenta 
or 2) an inherited genetic predisposition. In the current study, we have not been able to 
demonstrate a robust mediating effect of placental aromatase on the transfer of maternal 
testosterone to the fetus, therefore, it is plausible that maternal testosterone freely crosses the 
placenta and reaches fetal circulation.  
We hypothesized that maternal testosterone would be highly correlated with cord blood 
estradiol and that this relationship would reflect placental aromatase activity. We found that, as 
expected, maternal testosterone was significantly positively correlated with cord blood estradiol 
levels, which supports the hypothesis that placental aromatase may convert maternal testosterone 
into estradiol prior to reaching the fetus. However, contrary to our hypothesis, the relationship 
between maternal testosterone and cord blood estradiol was neither directly mediated nor 
moderated by placental aromatase mRNA. We found that after including aromatase and RORA 
expression levels as predictor variables along with maternal testosterone, maternal testosterone 
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remained the only significant predictor of cord blood testosterone and estradiol. In our 
hypothesized model of risk (defined as elevated cord blood testosterone), we expected there to be 
an additive effect of high maternal testosterone and low placental aromatase on cord blood 
testosterone levels. We found a main effect of 2nd trimester maternal testosterone on cord blood 
testosterone, but neither aromatase nor RORA were significantly associated with cord blood 
testosterone. However, in considering the percent of infants in each category with cord blood 
testosterone levels exceeding the median level of the sample, subtle effects of placental 
aromatase and RORA become apparent. 61.5% of infants exposed to high maternal testosterone 
and low placental aromatase compared to only 37.6% of infants exposed to low maternal 
testosterone and high placental aromatase had testosterone levels exceeding the median. It is 
notable that the statistically significant differences in cord blood testosterone across the four 
exposure groups was only observed in males. Considering previous reports that elevated 
steroidogenic activity in amniotic fluid is associated with autism and our finding of male 
susceptibility to the effects of maternal testosterone and placental aromatase/RORA may partially 
explain the sex bias observed in autism and other neurodevelopmental disorders. 
In light of our finding that placental aromatase and RORA are not primary predictors of 
cord blood testosterone, a possible alternative explanation for the correlation between maternal 
and cord blood testosterone is a heritable genetic predisposition for expression of CYP17A1 
which encodes for the P450c17 cytochrome. The fetal zone of the adrenal cortex begins to 
express P450c17 by the 10th week of gestation and is responsible for the synthesis of 
dehydroespiandrosterone (DHEA) and DHEA-S from cholesterol and other androgen precursors 
(Kaludjerovic & Ward, 2012). The fetal adrenal gland also expresses the 3-hydroxysteroid 
dehydrogenase (3-HSD) enzyme that converts DHEA into androstenedione, the precursor for 
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testosterone. Therefore, maternal circulating testosterone may be indicative of genetic regulation 
of androgen synthesis that is shared by both mother and fetus.  
Given the widely discussed supposition that placental aromatase acts as a fetal barrier 
against maternal testosterone, we expected to detect a more robust direct effect of aromatase 
expression on cord blood testosterone and estradiol levels. However, it is important to consider 
potential timing-dependent and tissue-dependent effects that could not be addressed by this 
study. With regard to timing effects of the interplay between placental aromatase and fetal 
testosterone, it is possible that aromatase activity in the placenta during the second trimester (not 
measured here) may play a larger role in protecting the fetus against maternal testosterone. To 
determine the regulatory function of placental aromatase earlier in pregnancy, it would be 
advantageous to conduct this investigation in a cohort of preterm infants.  
Our hypothesis that placental aromatase would be associated with maternal or neonatal 
testosterone levels was based on literature focused on brain tissue. However, even within the 
brain, aromatase is not distributed equally (Charles E. Roselli, Horton, & Resko, 1985) and the 
co-localization and regulatory function of androgen receptors on aromatase activity is not 
necessarily conserved across all mammalian species (Charles E. Roselli, 1991). Steroid 
regulation of aromatase has been widely observed in brain regions involved in sexual behavior 
and reproductive physiology, such as the hypothalamus and amygdala, but aromatase activity is 
less regulated by steroid hormones in hippocampal brain regions (Charles E. Roselli, Liu, & 
Hurn, 2009). In adult male rats, castration results in a significant reduction in aromatase activity 
in the preoptic area of the hypothalamus and subsequent administration of testosterone reverses 
this effect and causes a robust increase in aromatase activity (Charles E. Roselli & Resko, 1984). 
Administering a nonsteroidal antiandrogen reduced aromatase activity in the hypothalamus and 
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blocked the upregulation of aromatase even in the presence of testosterone administration, 
suggesting that aromatase activity is regulated by androgen receptors in the brain. However, in a 
non-human primate model, effects of castration or testosterone administration on brain aromatase 
activity have not yet been observed (C. E. Roselli & Resko, 1986), but it has been shown that 
androgens down-regulate RORA activity in human neuronal cells, which can have downstream 
effects on aromatase expression, presumably resulting in reduced aromatase activity. Therefore, 
it remains unclear whether aromatase is regulated by androgens in humans, especially in human 
placenta tissue. 
In contrast to reports in neuronal cells and our finding in the placenta reported in 
Chapter 3, we did not detect a significant correlation between aromatase and RORA in the 
placenta. Similar to the null effects of androgen treatment on brain aromatase shown in non-
human primates, we did not find a significant relationship between maternal or neonatal 
androgen levels and RORA or aromatase expression in the placenta, which parallels the finding 
that brain aromatase is not impacted by fetal gonadectomy or androgen treatment in rhesus 
macaques (C. E. Roselli & Resko, 1986). Aromatase activity in the macaque hypothalamus and 
cortex is significantly higher during mid-gestation than in adulthood. It is possible that placental 
aromatase activity is regulated by androgens, but that this relationship is only measurable or 
present during specific, earlier developmental periods. It is also possible that under extreme 
steroidogenic conditions, placental aromatase may be altered. In humans, pregnant women 
diagnosed with preeclampsia have elevated circulating testosterone and increased expression of 
androgen receptors in placental tissue at delivery (Sathishkumar et al., 2012b; R. Troisi, 2003). 
In this population, affected females demonstrate elevated aromatase expression in the placenta, 
whereas affected males demonstrate decreased aromatase expression levels despite the increased 
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androgen receptor level across both sexes (Hertig et al., 2010; Perez-Sepulveda et al., 2015b; 
Sathishkumar et al., 2012b). 
The trajectory of aromatase activity across gestation is highly dependent on the species 
and whether the gestational period is short or long. Aromatase expression in the fetal 
hypothalamus peaks during late gestational and early neonatal periods in short gestating species, 
whereas in long gestating species experience elevated aromatase activity in the first half of the 
gestational period (Charles E. Roselli et al., 2009). In humans, testosterone in male fetuses peaks 
during the second trimester and decreases gradually until birth. Therefore, aromatization is 
possible during the testosterone peak, resulting in higher estrogen levels during the critical 
periods of sex steroid-dependent brain organization. 
The placenta can provide important insight regarding the health of a pregnancy. 
However, to effectively use the placenta as a record of fetal exposure to hormones throughout 
gestation, more detailed observations regarding changes in gene expression in the larger context 
of the pregnancy are required. The present study provides important information regarding 
covariates that should be considered in future analyses of fetal hormone exposure. Further, this is 
the first study to assess the relationship between 2nd trimester maternal sex hormones and 
neonatal sex hormones at birth in relation to direct placental measurements of expression of 








Chapter 5: In vitro examination of placental aromatization of 
exogenous testosterone: A pilot study 
 
5.1 Introduction 
 The human placenta is a highly-specialized organ that carries out several unique 
endocrine functions throughout pregnancy. In particular, the placenta expresses high levels of 
aromatase, a rate-limiting enzyme that is a member of the P450 cytochrome family. In the human 
placenta, aromatase activity has been shown to be important for normal blood vessel growth 
through the regulation of estradiol and is involved in inducing labor and parturition (Berkane et 
al., 2018; Guan, Lu, Wang, & Xue, 2019). Globally, one of the primary actions of the aromatase 
enzyme is the conversion of testosterone into estradiol, and this is believed to be conserved in the 
human placenta. It has been widely suggested that placental aromatase converts testosterone of 
maternal and fetal origin into estradiol (Berkane et al., 2018; Doody & Carr, 1989; Guan et al., 
2019; Kragie, 2002; P. Kumar, Kamat, & Mendelson, 2009; Shin et al., 2018). Evidence from 
studies of clinical conditions that involve abnormal aromatase activity, such as aromatase 
deficiency, support the notion that prenatal aromatase activity is important for the development 
of sex steroid-sensitive processes (Lin et al., 2007; Morel et al., 2016). However, the explicit 
conversion of testosterone to estradiol by aromatase has not been extensively examined. 
In Chapters 3 and 4, we investigated the role of the human placenta in regulating fetal 
exposure to maternal testosterone by assessing whether aromatase expression in the placenta at 
birth moderated relationship between maternal and neonatal hormone concentrations. Placental 
aromatase activity cannot be easily assessed in-utero and so the previous studies were limited to 
correlational analyses spanning a wide developmental time period. To study the role of placental 
aromatase more directly, we conducted a two-part study using placental explant tissue (R. K. 
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Miller et al., 2005). 
Rodent studies are often used as a valuable tool for determining causal relationships. One 
of the greatest challenges in studying aromatase activity in the placenta as it relates to the 
synthesis of estradiol is the fact that expression of aromatase in the murine placentas does not 
perfectly parallel that in the human placenta. Only 3-4 of the 11 exons of the human gene have 
been identified in the murine placenta and moreover, it has been suggested that the murine 
placenta may lack certain transcriptional factors that are necessary for aromatase expression in 
the placenta (Chow, Simpson, & Boon, 2009; Harada, Yoshimura, & Honda, 2003). In an effort 
to experimentally study the mechanism of aromatase in the human placenta and how it may 
impact steroid metabolism and synthesis, several in vitro and ex vivo methods can be considered. 
Whole tissue ex vivo  placental perfusion is recommended for studies assessing the transplacental 
transfer or substances between mother and fetus (Myllynen & Vähäkangas, 2013). On the other 
end of the spectrum, cultured primary trophoblast cells can be used to study mechanisms that 
affect placental functioning and transplacental transfer on a cellular level. As a middle ground, 
explant cultures combine the benefits of whole tissue perfusion and cell culture by preserving the 
integrity of multiple cell types while allowing for complex experimental manipulations and long-
term incubation of the tissue. 
 Using a placental explant system, William Y. Ling experimentally examined placental 
estradiol synthesis in 1983 (Ling, 1983). Fresh placenta explants were incubated in cell culture 
medium and treated with methyltestosterone for up to 96 hours and the medium was analyzed for 
estradiol levels at every 24-hour increment. This process was repeated using the non-
aromatizable androgen, dihydrotestosterone (DHT) and estradiol measurements were also taken 
after 30, 90, 180 minutes of incubation. Consistent with the hypothesis that the human placenta 
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converts testosterone to estradiol, the addition of methytestosterone to the medium resulted in 
increased estradiol output after 24 hours of treatment. Curiously, the DHT treatment also induced 
an increased in estradiol output in as few as 30 minutes. Since DHT is not aromatizable, this 
finding suggests the potential for an alternative mechanism by which placental exposure to 
androgens stimulates the production of estradiol. 
 Given the limited and somewhat counter-intuitive literature on this topic, the present 
study aimed to replicate and expand the Ling’s 1983 paper by considering additional variables 
known to affect placental steroidogenesis and aromatase activity. Specifically, Ling’s original 
study did not account for the sex of the placenta, mode of delivery, or onset of labor. 
Additionally, the effects of methyltestosterone on estradiol output were not measured before 24 
hours of incubation, so we sought to study these effects on a shorter time scale. Finally, to more 
thoroughly investigate the role of aromatase in the production of estradiol following androgen 
treatment, we treated the tissue with Letrozole, an aromatase inhibitor. 
 In Part I of this study, we collected one male and one female placenta, both of which 
were collected following non-laboring Cesarean section deliveries. To measure the effects of 
androgen treatment on a shorter time scale, we collected estradiol measurements in the medium 
after 10, 30, and 60 minutes. We also pre-treated the tissue with Letrozole, an aromatase 
inhibitor, to more directly investigate the role of aromatase in the production of estradiol 
following androgen treatment. We found intriguing patterns that suggest that testosterone 
induced an increase in estradiol output and that Letrozole attenuated the effects of testosterone 
on estradiol production. Our sample size was limited (n = 2), but we were able to use this 
preliminary analysis to optimize and refine the protocol. In Part II, we refined the protocol used 
in Part I and performed an expanded analysis using 17 fresh placenta explants. 
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5.2 Part I Methods  
5.2.1 Participants 
Two pregnant women, one carrying a male fetus and one carrying a female fetus, were 
enrolled upon admission to the labor and delivery unit of Sloane Hospital for Women at New 
York Presbyterian Hospital/Columbia University Medical Center. All procedures were reviewed 
and approved by the Columbia University Medical Center Institutional Review Board and 
participants provided informed written consent prior to all study procedures. To meet all 
inclusion criteria, participants must have been fluent in English, 18 years old, between the 38th 
and 40th week of the pregnancy (380 - 406), and admitted to the unit for an elective cesarean 
section. We restricted our enrollment to non-laboring patients who were admitted for delivery by 
an elective cesarean section in order to avoid the hormonal fluctuations that occur during labor 
(Hickey et al., 2014; Keelan et al., 2012; Mathur et al., 1980). Further, elective cesarean 
deliveries are scheduled during a narrow time frame, which limited variability in the diurnal 
effects on hormone levels. We excluded women who had been diagnosed with polycystic ovary 
syndrome (PCOS), congenital adrenal hyperplasia (CAH), or preeclampsia during the current 
pregnancy because these conditions can alter circulating levels of testosterone and estrogen. 
 
5.2.2 Placenta tissue collection and preparation 
Within 15 minutes of delivery, whole placentas were brought to the laboratory for further 
processing. Placentas were placed on a sterile hospital pad with the chorionic plate facing up. 
Using a sterile dissection knife, the tissue was cut in half at the umbilical cord line. While 
carefully avoiding the maternal and fetal surfaces of the placenta, tissue from the center of the 
villous parenchyma was then serially dissected into 5mm x 5mm x 3mm pieces. 
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5.2.3 Tissue culture 
Tissue explants were placed in 6-well cell culture plates and each well contained 5ml of 
DMEM/F-12 culture medium (Figure 5.1). Three pieces of tissue were placed in each well to 
incubate for approximately 5 minutes at 110 rpm at 37°C. A testosterone stock solution was 
prepared using 100% ethanol and was further diluted in saline to generate three concentrations: 
low (.003 ng/ml), medium (.01 ng/ml), and high (.03 ng/ml). We added 50 ul of the working 
testosterone solutions into the designated wells. This procedure was repeated so that for each 
treatment, there were two wells. The tissue samples incubated for 10, 30 or 60 minutes. At each 
time point, we removed 200 ul of the culture medium from one well and stored it at -80°C until 
conducting the estradiol radioimmunoassay. Similarly, one of the three pieces of tissue from the 
second well was removed at each time point and was flash frozen in liquid nitrogen and stored at 
-80°C for RT-qPCR analyses.  
To determine whether aromatase is necessary for placental conversion of testosterone 
into estradiol, we performed a second manipulation using Letrozole (Femera), an aromatase 
inhibitor. A Letrozole stock solution was prepared used DMSO and further diluted in saline to 
make three concentrations: low (1 nmol/l), medium (100 nmol/l), and high (1000 nmol/l). Tissue 
was pretreated with one of the Letrozole doses for 10 minutes. Following previous methods, 50 
ul of testosterone was added to each well. Thus, each testosterone  
concentration (low, medium, and high) was paired with each of the Letrozole concentrations 
(low, medium, and high). At each time point, we removed 200 ul of the culture medium and 
stored it at -80°C for an estradiol radioimmunoassay. Similarly, one of the three pieces of tissue 
was removed at each time point and was flash frozen in liquid nitrogen and stored at -80°C for 
RT-qPCR analyses. Finally, we performed two control conditions. As the first control, we did 
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not add any tissue to the plates. As a second control condition, we incubated the tissue in 
untreated DMEM/F-12 culture medium for 10, 30, or 60 minutes. We performed a control for 
each experimental manipulation (e.g. vehicle + low testosterone, vehicle + high Letrozole, etc.). 
At each time point, we removed 200 ul of the culture medium and stored it at -80°C for an 
estradiol radioimmunoassay. Similarly, one of the three pieces of tissue was removed at each 
time point and was flash frozen in liquid nitrogen and stored at -80°C for RT-qPCR analyses.  
 
 
Figure 5.1 Schematic of placenta explant methods 
 
5.2.4 Measurement of estradiol concentrations in cell culture medium  
An estradiol radioimmunoassay was conducted using commercially available kits and 
performed as indicated by the supplier (MP Biomedicals; Solon, OH).  For the estradiol assays, 
samples were run in duplicate and values were averaged. The average intra-assay coefficient of 
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variations (CV) was 9.8% and the average lowest limit of detectability (LLD) was 11.05 pg/ml 
(see Table 2.2,Chapter 2). Samples that were below detection (e.g. <0.08) were assigned the 
value of the lowest level of detectability. 
 
5.3 Part I results 
5.3.1 Testosterone treatment induced increases in estradiol output 
When placenta tissue was not added to the wells, estradiol was completely undetectable, 
which ensures that estradiol measurements from the experimental conditions were not 
confounded by any of our materials. When we added tissue to the vehicle, we were able to detect 
estradiol in the culture medium. The placenta produces high levels of endogenous estradiol and it 
is likely that it leached from the tissue during the experiment. Due to the small sample size of 
this dataset, we are unable to perform robust statistical testing of our experimental 
manipulations. However, from a qualitative perspective, the data from the male placenta show an 
increase in estradiol in the culture medium following the low testosterone treatment compared to 
the vehicle after 10, 30 and 60 minutes of incubation (Figure 5.2). Data from the female placenta 
show a similar increase in estradiol after 30 and 60 minutes, but a decrease in estradiol was 
observed after 10 minutes of incubation. In contrast, exposing the male and female tissue to the 
medium or high doses of testosterone resulted in decreased estradiol levels in the culture medium 






Figure 5.2 Radioimmunoassay of estradiol following testosterone treatment 
(A) Estradiol levels from wells containing placental tissue from a male infant. (B) 
Estradiol levels from wells containing placental tissue from a female infant. Each bar 
represents one measurement therefore, standard error bars could not be generated. 
 
5.3.2 Letrozole inhibits estradiol output in a dose-dependent manner 
Due to methodological errors, only data from the female placenta was analyzed. 
Compared to the vehicle, treating the tissue with vehicle + low Letrozole and vehicle + medium 
Letrozole resulted in lower estradiol levels in the culture medium after 10, 30, and 60 minutes of 
incubation (Figure 5.3Figure 5.3). Curiously, the effects of treating the tissue with vehicle + 
high Letrozole was highly variable. After 10 minutes, estradiol levels were comparable to those 
in the vehicle condition. However, we see a substantial decrease in estradiol following the 
vehicle + high Letrozole treatment after 30 minutes and a moderate decrease after 60 minutes 
(Figure 5.3). 
We found that after 10 minutes, estradiol in culture medium from the low testosterone + 
low Letrozole condition was similar to estradiol in the low testosterone + vehicle condition 
(Figure 5.3). By 30 and 60 minutes, estradiol was lower in the low testosterone + low Letrozole 
condition. At all three time points, low testosterone + medium Letrozole and low testosterone + 
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high Letrozole resulted in significantly lower levels of estradiol compared to the culture medium 
from the low testosterone + vehicle condition. Further, all of the low testosterone + Letrozole 
conditions yielded lower estradiol levels than the vehicle condition, with the exception of low 
testosterone + low Letrozole at 30 minutes (Figure 5.3). This is consistent with our findings 
from the vehicle + Letrozole conditions, which suggests that the addition of testosterone did not 
greatly impact the effects of the Letrozole.  
 
Figure 5.3 Radioimmunoassay of estradiol following Letrozole and 
testosterone treatment 
(A) Estradiol levels from wells containing vehicle and vehicle + Letrozole. (B) Estradiol 
levels from wells containing vehicle and low testosterone + Letrozole. (C) Estradiol 
levels from wells containing vehicle and medium testosterone + Letrozole. (D) Estradiol 
levels from wells containing vehicle and high testosterone + Letrozole. Each bar 




Additionally, tissue was treated with a medium dose of testosterone and either low, 
medium, or high Letrozole. Treating the tissue with medium testosterone + low Letrozole and 
medium testosterone + medium Letrozole had very moderate effects on estradiol levels at 10, 30, 
and 60 minutes (Figure 5.3). However, the medium testosterone + high Letrozole treatment 
yielded substantially lower estradiol levels at all three time points, with the most striking 
decrease at 60 minutes (Figure 5.3). 
Finally, the tissue samples were treated with a high dose of testosterone and either low, 
medium, or high Letrozole. The high testosterone + low Letrozole treatment resulted in moderate 
to large decreases in estradiol at 10, 30, and 60 minutes (Figure 5.3). Interestingly, the high 
testosterone + medium Letrozole treatment yielded moderate increases in estradiol at 10 and 60 
minutes, but there was no effect of the Letrozole at 30 minutes. Finally, substantial decreases in 
estradiol levels were measured in the culture medium from the high testosterone + high Letrozole 
treatment compared to the culture medium from the high testosterone + vehicle treatment 
(Figure 5.3). 
 
5.4 Part I discussion 
Using a placental explant system, we were able to preserve the integrity of the tissue and 
evaluate how placental tissue responds to different hormonal environments in vitro. As a 
preliminary analysis, we collected data on two placentas - one male and one female - and the 
results indicate a complex system of hormonal regulation and metabolism by the human 
placenta. 
Overall, the data from Part I of this study support our overarching hypothesis that 
increased maternal testosterone paired with decreased aromatase expression may result in 
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elevated fetal exposure to testosterone. In an effort to mimic circulating maternal androgens in 
the in-utero environment. we treated tissue with exogenous testosterone at a low, medium, or 
high dose. Under the assumption that the placenta is responsible for protecting the fetus from 
exposure to maternal testosterone via aromatization, exposing the tissue to testosterone should 
yield a higher output of estradiol.  
Estradiol concentrations were higher following treatment with low testosterone in both 
the male and female placentas. In the samples from the male placenta, estradiol levels were 
higher following treatment with the low, medium, and high testosterone. Surprisingly, we found 
that exposing the female placenta to the medium and high doses of testosterone actually resulted 
in a decrease in estradiol output. As previously discussed, estradiol is thought to drive sexual 
differentiation of several neural systems and behaviors via aromatization. While we often 
consider estradiol to be the “female hormone,” it is responsible for masculinizing the brain and 
ultimately, behavior. Alpha-fetoprotein, which is especially ubiquitous during the prenatal 
period, is thought to protect the female fetus from high levels of estradiol by binding to estradiol 
so that it cannot activate estrogen-sensitive cells. Female mice that do not express alpha-
fetoprotein (AFP-/-) are highly masculinized, which supports the notion that alpha-fetoprotein is 
critical for maintaining the hormonal milieu that is necessary for normal sexual differentiation 
(Bakker et al., 2006). With this in mind, our observation that estradiol decreased following 
exposure to medium and high doses of testosterone becomes much more easily understood. The 
decrease in estradiol may reflect an upregulation of alpha-fetoprotein in response to higher 
exposure to testosterone. 
In an effort to isolate the contribution of placental aromatase in the testosterone-to-
estradiol conversion pathway, we pre-treated tissue with Letrozole, an aromatase inhibitor. In 
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general, pre-treating the tissue with the aromatase inhibitor followed by exposure to one of the 
three testosterone doses (low, medium, or high) resulted in lower estradiol output in the culture 
medium. Importantly, however, this was not true in every condition. Consistently, by the 60-
minute timepoint, Letrozole at any dose (low, medium, or high) was associated with lower 
estradiol concentrations in the culture medium compared to the non-Letrozole treated tissue. The 
only exception to this was observed in tissue in the high testosterone + medium Letrozole 
condition. This finding provides strong evidence in support of the hypothesis that the placenta 
aromatizes testosterone into estradiol. The nuanced fluctuations in estradiol levels in response to 
changes in the hormonal environment may point to the sensitive nature of this regulatory system.  
 
5.5 Part II methods 
5.5.1 Participants 
Between September 2018 – November 2018, 17 pregnant women undergoing elective 
Cesarean sections, ten carrying a female fetus and seven carrying a male fetus, were enrolled 
upon admission to the labor and delivery unit of Sloane Hospital for Women at New York 
Presbyterian Hospital/Columbia University Medical Center. All procedures were reviewed and 
approved by the Columbia University Medical Center Institutional Review Board and 
participants provided informed written consent prior to all study procedures. Eligible mothers 
were fluent in English or Spanish, were 18-45 years old at the time of delivery, were delivering 
full-term (370 - 420 weeks GA), and were admitted to the unit for an elective Cesarean section. 
We restricted our enrollment to non-laboring patients who were admitted for delivery by an 
elective cesarean section in order to avoid the hormonal fluctuations that occur during labor 
(Hickey et al., 2014; Keelan et al., 2012; Mathur et al., 1980). Further, elective cesarean 
deliveries are scheduled during a narrow time frame, which limited variability in the diurnal 
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effects on hormone levels. We excluded women who had been diagnosed with polycystic ovary 
syndrome (PCOS), congenital adrenal hyperplasia (CAH), or preeclampsia during the current 
pregnancy because these conditions can alter circulating levels of testosterone and estrogen. 
Additionally, we excluded pregnancies where major placental pathologies had been noted by the 
physician. 
 
5.5.2 Placenta tissue collection and preparation 
Within 15 minutes of delivery, fresh whole placentas were brought to the laboratory for 
further processing. Placentas were placed on a sterile hospital pad with the chorionic plate facing 
up. Using a sterile dissection knife, the tissue was cut in half at the umbilical cord line. While 
carefully avoiding the maternal and fetal surfaces of the placenta, tissue from the center of the 
villous parenchyma was then serially dissected into 5mm x 5mm x 3mm pieces. 
 
5.5.3 Tissue culture 
Tissue explants were placed in 6-well cell culture plates and each well contained 5ml of 
DMEM/F-12 culture medium (Figure 5.1). One piece of tissue was placed in each well to 
incubate for approximately 5 minutes at 110 rpm at 37°C. A testosterone stock solution was 
prepared using 100% ethanol and was further diluted in saline to generate two concentrations: 
low (0.3 ng/ml) and high (3.0 ng/ml). We added 50 ul of the working testosterone solutions into 
the designated wells. The tissue samples incubated for either 10 or 60 minutes. At each time 
point, we removed 200 ul of the culture medium from the designated wells and stored it at -80°C 
until conducting the estradiol radioimmunoassay. Similarly, the tissue was removed at each time 
point and was immediately submerged in RNAlater stabilization solution (Invitrogen). The tissue 
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incubated in RNAlater for 24 hours at 4°C before being transferred and stored at -80°C until 
further processing for RT-qPCR procedures.  
To determine whether aromatase is necessary for placental conversion of testosterone 
into estradiol, we performed a second manipulation using Letrozole (Femera), an aromatase 
inhibitor. A Letrozole stock solution was prepared using DMSO and further diluted in saline to 
generate a concentration of 10 uM. The tissue explants were placed into each well and were 
pretreated with the Letrozole for 10 minutes. Following previous methods, 50 ul of testosterone 
(low or high) was added to each well. Thus, each testosterone concentration (low, high) was 
paired with the Letrozole treatment. At each time point (10, 60 minutes), we removed 200 ul of 
the culture medium and stored it at -80°C until we conducted the estradiol radioimmunoassay. 
Similarly, the tissue was removed at each time point and was immediately submerged in 
RNAlater stabilization solution (Invitrogen). The tissue incubated in RNAlater for 24 hours at 
4°C before being transferred and stored at -80°C until further processing for RT-qPCR 
procedures. 
 
5.5.4 Measurement of estradiol concentrations in cell culture medium  
An estradiol radioimmunoassay was conducted using commercially available kits and 
performed as indicated by the supplier (MP Biomedicals; Solon, OH).  For the estradiol assays, 
samples were run in duplicate and values were averaged. Samples were run across two batches. 
The intra-assay coefficient of variations (CV) were 12.9% and 12.5% and the lowest limits of 
detectability (LLD) were 9.37 pg/ml and 8.38 pg/ml (see Table 2.2, Chapter 2). Samples that 




5.6 Part II results 
5.6.1 Estradiol biosynthesis following testosterone treatment 
 Estradiol concentrations measured using radioimmunoassay procedures were highly 
significantly correlated with the weight of the tissue explant. Therefore, we divided the estradiol 
value by the weight of the tissue in an effort to account for the effects of sample weight. We 
performed a one-way analysis of variance (ANOVA) to determine whether estradiol 
concentrations in the cell culture media differed across samples exposed to the three testosterone 
treatments (control, low testosterone, high testosterone). After a 10-minute incubation period, 
estradiol levels were moderately higher in the media of male placenta tissue treated with low 
testosterone compared to the control condition (p = 0.04, Figure 5.4, Figure 5.5). There was no 
difference in estradiol concentrations between the high testosterone and low testosterone or 
control conditions. There was no observed effect of testosterone treatment on the female placenta 
tissue with regards to estradiol measured in the media. After a 60-minute incubation period, there 
was a similar, but weaker effect among males such that media from the low testosterone 
condition had a lower estradiol concentration compared to media from the control condition (p 
=0.08, Figure 5.5). No other group differences were observed at the 60-minute incubation time 
point. 
 
5.6.2 Estradiol biosynthesis following aromatase inhibition 
  A two-way ANOVA of testosterone treatment and Letrozole treatment revealed no 
statistically significant effects of Letrozole on the estradiol concentrations of the cell culture 
media (Figure 5.4). In male placenta explants, Letrozole did not significantly impact estradiol 
levels at either the 10- or 60-minute time points or when comparing within testosterone treatment 
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groups. Similarly, Letrozole treatment did not affect estradiol levels at either time point or for 
any of the testosterone conditions in female placenta explants. 
 
 
Figure 5.4 Effect of testosterone and Letrozole treatment on estradiol in 
culture media 
(A) Results for all placenta explants. (B) Results for male placenta explants. (C) Results 





Figure 5.5 Effect of testosterone and Letrozole on estradiol in culture media 
by sex and incubation time 
(A) Results for male placenta explants after the 10 minute incubation. (B) Results for 
female placenta explants after the 10 minute incubation. (C) Results for male placenta 
explants after the 60 minute incubation. (D) Results for female placenta explants after the 
60 minute incubation. Error bars represent 1 standard deviation. 
 
5.7 Part II discussion 
Part II of this study was conducted to further investigate the effects of exogenous 
testosterone administration on placental biosynthesis of estradiol and to determine whether the 
aromatase enzyme is required for the conversion of testosterone to estradiol. Part I of this study 
found evidence suggestive of placental involvement in testosterone metabolism, but expanding 
the sample size in Part II did not support our initial findings, suggesting that a broad range of 
factors contribute to this process. 
Based on an previous study and our results from Part I of this study, we expected that 
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estradiol concentrations in the culture media would increase following treatments of .3ng/ml 
(low) and 3ng/ml (high) testosterone concentrations (Ling, 1983). Further, we expected that 
Letrozole, an aromatase inhibitor, would block the steroidogenic effects of exogenous 
testosterone treatment. Contrary to our hypotheses, we found that incubating fresh, term 
placental tissue with exogenous testosterone did not result in robust increases in estradiol output 
measured in the cell culture media. Moreover, we found that estradiol levels in the cell culture 
media remained equally high following Letrozole treatment. 
 Both the low and high concentrations of testosterone fall within the range of maternal 
testosterone measured during the 3rd trimester. Based on biological measurements of total 
testosterone collected upon admission to labor and delivery units that have been reported 
elsewhere, we selected 0.3ng/ml and 3ng/ml testosterone concentrations (Salamalekis et al., 
2006; R. Troisi, 2003). Based on samples that we previously collected from approximately 600 
pregnant women during the second trimester, it is possible that the concentrations that we used 
were too low to elicit a difference from endogenous testosterone. We were unable to fully 
perfuse the tissue to remove all maternal blood, therefore, maternal circulating endogenous 
testosterone at the time of delivery may have dampened the effectiveness of our intervention. 
Although the low and high testosterone concentrations are comparable to those used in a 
previous report, differences in our tissue preparation and incubation procedures may have 
contributed to our inability to detect an effect of exogenous testosterone treatment. 
With regard to tissue preparation, we dissected sections of placenta tissue that were 
approximately 5x5x3 mm and weighed an average of 88 mg. Our procedures were based 
primarily on cell culture protocols and protocols that used smaller sections of tissue, with 
weights closer to 50 mg. The larger sections of tissue used here may have reduced the extent to 
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which the substrates could penetrate the tissue and affect the relevant cells (e.g. 
syncytiotrophoblast cells). In future studies, it may be advantageous to optimize the protocol 
with dissociated trophoblast cells to ensure that the testosterone and Letrozole are absorbed by 
the steroid-active cells. Another potential explanation for the lack of an observed effect of 
testosterone and Letrozole is the very brief incubation period. Compared to most cell and tissue 
culture protocols, our incubation time points of 10 and 60 minutes are very brief and may be too 
short to allow for significant cellular processes to occur at measurable levels. Our incubation 
protocol also did not control for the endogenous estradiol that was likely present in the tissue at 
the time of preparation. Endogenous estradiol of placental origin may have masked the more 
subtle changes caused by our treatments. To account for this in future studies, it may be 
necessary to incubate the tissue for a preliminary period and to remove the initial culture media 
containing placental secretions, such as estradiol. Finally, it is very difficult to completely 
eliminate maternal and fetal blood from the placenta tissue. Therefore, it is possible that some of 
the estradiol that we measured in the culture medium was a direct measurement of plasma 
estradiol. To address this, it would be beneficial to measure the endogenous levels of testosterone 
and estradiol in the mother and fetus (via cord blood). Through measuring maternal and fetal 
hormone levels, we would be able to better control for pre-existing endogenous estradiol. 
Moreover, measuring maternal and fetal hormone levels could provide important information 
about an individual’s prenatal hormonal milieu which may have programmatic effects on the 
hormonal regulatory function of the placenta.  
It is surprising that the Letrozole treatment did not affect estradiol output in the culture 
media. In addition to the limitations discussed above, it is also possible that Letrozole is not an 
appropriate aromatase inhibitor in placenta tissue. Letrozole is a reversible nonsteroidal 
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competitive inhibitor, but the aromatase may respond more strongly to a steroidal type I 
inhibitor, such as Exemestane (W. R. Miller et al., 2008).  
Finally, it is possible that placental estradiol synthesis is not dependent on the direct 
aromatization of testosterone into estrogen. In a study by William Y. Ling, fresh placental 
explants were treated with methyltestosterone or DHT for either short (30, 90, and 180 minutes) 
or long-term (24, 48, and 72 hours) incubation periods and estradiol output in cell culture media 
was measured (Ling, 1983). After 24-hour treatment of methyltestosterone, estradiol levels in the 
media increased. However, a less robust increase in estradiol levels was also measured in the 
media following DHT treatment. DHT is not aromatizable and therefore, cannot be directly 
converted into estradiol. The researchers propose that the presence of androgens (testosterone 
and/or DHT) may induce increased activity of steroidogenic enzymes including aromatase and 
3-HSD. If this feedback mechanism is at play, it suggests that hormone-dependent expression 
of aromatase is tissue-specific because in neuronal cells, increased androgen-receptor binding 
decreases aromatase activity (Sarachana, Xu, Wu, & Hu, 2011b). 
To further assess the parallels between our placental explant system and the naturalistic 
processes of the mother-fetal-placental unit, it would be advantageous to expose placental tissue 
to fluorescently-labeled testosterone. This method would allow one to visualize and localize the 
testosterone and visually track it as it travels through the placenta. Perhaps most importantly, 
using the fluorescently-labeled testosterone would allow one to determine whether the 
exogenous testosterone is carried to the fetal blood vessels. If the testosterone were detectable in 
the fetal vessels, then it would be highly probable that maternal testosterone can also reach the 




Chapter 6: Effects of prenatal exposure to maternal testosterone 
on child neurobehavioral outcomes: Investigating the 
regulatory role of the human placenta 
 
6.1 Introduction 
The prevalence and presentation of many psychiatric conditions often differ between 
males and females (Afifi, 2007; Eaton et al., 2012; Young & Pfaff, 2014). In the case of autism 
spectrum disorder (ASD), males are estimated to be four times more likely to be diagnosed than 
females (Werling & Geschwind, 2013; Young & Pfaff, 2014). Given the sex bias in ASD and 
our understanding that sex hormones during gestation are critical for the organization of sex 
steroid-sensitive brain regions important for behavioral and cognitive domains that are impaired 
in individuals with autism, exposure to atypical levels of androgens and estrogens may contribute 
to risk for ASD and related disorders (Arnold & Gorski, 1984; Cohen-Bendahan et al., 2004; J.-
A. K. Finegan et al., 1992; Melissa Hines, 2006b; Roberts & Martel, 2013).  
Elevated steroidogenic activity in amniotic fluid has been associated with autism-related 
behaviors in childhood, as well as several sub-clinical behavioral and physiological differences 
(Auyeung et al., 2010; S. Baron-Cohen et al., 2015a; Simon Baron-Cohen et al., 2019; R. C. 
Knickmeyer & Baron-Cohen, 2006; S. Lutchmaya et al., 2004; Svetlana Lutchmaya et al., 2001). 
As discussed in Chapter 1, the placenta is thought to serve as both a source of steroidogenesis 
and as a fetal barrier against maternal hormones. Specifically, it has been suggested that 
aromatization of testosterone into estradiol via placental aromatase precludes the transfer of 
maternal testosterone to the fetus (Bedin, Ferre, Alsat, & Cedard, 1980; Kaludjerovic & Ward, 
2012). This has led to the conclusion that androgens detected in amniotic fluid are of fetal, not 
maternal, origin. However, the question of whether variability in the aromatase barrier of the 
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placenta relates to child neurobehavioral outcomes has not been thoroughly evaluated.  
Preeclampsia, polycystic ovary syndrome, and congenital adrenal hyperplasia, conditions 
that are all associated with elevated maternal testosterone, are all associated with risk for 
abnormal neurobehavioral development in the offspring (R. Knickmeyer et al., 2006; Kosidou et 
al., 2015; Maher et al., 2018). In addition, aromatase and its transcriptional regulator, RORA, are 
reduced postmortem brain tissue of individuals with autism (Crider, Thakkar, Ahmed, & Pillai, 
2014b; Hu et al., 2015; Sarachana et al., 2011b). In Chapter 4, we found strong evidence that 
maternal testosterone, especially in male children, is associated with elevated testosterone in the 
term-age fetus, suggestive of some maternal androgen transfer across the placenta. Taken 
together, it is plausible that the relationship between androgens in amniotic fluid and 
neurodevelopmental risk can be explained by elevated maternal testosterone and/or insufficient 
placental aromatase. In this study, we aimed 1) to determine the relationship between maternal 
sex hormones and child neurobehavioral outcome, 2) to determine the relationship between 
neonatal sex hormones and child neurobehavioral outcome 3) to determine the relationship 
between placental aromatase and RORA and child neurobehavioral outcome, and 4) to determine 
whether placental aromatase and/or RORA moderates the relationship between maternal or 




Between 2010-2013, 8 participating clinical centers across the United States enrolled 
10,037 nulliparous women with singleton pregnancies into the Nulliparous Pregnancy Outcomes 
Study: Monitoring Mothers-to-be (nuMoM2b) study (Haas et al., 2015). To participate in the 
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nuMoM2b study, nulliparous pregnant women were screened for eligibility during the 1st 
trimester. Eligible women were between 60-136 weeks of gestation based on an ultrasound 
crown-rump length measurement. Pregnant women were excluded if they had a prior pregnancy 
lasting 20 weeks’ gestation or more, were younger than 13 years of age, had a history of 3 or 
more spontaneous abortions, or if a likely fatal fetal malformation was identified during 
screening.  
Approximately 1,000 of the nuMoM2b study participants were enrolled at Columbia 
University Medical Center. Of these 1,000 participants, 661 met inclusion criteria to be included 
in the secondary analyses presented here. Mothers were eligible to participate in the secondary 
analyses if they participated in the original nuMoM2b study, delivered at the Columbia 
University Medical Center site, were fluent in English or Spanish, and were ≥ 18 years old at the 
time of enrollment in the nuMoM2b study. As part of the nuMoM2b study, participants were 
asked to provide a sample of maternal plasma during the second trimester, a sample of cord 
blood plasma at birth, and a sample of frozen placenta tissue at birth. Participants must have 
provided all three of these samples in order to be included in these secondary analyses. Finally, 
to be included in the analyses presented here, mothers had to have provided written consent to 
the future use of their biological samples and written consent to be re-contacted by study staff. 
Data was requested for the 661 eligible infants. Upon receiving the data, one pregnancy was 
deemed ineligible due to intrauterine fetal demise.  
In addition to providing the biological samples during pregnancy, mothers whose 
children had reached the age of 4.5-6.5 years were re-contacted via telephone and email and 
were asked to complete a brief online questionnaire. Of those who completed the questionnaire, 
the average age at the time of assessment was 61.75 months (range = 54.0-79.0 months). The 
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questionnaire included items pertaining to any physical and psychiatric diagnoses that the child 
may have received since birth, maternal diagnoses of endocrine-related conditions (e.g. 
polycystic ovary syndrome), and maternal use of medications with the potential to alter 
endocrine function (e.g. oral contraceptives). The online questionnaire included a subset of items 
from the Behavioral Assessment System for Children (BASC-3) Parent Rating Scales 
(Preschool), the Social Communication Questionnaire (SCQ), and the Children’s Empathy 
Quotient (EQ-C). All procedures were reviewed and approved by the Columbia University 
Medical Center Institutional Review Board and participants provided informed written consent 
prior to all study procedures. A complete consort diagram is presented in Figure 6.1. 
 
6.2.2 Maternal plasma collection 
Maternal plasma was collected between 160-216 weeks gestational age. Whole blood was 
collected by venipuncture into an EDTA-coated collection tube. Detailed methods are described 
elsewhere (see Chapter 2). 
 
6.2.3 Umbilical cord plasma collection 
Cord blood plasma was collected and processed within 30 minutes of the delivery of the 
placenta. At the time of delivery, the umbilical cord was clamped and study staff transported the 
whole placenta in a closed container to a laboratory for further processing. Detailed methods are 







Figure 6.1 Consort diagram 
*Eligible mothers participated in nuMoM2b study, delivered at Columbia University 
Medical Center site, were fluent in English or Spanish, were ≥ 18 years old at the time of 
enrollment in the nuMoM2b study, provided maternal plasma during the second 
trimester, provided cord blood plasma at birth, provided placenta tissue at birth, provided 




6.2.4 Placenta tissue collection 
After delivery, whole placentas were stored on ice and brought to the laboratory for 
further processing. Efforts were made to obtain placenta tissue within 30 minutes of delivery, but 
in some cases, placentas were stored on ice or in refrigerators at 4°C for up to 72 hours prior to 
processing. Placentas were rinsed in normal saline to remove blood clots and placed on a sterile 
hospital chuck with the fetal side of the placenta facing up. Using a punch biopsy or a scalpel, a 
piece of tissue (0.7 x 0.7 x 1cm or 8 mm x 1cm punch biopsy) was carefully dissected from the 
midpoint between the cord insertion and the edge of the placenta (Figure 4.2). The first 258 
samples (39%) were flash frozen in liquid nitrogen and stored at -80°C. The subsequent 401 
samples (61%) were stabilized in RNAlater (Invitrogen) for 48 hours and then stored at -80°C. 
Detailed methods are described elsewhere (see Chapter 2). 
 
6.2.5 Sex hormone radioimmunoassay of maternal and umbilical cord plasma 
Total testosterone and estradiol radioimmunoassays were conducted using commercially 
available kits and standard procedures, described in Chapter 2, were followed. For the 
testosterone assays of the maternal plasma samples, the average intra-assay coefficient of 
variations (CV) and average lower limits of detectability (LLD) were 11.15% and 0.09 ng/ml, 
respectively (see Table 2.2, Chapter 2). For estradiol assays of the maternal plasma samples, the 
average intra-assay CVs and average LLDs were 13.72% and 9.07 pg/ml, respectively (see 
Table 2.2, Chapter 2). For the testosterone assays of the umbilical cord plasma samples, the 
average intra-assay coefficient of variations (CV) and average lower limits of detectability 
(LLD) were 16.48% and 0.10 ng/ml, respectively (see Table 2.2, Chapter 2). For estradiol 
assays of the umbilical cord plasma samples, the average intra-assay CVs and average LLDs 
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were 8.51% and 8.12 pg/ml, respectively (see Table 2.2, Chapter 2). Samples that were below 
detection (e.g. <0.08) were assigned the value of the lowest level of detectability. 
 
6.2.6 Aromatase (CYP19A1) and RORA Gene Expression Assays in Placenta Tissue 
30 mg sections of placental tissue were dissected from the original sample. Details 
regarding the RNA/DNA extraction and RT-qPCR procedures are described elsewhere (see 
Chapter 4). Due to variability in placenta collection, we excluded 251 samples with RNA 
concentrations <100ng/ul as measured by a spectrophotometer. As an additional quality control 
measure, we excluded samples with Ct values that were equal to or greater than 35. Thus, we had 
high quality gene expression data for 353 subjects. Maternal age was significantly higher in 
participants whose placentas were included compared to those who were excluded, but there 
were no other differences in maternal, paternal, or infant demographic and health variables. With 
regard to our outcome variables of interest, total SCQ scores and T-scores on the Hyperactivity 
scale of the BASC-3 were significantly higher in those who were excluded from the gene 
expression analyses. Since this study does not involve a control group, we calculated the 2-ΔΔCt 
using females as the reference group. We excluded samples from analyses that were identified as 
outliers using Grubbs’ test for outliers (Grubbs, 1969). 
 
6.2.7 Behavioral Assessment System for Children (3rd Ed.) (BASC-3) 
The BASC-3 Parent Rating Scale (PRS) is a validated parent-report questionnaire that is 
designed to assess a child's neurobehavioral development between the ages of 2 years 0 months 
and 21 years 11 months (Altmann et al., 2017). A detailed description of the BASC-3 is provided 




6.2.8 Social Communication Questionnaire (SCQ) 
The SCQ lifetime version is a parent-report questionnaire to evaluate autism-related 
behaviors in children 4 years (or mental age of 2 years) and older (Allen et al., 2007). A detailed 
description of the SCQ is provided in Chapter 2. 
 
6.2.9 Children’s Empathizing Quotient (EQ-C) 
The EQ-C is a parent-report questionnaire that was adapted from the adult version of the 
Empathizing Quotient questionnaire (EQ) and is designed to assess trends in sex-typical 
empathizing behavior in children (Auyeung, Wheelwright, et al., 2009). A detailed description of 
the EQ-C is provided in Chapter 2. 
 
6.2.10 Statistical analyses 
 Statistical analyses were conducted using R and SPSS software. Maternal testosterone 
and cord blood testosterone values were positively skewed and 1-minute Apgar scores, neonatal 
head circumference, and infant gestational age were negatively skewed, so they were square root 
transformed prior to statistical analysis. We examined several covariates relating to parental 
characteristics, the course of the pregnancy, and neonatal outcomes that were a priori identified 
as potential confounding risk factors. Variables that were considered included maternal and 
paternal age at delivery, maternal and paternal education, annual family income, maternal and 
paternal ethnicity, infant gestational age at birth, infant birth weight, 1-minute Apgar scores, 
neonatal head circumference, and the child’s age at the time of follow-up. Specifically, analyses 
of bivariate correlations between continuous covariates and the primary dependent and 
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independent variables, which included the maternal hormone variables, cord blood hormone 
variables, and placental gene expression variables, were conducted. We also performed Welch’s 
two sample t-tests to determine whether any of our variables of interests differed by mode of 
delivery, labor onset, and sex of the infant. Candidate covariates were included in the adjusted 
linear models if they were associated with either the dependent and independent variables at a 
significance level of 0.1. The sex of the infant (male versus female) and age at follow-up were 
the only covariates that significantly affected our outcome variables of interest. Specifically, 
females has significantly higher scores on the EQ-C (M = 41.56, SD = 8.23) compared to males 
(M = 37.60 , SD = 10.21) (t(227) = 3.25,  p = 0.001). Female children had significantly lower T-
scores on the hyperactivity scale of the BASC-3 (M = 47.32, SD = 6.57) compared to males (M 
= 49.28 , SD = 7.10) (t(258) = -2.31,  p = 0.02). Female children had significantly lower T-scores 
on the developmental social disorders scale of the BASC-3 (M = 45.60, SD = 6.60) compared to 
males (M = 47.40 , SD = 7.73) (t(257) = -2.02,  p = 0.045). Female children had significantly 
lower T-scores on the clinical probability scale of the BASC-3 (M = 45.43, SD = 6.14) compared 
to males (M = 48.14 , SD = 7.51) (t(257) = -3.20,  p = 0.002). Therefore, all analyses either 
included sex as a covariate or are performed separately within each sex. 
 
6.3 Results 
6.3.1 Sample characteristics 
 Demographic and medical information for infants and their mothers were provided by the 
NuMoM2b data management center and are provided in Table 6.1. The average maternal age at 
delivery was 29.46 years (range 18.0 – 43.0 years) and the average paternal age at delivery was 
31.16 years (range 18.0 – 55.0 years). Detailed information regarding participants’ race was 
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unavailable. 51.1% of the mothers self-identified as being Hispanic/Latino and 50.4% of the 
fathers self-identified as being Hispanic/Latino. The primary reasons for delivery, in order of 
prevalence, were: labor onset (n = 141), rupture of membranes (n = 30), convenience (n = 24), a 
maternal condition (n = 21), oligohydramnios (n = 17), abnormal fetal testing (n = 7), 
intrauterine growth restriction (n = 3), a fetal condition (n = 3), abruptio placenta (n = 1), and 
unknown reasons (n = 1). 29.6% of the infants were delivered by Cesarean section (C-section). 
In two cases, detailed regarding the C-section delivery were unavailable. The average gestational 
age at delivery was 39.37 weeks (range 31.0 – 42.1 weeks), with an average birth weight of 3279 


















Table 6.1 Study sample characteristics 
Characteristics 
Total n = 270* 
Mean SD 
Gestational age at delivery (weeks) 39.37 1.48 
Birth weight (grams) 3279.47 457.59 
Infant head circumference (cm) 34.09 1.49 
Maternal age (years) 29.46 5.88 
Paternal age (years) 31.16 6.76 
 % n 
Infant sex (male) 55.2 149 
Cesarean section 29.6 80 
Laboring delivery 90.0 243 
Reason for delivery   
Abnormal fetal testing 2.6 7 
Placental abruption 0.37 1 
Convenience 8.9 24 
Fetal health condition 1.1 3 
Intrauterine growth restriction (IUGR) 1.1 3 
Labor onset 52.2 141 
Maternal health condition 7.8 21 
Oligohydramnios 6.3 17 
Rupture of membranes 11.1 30 
Polyhydramnios 0 0 
Post due-date 8.1 22 
Unknown 0.37 1 
Maternal hypertensive disorder 14.8 40 
Maternal diabetes   
None 96.3 260 
Before pregnancy 0.37 1 
During pregnancy 3.3 9 
Unknown 0 0 
Maternal Education   
No high school degree 1.5 4 
High school degree 7.4 20 
Some college, no degree 17.0 46 
College degree 27.8 75 
Graduate/professional degree 46.3 125 
Refused 0 0 
Maternal ethnicity (Hispanic/Latino) 51.1 138 
Paternal ethnicity (Hispanic/Latino) 50.4 136 
Annual household income   
< $50,000 20.4 55 
$50,000 - $99,999 15.6 42 
$100,000 - $199,999 26.7 72 
 $200,000 15.6 42 
Refused 21.9 59 
*270 participants completed at least some portion of the follow-up assessment. 





6.3.2 Sex differences in neurobehavioral outcome measures 
 No sex differences were observed with regard to total SCQ scores. Total EQ-C scores 
were significantly higher in female children compared to male children (t(225) = 3.29, p = 
0.001). Males had significantly higher scores on the Hyperactivity, Developmental Social 
Disorders, and Clinical Probability scales of the BASC-3 (t(252) = -2.31, p = 0.02; t(256) = -
2.02, p = 0.04; t(256) = -3.20, p = 0.001, respectively). 
 
6.3.3 Maternal sex steroids in the second trimester and child neurodevelopmental outcome 
 Bivariate Pearson correlations between maternal sex hormones (testosterone and 
estradiol) and child neurobehavioral measures (SCQ, EQ-C, and the Hyperactivity, 
Developmental Social Disorders, and Clinical Probability scales of the BASC-3) were performed 
(Table 6.2). Maternal testosterone was significantly positively correlated with total SCQ scores 
in the overall sample (r = 0.18, p = 0.003), among female children (r = 0.18, p = 0.02), and 
weakly among male children (r = 0.15, p = 0.06) (Table 6.2, Figure 6.2). An unadjusted linear 
regression model further supported a significant association between maternal testosterone in the 
second trimester and total SCQ scores. Using a stepwise linear regression analysis that included 
maternal and paternal age at delivery as pre-determined covariates that were associated with both 
the independent and dependent variables, maternal testosterone was a less significant predictor of 
total SCQ scores, though it still remained significant at the p < 1.0 level (Table 6.3). Maternal 
testosterone no longer significantly predicted total SCQ scores after including all covariates that 
were associated with either the dependent or independent variables (Table 6.3). After performing 
a median split analysis, male children born to mothers with testosterone levels equal to or greater 
than the median value scored significantly higher on the SCQ (t(145) = -2.80, p = 0.005, Figure 
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6.3). One outlier was identified and removed, though removal of this data point did not affect 
these results. Maternal testosterone was not associated with any of the other outcome measures 
including the EQC and the Hyperactivity, Developmental Social Disorders, and Clinical 
Probability scales of the BASC-3.  
 
Table 6.2 Pearson correlations between maternal sex hormones and child neurobehavioral scores 
 Overall  Females  Males 
 M-T M-E2  M-T M-E2  M-T M-E2 
 r r  r r  r r 
SCQ 0.18** -0.00  0.21* 0.01  0.15# -0.01 
EQ-C -0.06 0.02  -0.156 0.01  0.01 0.00 
BASC-3         
Hyperactivity 0.032 -0.08  0.08 0.04  -0.01 -0.16# 
Developmental Social Disorders 0.04 -0.01  0.12 0.03  -0.03 -0.16# 
Clinical Probability 0.03 -0.09  0.01 0.07  -0.01 -0.20* 
M-T: maternal testosterone, M-E2: maternal estradiol 
 
 
Figure 6.2 Correlation between maternal testosterone and total SCQ scores 
Maternal testosterone levels in the second trimester are positively associated with total 
SCQ scores. Solid lines represent the regression line. Shading represents the 95% 




Table 6.3 Stepwise linear regression model for maternal testosterone and total SCQ scores 
  B SE B  t p 
Model 1 Paternal age at delivery (years) 0.01 0.01 0.10 1.11 0.27 
Maternal age at delivery (years) -0.05 0.02 -0.29 -2.87 0.00 
Maternal testosterone (ng/ml) 0.41 0.24 0.11 1.67 0.09 
       
Model 2       
 Age at follow-up (months) 0.01 0.01 0.05 0.74 0.46 
 Head circumference (cm) -0.01 0.04 -0.02 -0.31 0.76 
 Paternal age at delivery (years) 0.01 0.01 0.09 0.98 0.33 
 Maternal age at delivery (years) -0.04 0.02 -0.26 -2.50 0.01 
 Maternal testosterone (ng/ml) 0.37 0.26 0.10 1.43 0.15 
Model 1: Covariates were associated with both the dependent and independent variables 
Model 2: Covariates were associated with either the dependent or independent variables 
 
 
Figure 6.3 Median split analysis of maternal testosterone and total SCQ 
scores 
Male children whose mothers had high testosterone in the second trimester have 
significantly higher total SCQ scores. Error bars represent SEM. # significance at p <0.1; 
* significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 0.001, 
**** significance at p < 0.0001. 
 
Overall and among female children, maternal estradiol was not associated with total SCQ 
scores, total EQC scores, or scores on the Hyperactivity, Developmental Social Disorders, and 
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Clinical Probability scales of the BASC-3. In males only, maternal estradiol collected during the 
second trimester was weakly negatively correlated with scores on the Hyperactivity, 
Developmental Social Disorders, and Clinical Probability scales of the BASC-3 (r = -0.16, p = 
0.05; r = -0.16, p = 0.06; r = -0.20, p = 0.01, respectively, Table 6.2). An unadjusted linear 
regression model further supported a significant association between maternal estradiol and  
BASC-3 T-scores. Using a stepwise linear regression analysis that included paternal and 
maternal age at delivery as covariates, maternal estradiol remained a moderately significant 
predictor of scores on the Hyperactivity, Developmental Social Disorders, and Clinical 
Probability scales (Table 6.4). Further, male children whose mothers had estradiol levels equal 
to or greater than the median value had significantly lower T-scores on the Hyperactivity, 
Developmental Social Disorders, and Clinical Probability scales of the BASC-3 (t(118) = 2.20, p 
= 0.03; t(133) = 2.53, p = 0.01; t(126) = 2.99, p = 0.003, respectively, Figure 6.4). 
 
Table 6.4 Stepwise linear regression model for maternal estradiol and BASC-3 scales in male children 
  B SE B  t p 
Hyperactivity Paternal age (years) 0.25 0.14 0.23 1.86 0.07 
 Maternal age (years) -0.31 0.15 -0.25 -1.10 0.05 
 Maternal estradiol -0.00 0.00 -0.16 -1.80 0.08 
       
Developmental Social Disorders Paternal age(years) 0.01 0.15 0.01 0.09 0.93 
 Maternal age (years) -0.04 0.17 -0.03 -0.25 0.80 
 Maternal estradiol -0.00 0.00 -0.17 -1.84 0.07 
       
Clinical Probability Paternal age 0.09 0.15 0.08 0.64 0.52 
 Maternal age (years) -0.00 0.16 -0.00 -0.01 1.0 






Figure 6.4 Median split analysis of maternal estradiol and BASC-3 T-scores 
(A) T-scores on the Hyperactivity scale are lower in male children born to mothers with 
estradiol levels  the median. (B) T-scores on the Developmental Social Disorders scale 
are lower in male children born to mothers with estradiol levels  the median. (C) T-
scores on the Clinical Probability scale are lower in male children born to mothers with 
estradiol levels  the median. Horizontal lines represent the mean. # significance at p 
<0.1; * significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 




6.3.4 Neonatal sex steroids and child neurodevelopmental outcome 
Bivariate Pearson correlations between cord blood sex hormones (testosterone and 
estradiol) and child neurobehavioral measures (SCQ, EQ-C, and the Hyperactivity, 
Developmental Social Disorders, and Clinical Probability scales of the BASC-3) were performed 
(Table 6.5). Cord blood testosterone collected at birth was significantly positively correlated 
with total SCQ scores in males only (r = 0.20, p = 0.02) (Figure 6.5). An unadjusted linear 
regression model further supported a significant association between cord blood testosterone at 
birth and total SCQ scores in males. Using a stepwise linear regression analysis that included age 
at follow-up, cord blood testosterone remained a significant predictor of total SCQ scores (Table 
6.6). After performing a median split analysis, male children with cord blood testosterone levels 
equal to or greater than the median value scored significantly higher on the SCQ (t(143) = -2.13, 
p = 0.03, Figure 6.6). Cord blood testosterone was not associated with any of the other outcome 
measures including the EQC and the Hyperactivity, Developmental Social Disorders, and 
Clinical Probability scales of the BASC-3.  
Overall and within each sex, cord blood estradiol was not associated with total SCQ 
scores, total EQC scores, or scores on the Hyperactivity, Developmental Social Disorders, and 
Clinical Probability scales of the BASC-3 (Table 6.5). 
 
Table 6.5 Pearson correlations between cord blood sex hormones and neurobehavioral scores 
 Overall  Females  Males 
 UC-T UC-E2  UC-T UC-E2  UC-T UC-E2 
 r r  r r  r r 
SCQ 0.02 0.04  -0.16# 0.01  0.20* 0.08 
EQ-C -0.05 0.01  -0.02 0.02  -0.13 -0.03 
BASC-3         
Hyperactivity -0.04 -0.00  -0.13 0.02  0.12 -0.01 
Developmental Social Disorders 0.01 -0.04  0.12 -0.07  -0.03 -0.01 
Clinical Probability -0.00 -0.06  0.11 -0.05  0.10 -0.06 





Figure 6.5 Correlation between cord blood testosterone and total SCQ 
scores  
Cord blood testosterone is positively associated with total SCQ scores among males. 
Solid lines represent the regression line. Shading represents the 95% confidence bands of 
the best-fit line. 
 
 
Table 6.6 Stepwise linear regression model for cord blood testosterone and total SCQ scores in male children 
  B SE B  t p 
Model 1 Age at follow-up 0.01 0.01 0.07 0.89 0.37 





Figure 6.6 Median split analysis of cord blood testosterone and total SCQ 
scores by sex 
Male children with high cord blood testosterone at birth have significantly higher total 
SCQ scores. Females children with high cord blood testosterone have moderately lower 
total SCQ scores. Error bars represent SEM. # significance at p <0.1; * significance at p 
> 0.05; ** significance at p < 0.01, *** significance at p < 0.001, **** significance at p 
< 0.0001. 
 
6.3.5 Placental aromatase and RORA expression and child neurodevelopmental outcome 
Bivariate Pearson correlations between placental candidate gene expression (aromatase 
and RORA) and child neurobehavioral measures (SCQ, EQ-C, and the Hyperactivity, 
Developmental Social Disorders, and Clinical Probability scales of the BASC-3) were performed 
(Table 6.7). Aromatase expression was not significantly correlated with total SCQ scores, total 
EQ-C scores, or scores on the Hyperactivity, Developmental Social Disorders, and Clinical 
Probability scales of the BASC-3 in the overall sample or within each sex (Table 6.7). Overall 
and within each sex, placental RORA expression was not associated with total SCQ scores, total 
EQC scores, or scores on the Hyperactivity, Developmental Social Disorders, and Clinical 
Probability scales of the BASC-3 (Table 6.7). 
We also performed a median split analysis of aromatase (low aromatase = below the 
sample median aromatase expression; high aromatase = equal to or above the sample median 
aromatase expression). EQ-C scores were almost significantly lower among females whose 
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placentas expressed high levels of aromatase (t(52) = 1.95, p = 0.06) (Figure 6.7). We repeated 
this analysis for the relative RORA mRNA variable as well. An independent samples t-test 
revealed that total SCQ scores were almost significantly higher among male infants with high 
placental RORA expression (t(80) = -1.86, p =0.07) (Figure 6.7). Female infants with high 
RORA expression had lower Hyperactivity scores (t(67) = 1.96, p = 0.05), lower Clinical 
Probability scores (t(67) = 2.37, p = 0.02), and lower EQ-C scores (t(52) = 1.95, p = 0.06) 
(Figure 6.7).  
 
Table 6.7 Pearson correlations between placental gene expression and child neurodevelopmental 
outcomes in the overall sample and by sex of the child 
 Overall  Females  Males 
 AROM RORA  AROM RORA  AROM RORA 
 r r  r r  r r 
SCQ -0.10 0.12  -0.05 0.04  -0.11 0.19 
EQ-C -0.04 0.11  -0.21 0.10  0.02 0.11 
BASC-3         
Hyperactivity -0.02 -0.11  -0.03 -0.21  -0.00 -0.01 
Developmental Social Disorders -0.11 -0.01  0.03 -0.08  -0.21 0.10 
Clinical Probability -0.11 -0.11  0.01 -0.21  -0.11 -0.00 






Figure 6.7 Median split analysis of placental aromatase/RORA and 
neurobehavioral measures 
(A) SCQ scores are higher among males with high placental RORA. (B) Hyperactivity 
scores are lower among females with high RORA. (C) Clinical Probability scores are 
lower among females with high RORA. (D) EQ-C scores are lower among females with 
high aromatase. Error bars represent SEM. # significance at p <0.1; * significance at p > 
0.05; ** significance at p < 0.01, *** significance at p < 0.001, **** significance at p < 
0.0001. 
 
We hypothesized that infants exposed to high maternal testosterone and low placental 
aromatase/RORA would have higher total scores on the SCQ compared to infants exposed to low 
maternal testosterone and high placental aromatase/RORA. Infants were categorized into four 
hormonal exposure groups based on maternal testosterone levels and aromatase expression in the 
placenta. For each infant, we determined whether the maternal testosterone value was below 
(low maternal testosterone) versus equal to or greater than (high maternal testosterone) the 
median value in our sample. Similarly, we determined whether the placental aromatase 
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expression value was below (low aromatase) versus equal to or greater than (high aromatase) the 
median value in our sample. The four groups, in order from lowest to highest expected impact on 
cord blood testosterone were: 1) low maternal testosterone + high aromatase, 2) low maternal 
testosterone + low aromatase, 3) high maternal testosterone + high aromatase, 4) high maternal 
testosterone + low aromatase. This procedure was repeated for RORA expression in the placenta. 
We performed a one-way analysis of variance (ANOVA) using a two-sided 0.05 level of 
significance to determine whether the mean SCQ total score differed across the four groups. 
There was a statistically significant difference in total SCQ scores across the maternal 
testosterone/aromatase groups as determined by the one-way ANOVA (F(3, 145) = 3.62, p = 
0.02). Tukey’s post-hoc test was applied to identify how the groups differed from one another. 
The post-hoc analysis revealed that the two low maternal testosterone groups (groups 1 and 2) 
did not differ from one another, nor did the two high maternal testosterone groups (groups 3 and 
4) (Figure 6.8). Both the low maternal testosterone + high aromatase group (group 1) and the 
low maternal testosterone + low aromatase group (group 2) differed significantly from the high 
maternal testosterone + low aromatase group (group 4) (p = 0.05 and p = 0.02, respectively) 
(Figure 6.8). 
There was a similar statistically significant difference in total SCQ scores across the 
maternal testosterone/RORA groups as determined by the one-way ANOVA (F(3, 147) = 3.31, p 
= 0.02). Tukey’s post-hoc test was applied to identify how the groups differed from one another. 
The post-hoc analysis revealed that the two low maternal testosterone groups (groups 1 and 2) 
did not differ from one another, nor did the two high maternal testosterone groups (groups 3 and 
4) (Figure 6.8). In this case, only the low maternal testosterone + low RORA group (group 2) and 
the high maternal testosterone + high RORA group (group 3) differed significantly from one 
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another (p = 0.02) (Figure 6.8). 
 
 
Figure 6.8 One-way ANOVA of the effect of maternal testosterone and 
placental aromatase/RORA expression on total SCQ scores 
(A) Infants exposed to high maternal testosterone and low aromatase had significantly 
higher total SCQ scores than infants in both of the low maternal testosterone groups. (B) 
Infants exposed to high maternal testosterone and high RORA had higher total SCQ 
scores compared to infants exposed to low maternal testosterone and low RORA. 
Horizontal lines represent the mean. # significance at p <0.1; * significance at p > 0.05; 





 We investigated the association between maternal sex hormones and neurodevelopmental 
outcome. Additionally, we sought to determine whether neurobehavioral development was 
predicted by placental aromatase/RORA expression either directly or indirectly through 
regulating fetal exposure to maternal sex hormones. This is the first study to report an association 
between prenatal maternal testosterone and autism-related behaviors in childhood. To date, most 
studies investigating the effects of prenatal hormone exposure have dismissed androgens of 
maternal origin as a plausible contributor to autism risk because of the placental aromatase 
barrier (S. Baron-Cohen et al., 2015a; James, 2014; S. Lutchmaya et al., 2004). Thus, the 
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emphasis has been placed on testosterone produced by the fetal adrenal gland and, in the case of 
males, by the fetal testes (Auyeung et al., 2006, 2010; S. Baron-Cohen et al., 2015b; Svetlana 
Lutchmaya et al., 2001, 2002; Wakabayashi & Nakazawa, 2010). With regard to maternal 
testosterone, one study reported elevated testosterone in mothers of children with autism, 
however, these measures only reflect hormone levels long after birth and postnatal factors (e.g. 
maternal stress) could not be accounted for (Xu et al., 2013). Studies involving populations with 
specific clinical conditions offer further support for the role of maternal testosterone in autism 
etiology. Women with pregnancy-related hypertensive disorders including preeclampsia and 
women with polycystic ovary syndrome exhibit elevated circulating testosterone during 
pregnancy and their offspring are at increased risk for autism and other developmental delays 
(Kelley et al., 2019; Kosidou et al., 2015; Maher et al., 2018; Palomba et al., 2012; R. Troisi, 
2003). Many of these empirical studies have measured the effects of maternal hypertension and 
polycystic ovary syndrome on child neurodevelopmental outcomes as a proxy for elevated 
maternal testosterone during pregnancy. However, none of these studies have measured the 
direct relationship between maternal testosterone and child neurobehavior. As part of the present 
study, we directly assessed this relationship and found that mothers with higher testosterone in 
mid-pregnancy gave birth to children who demonstrated greater autism-related behaviors by 4.5-
6.5 years of age. 
 This was also the first study to directly measure the relationship between aromatase 
expression in the placenta and neurodevelopmental outcomes in children. Proxy measures for 
aromatase activity have been measured previously by calculating a testosterone:estradiol ratio 
(Simon Baron-Cohen et al., 2019). Aromatase protein and expression in brain tissue have been 
associated with autism, but until now, this finding has not been expanded to other tissues (Crider 
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et al., 2014b; Sarachana et al., 2011b). We hypothesized that decreased placental aromatase 
expression would be associated with poorer neurobehavioral outcomes in childhood. We did not 
detect a direct effect of placental aromatase on child neurobehavioral development, however, the 
degree to which maternal testosterone impacted SQ scores differed depending on placental 
aromatase expression. Children who were exposed to high maternal testosterone had higher SCQ 
scores and higher cord blood testosterone than children exposed to low maternal testosterone, but 
only if their placentas expressed low levels of aromatase. This finding suggests that maternal 
testosterone may not be harmful to the developing fetal brain in the context of a robust placental 
barrier that aromatizes the excess maternal testosterone into estradiol. The lack of a direct 
relationship between placental aromatase and SCQ scores may be partially attributed to the 
timing of sample collection. The expression and activity of aromatase and other cytochrome 
P450 (CYP) genes in the placenta increases from the first trimester through term age (Hakkola et 
al., 1996; Kitawaki et al., 1992). Aromatase is exclusively expressed in the cytoplasm of the 
syncytiotrophoblast cells of the placenta (Fournet-Dulguerov et al., 1987; Inkster & Brodie, 
1989). Syncytiotrophoblast cells form as the result of fusion of the more primitive 
cytotrophoblast cells (Rejniak et al., 2004). Thus, aromatase expression by syncytiotrophoblast 
cells is dependent on cellular and structural maturation of the placenta. Indeed, trophoblast 
inclusions, which are the result of abnormal folding of the trophoblast bilayer, are significantly 
more prevalent in placentas of children who are diagnosed with autism (Walker et al., 2013). 
Low placental weight, another indicator of atypical placental maturation and structure, has been 
associated with hypospadias in male infants, which is symptomatic of abnormal fetal exposure to 
sex hormones (Arendt et al., 2016). Children with autism tend to have lower birth weights and 
placental weight is a robust predictor of infant birth weight in a sex-specific manner (Salafia et 
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al., 2005; Straughen et al., 2017). In our study, larger head circumference was associated with 
higher EQ-C scores, lower SCQ scores, and lower T-scores on the Social Developmental 
Disorders and Clinical Probability scales of the BASC-3. It has been widely reported that 
children with autism have a larger head circumference, possibly as a compensatory response to 
restricted levels of insulin-like growth factors earlier in pregnancy (Steinman & Mankuta, 2013). 
Fetal testosterone production is highest during the second trimester and therefore, 
steroidogenesis and regulation during the mid-gestational period may be more dynamic than 
what we can capture at birth (van de Beek, Thijssen, Cohen-Kettenis, van Goozen, & Buitelaar, 
2004b). Our measure of placental aromatase at birth may not appropriately reflect aromatase 
activity in the placenta during the early and mid-periods of gestation when placental hormone 
regulation may be most critical. 
 As has been discussed, there is a very robust sex bias in autism spectrum disorders such 
that males are roughly four times more likely to be diagnosed with the condition compared to 
females. Androgens and estrogens play a critical role in organizing the brain during fetal 
development. Sex steroids are unique in their ability to program brain development both directly 
through receptor binding and indirectly through transcriptional and epigenetic regulation of DNA 
(Nugent & McCarthy, 2011). There are many pathways through which variability in sex steroids 
during prenatal development could impact the developing brain and contribute to the sex bias 
observed in autism. Our finding that maternal testosterone in the second trimester and cord blood 
testosterone at birth were positively associated with total SCQ scores was only observed in male 
children. We cannot determine whether this is due to increased male susceptibility to the effects 
of elevated in-utero androgen exposure or whether males have a smaller window of tolerance for 
variability in androgen exposure because they endogenously produce higher levels of 
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testosterone. These causal mechanisms should be further investigated, but our results suggest that 
elevated maternal testosterone in mid-gestation could be one factor that explains the sex bias in 
autism. 
There are several important limitations to the present study that should be considered. All 
of our measures of child neurobehavior were developed to detect sub-clinical behaviors and traits 
in children and this sample was not enriched for neurodevelopmental disorders. Therefore, the 
weak effects reported here may be more robust in a study population that includes participants 
with clinically-relevant diagnoses and behaviors. Along similar lines, our outcome measures 
were dependent on parent reporting of child behavior, which may not be as sensitive to atypical 
child behavior as clinician-reported observations. 
Finally, when interpreting the data from the nuMoM2b study sample, it is important to 
note the significant time lapse between when the maternal blood samples were collected and 
when the cord blood and placenta samples were collected. Typically, the maternal blood sample 
was collected between 19 and 24 weeks before the cord blood and placenta samples were 
collected. It is well documented that maternal hormones fluctuate and change dramatically over 
the course of pregnancy (Kuijper et al., 2013). By the second trimester, the fetus is also 
independently able to produce and secrete endogenous testosterone. An analysis of fetal plasma 
testosterone between the 16th-20th week of gestation compared to samples collected at term 
suggests that testosterone levels in male fetuses peak during the second trimester and gradually 
decrease until birth (Abramovich & Rowe, 1973b; J. A. Finegan et al., 1989b; Reyes et al., 1973; 
Shigeo et al., 1977). The placenta also remains a source of endogenous estradiol throughout the 
pregnancy and evidence suggests that aromatase activity in the placenta increases across 
gestation, reflected by a rise in relevant steroid hormone ratios (e.g. estradiol:testosterone, 
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estrone:androstenedione) (Hill et al., 2010, 2014). Taken together, it is clear that the hormonal 
milieu during pregnancy is complex and highly-dependent on timing. Given that we compared 
maternal hormone levels during the second trimester to neonatal hormone levels at term-age, it is 
difficult to draw definitive conclusions about the role of the placenta in regulating fetal exposure 
to maternal hormones at a specific time point during pregnancy. Further, the weak correlation 
coefficients likely reflect the influence of numerous prenatal and postnatal factors that we were 
unable to capture in this study and with the existing sample size. 
Despite these limitations, our results that elevated prenatal maternal testosterone, 
especially in the context of low placental aromatase provide an important basis for further 



























Chapter 7: Child neurobehavioral effects of prenatal exposure to 
maternal testosterone: Maternal hypertension and polycystic 
ovary syndrome as clinical models of exposure 
 
7.1 Introduction 
As has been discussed in prior chapters, sex hormones measured in amniotic fluid during 
a critical period of brain development during gestation are associated with a broad range of 
autism-related traits in early childhood including altered play behavior, reduced eye contact and 
vocabulary size, poorer emotion recognition, poorer quality of social relationships, restricted 
interests and sex-dependent cognitive styles (Auyeung et al., 2013; S. Baron-Cohen et al., 2015b; 
R. C. Knickmeyer & Baron-Cohen, 2006). Of the many genes that have been implicated in ASD, 
aromatase (CYP19A1) and its transcriptional regulator, RORA, have been identified as autism 
candidates genes that could have a direct role in the regulation of sex hormones in the brain 
(Sarachana et al., 2011b).  
Our overarching hypothesis is that in individuals with low placental aromatase/RORA 
activity and whose mothers have relatively high testosterone during pregnancy are exposed to 
elevated androgens and, are more likely to exhibit deficits in neurobehavioral domains 
influenced by prenatal androgens. If our hypothesis is correct, maternal testosterone likely 
contributed to the androgens detected in amniotic fluid collected in earlier studies. In a previous 
analysis of data from a large, low-risk sample of nulliparous pregnancies, we found that maternal 
testosterone in the 2nd trimester, especially when paired with decreased placental aromatase 
expression, was associated with more autism-related behaviors in early childhood (Chapter 6). 
Our finding that maternal testosterone during pregnancy is related to child 
neurobehavioral outcomes is consistent with the reported increased risk for autism among 
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children born to mothers with health conditions that are associated with hyperandrogenism. As 
an avenue for non-invasively studying the relationship between prenatal hormone exposure and 
child neurodevelopment, health conditions that result in an atypical hormone environment in 
utero have been examined. As described in Chapter 1, three commonly studied conditions are 
congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and 
preeclampsia/pregnancy-related hypertension. Briefly, CAH is most commonly due to a 21-
hydroxylase deficiency in which the body is unable to produce sufficient levels of cortisol. This 
triggers over-stimulation the adrenal glands, which causes elevated levels of testosterone to be 
secreted (Melissa Hines, 2010; Manson, 2008; Speiser, 2001). Females with CAH engage in 
more male-typical play behavior including toy preference and aggression and display more 
autistic traits on the Autism Spectrum Quotient, especially on the subscales related to social 
skills and imagination compared to women without CAH (Berenbaum et al., 2000; Dittmann et 
al., 1992; Ehrhardt & Meyer-Bahlburg, 1981; M. Hines et al., 2003; R. Knickmeyer et al., 2006; 
V. L. Pasterski et al., 2005; Puts et al., 2007).  
PCOS is an endocrine condition notably associated with hyperandrogenism as well as 
reduced aromatase activity in placenta tissue (Kosidou et al., 2015; Maliqueo et al., 2013; 
Nisenblat & Norman, 2009; Palomba et al., 2012; Sir-Petermann et al., 2002, p.). Three studies 
have reported an increased risk for neurodevelopmental disorders in the children of women with 
PCOS (Cherskov et al., 2018; Kosidou et al., 2015; Palomba et al., 2012). Finally preeclampsia 
and other pregnancy-related hypertensive disorders are also associated with maternal 
hyperandrogenism (Acromite et al., 1999; Perez-Sepulveda et al., 2015a). In fact, women with 
PCOS are at increased risk for preeclampsia, potentially implicating testosterone as a causal risk 
factor (Kamalanathan et al., 2013; S. Kumar et al., 2018). In addition to the elevated 
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steroidogenic activity, differences in placenta aromatase activity have been observed in 
preeclamptic pregnancies (Berkane et al., 2018; Perez-Sepulveda et al., 2015a; Sathishkumar et 
al., 2012a). Pregnancy-related conditions of hypertension are associated with increased risk for 
autism and atypical neurobehavioral outcomes in the offspring (Maher et al., 2018; M. Robinson 
et al., 2009; Walker CK et al., 2015). A meta-analysis of 11 studies with adjusted estimates of 
autism risk reports a pooled adjusted odds ratio of 1.35, indicating a moderate increase in autism 
risk among children born to mothers with pregnancy-related hypertensive disorders (Maher et al., 
2018). 
It is under this premise that we sought to further investigate whether fetal exposure to 
elevated maternal testosterone during pregnancy increased risk for ASD using a matched case-
control analysis of women with pregnancy-related hypertension and/or PCOS. Though the 
increased risk of autism among the offspring of women with these conditions has been replicated 
by numerous research groups, few have empirically evaluated a causal mechanism. This study 
aimed to directly investigate whether the elevated maternal testosterone typical of these 
conditions explained the increased risk for atypical neurobehavioral development in the children. 
We also aimed to contribute to the literature by studying steroidogenic activity in maternal 
plasma from the 2nd trimester since most of the existing data has been collected during the 3rd 




The present study was conducted as a secondary analysis of the Nulliparous Pregnancy 
Outcomes Study: Monitoring Mothers-to-be (nuMoM2b) (Haas et al., 2015). In brief, the 
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nuMoM2b study was established in 2010 as a multi-site prospective cohort study to identify and 
evaluate mechanisms that could be used to predict adverse pregnancy outcomes in nulliparous 
women as they do not have medical histories from prior pregnancies. To participate in the 
nuMoM2b study, nulliparous pregnant women were screened for eligibility during the 1st 
trimester. Eligible women were between 60-136 weeks of gestation based on an ultrasound 
crown-rump length measurement. Pregnant women were recruited if they had a prior pregnancy 
lasting 20 weeks’ gestation or more, were younger than 13 years of age, had a history of 3 or 
more spontaneous abortions, or if a likely fatal fetal malformation was identified during 
screening.  
Of the 10,037 women who enrolled in the study, approximately 1000 delivered at 
Columbia University Medical Center. In total, 661 participants met criteria to participate in the 
current extension of the study, which aimed to identify pregnancy-related factors that may be 
used to predict neurodevelopmental risk in the children. Specifically, mothers were eligible to 
participate in the secondary analyses if they participated in the original nuMoM2b study, 
delivered at the Columbia University Medical Center site, were fluent in English or Spanish, and 
were ≥ 18 years old at the time of enrollment in the nuMoM2b study. As part of the nuMoM2b 
study participants were asked to provide a sample of maternal plasma during the second 
trimester, a sample of cord blood plasma at birth, and a sample of frozen placenta tissue at birth. 
Participants must have provided all three of these samples in order to be included in these 
secondary analyses. Finally, to be included in the analyses presented here, mothers had to have 
provided written consent to the future use of their biological samples and written consent to be 
re-contacted by study staff. 
In addition to providing the biological samples during pregnancy, mothers whose 
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children had reached the age of 4.5-6.5 years (mean = 61.75 months, range = 54.0-79.0 months) 
were contacted via telephone and email and were asked to complete a brief online questionnaire. 
The questionnaire included items pertaining to any physical and psychiatric diagnoses that the 
child may have received since birth, maternal diagnoses of endocrine-related conditions (e.g. 
polycystic ovary syndrome), and maternal use of medications with the potential to alter 
endocrine function (e.g. oral contraceptives). The online questionnaire included a subset of items 
from the Behavioral Assessment System for Children (BASC-3) Parent Rating Scales 
(Preschool), the Social Communication Questionnaire (SCQ), and the Children’s Empathy 
Quotient (EQ-C). The BASC-3 Preschool assessment can be used for children up to the age of 72 
months, thus, five children who were older than 72 months at the time of testing were not 
included in the analysis of the BASC-3. All procedures were reviewed and approved by the 
Columbia University Medical Center Institutional Review Board and participants provided 
informed written consent prior to all study procedures. 
In all, 270 participants provided the required biological samples and completed the 
neurobehavioral assessment. Using a retrospective matched case-control design, we identified 58 
mothers who had a diagnosis of hypertension and/or polycystic ovary syndrome (PCOS) and 
matched them with healthy controls (Figure 7.1). Based on the previous literature, we 
hypothesized that children born to mothers who had been diagnosed with either or both of these 
conditions would exhibit greater neurobehavioral difficulties in early childhood. Further, we 
hypothesized that maternal testosterone would be elevated among women who had received a 
diagnosis of hypertension and/or PCOS and that the elevated levels of testosterone would 











7.2.2 Maternal plasma collection 
Maternal plasma was collected between 160-216 weeks gestational age. Whole blood was 
collected by venipuncture into an EDTA-coated collection tube. Detailed methods are described 
elsewhere (see Chapter 2). 
 
7.2.3 Umbilical cord plasma collection 
Cord blood plasma was collected and processed within 30 minutes of the delivery of the 
placenta. At the time of delivery, the umbilical cord was clamped and study staff transported the 
whole placenta in a closed container to a laboratory for further processing. Detailed methods are 
described elsewhere (see Chapter 2). 
 
7.2.4 Placenta tissue collection 
After delivery, whole placentas were stored on ice and brought to the laboratory for 
further processing. A detailed description of the collection and processing procedure is provided 
in Chapter 4. 
 
7.2.5 Sex hormone radioimmunoassay of maternal and umbilical cord plasma 
Total testosterone and estradiol radioimmunoassays were conducted using commercially 
available kits and standard procedures, described in Chapter 2, were followed. For the 
testosterone assays of the maternal plasma samples, the average intra-assay coefficient of 
variations (CV) and average lower limits of detectability (LLD) were 11.15% and 0.09 ng/ml, 
respectively (see Table 2.2, Chapter 2). For estradiol assays of the maternal plasma samples, the 
average intra-assay CVs and average LLDs were 13.72% and 9.07 pg/ml, respectively (see 
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Table 2.2, Chapter 2). For the testosterone assays of the umbilical cord plasma samples, the 
average intra-assay coefficient of variations (CV) and average lower limits of detectability 
(LLD) were 16.48% and 0.10 ng/ml, respectively (see Table 2.2, Chapter 2). For estradiol 
assays of the umbilical cord plasma samples, the average intra-assay CVs and average LLDs 
were 8.51% and 8.12 pg/ml, respectively (see Table 2.2, Chapter 2). Samples that were below 
detection (e.g. <0.08) were assigned the value of the lowest level of detectability. 
 
7.2.6 Aromatase (CYP19A1) and RORA gene expression assays in placenta tissue 
30 mg sections of placental tissue were dissected from the original sample. Details 
regarding the RNA/DNA extraction and RT-qPCR procedres are described elsewhere (see 
Chapter 4). Due to variability in placenta collection, we excluded 251 samples with RNA 
concentrations <100ng/ul as measured by a spectrophotometer. As an additional quality control 
measure, we excluded samples with Ct values that were equal to or greater than 35. Of the 116 
participants in the matched-case control analysis, high quality aromatase and RORA gene 
expression data was available for 65 and 62 subjects, respectively. One-minute Apgar scores 
were moderately higher in participants whose placentas were included compared to those who 
were excluded, but there were no other differences in maternal, paternal, or infant demographic 
and health variables. With regard to our outcome variables of interest, total SCQ scores and T-
scores on the Hyperactivity scale of the BASC-3 were significantly higher in those who were 
excluded from the gene expression analyses. Since this study does not involve a control group, 
we calculated the 2-ΔΔCt using females as the reference group. We excluded samples from 




7.2.7 Behavioral Assessment System for Children (3rd Ed.) (BASC-3) 
The BASC-3 Parent Rating Scale (PRS) is a validated parent-report questionnaire that is 
designed to assess a child's neurobehavioral development between the ages of 2 years 0 months 
and 21 years 11 months (Altmann et al., 2017). A detailed description of the BASC-3 is provided 
in Chapter 2. 
 
7.2.8 Social Communication Questionnaire (SCQ) 
The SCQ lifetime version is a parent-report questionnaire to evaluate autism-related 
behaviors in children 4 years (or mental age of 2 years) and older (Allen et al., 2007). A detailed 
description of the SCQ is provided in Chapter 2. 
 
7.2.9 Children’s Empathizing Quotient (EQ-C) 
The EQ-C is a parent-report questionnaire that was adapted from the adult version of the 
Empathizing Quotient questionnaire (EQ) and is designed to assess trends in sex-typical 
empathizing behavior in children (Auyeung, Wheelwright, et al., 2009). A detailed description of 
the EQ-C is provided in Chapter 2. 
 
7.2.10 Identifying hypertension and/or PCOS 
 Between the onset of labor and 14 days postpartum, study staff recorded the provider’s 
primary reason for delivery and whether the participant had demonstrated hypertension or 
proteinuria during the pregnancy through 14 days postpartum. Participants for whom the primary 
reason for delivery was 1) gestational hypertension, 2) mild preeclampsia, 3) severe 
preeclampsia, 4) unspecified preeclampsia, 5) eclampsia, 6) HELLP syndrome, or 7) incomplete 
 
 152 
HELLP syndrome were classified as having maternal hypertensive disorder. Similarly, 
participants were classified as having maternal hypertensive disorder if they had demonstrated 
hypertension or proteinuria at any point during the pregnancy. Diagnoses of PCOC were not 
reliably available in the electronic medical records, but mothers were asked to self-report 
whether they had received a diagnosis of endocrine-related health conditions, including PCOS, 
as part of the online follow-up survey.  
 
7.2.11 Matched-case control 
Of the 270 children for whom neurodevelopmental outcome data was available, 58 were 
born to mothers diagnosed with hypertension and/or PCOS. From the remaining 212 children, 
we retrospectively identified 58 matched controls whose mothers had not been diagnosed with 
either hypertension or PCOS (Figure 7.1). To avoid biases in age at follow-up or other possible 
confounding factors related to data collection, potential controls were assigned a randomized 
numerical identifier. Following numerical order, we matched one to control to each case based 
on the children’s sex (male versus female) while remaining blind to all data regarding maternal 
and child health and developmental data. 
 
7.2.12 Statistical analyses 
 Statistical analyses were conducted using R and SPSS software. Maternal testosterone 
and cord blood testosterone values were positively skewed and 1-minute Apgar scores, neonatal 
head circumference, and infant gestational age were negatively skewed, so they were square root 
transformed prior to statistical analysis. We examined several covariates relating to parental 
characteristics, the course of the pregnancy, and neonatal outcomes that were a priori identified 
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as potential confounding risk factors. Variables that were considered included maternal and 
paternal age at delivery, maternal and paternal education, annual family income, maternal and 
paternal ethnicity, infant gestational age at birth, infant birth weight, 1-minute Apgar scores, 
neonatal head circumference, and the child’s age at the time of follow-up. Specifically, analyses 
of bivariate correlations between continuous covariates and the primary dependent and 
independent variables, which included the maternal hormone variables, cord blood hormone 
variables, and placental gene expression variables, were conducted. We also performed Welch’s 
two sample t-tests to determine whether any of our variables of interests differed by mode of 
delivery, labor onset, and sex of the infant. Candidate covariates were included in the adjusted 
linear models if they were associated with either the dependent and independent variables at a 
significance level of 0.1. Maternal testosterone was positively correlated with maternal age at 
delivery (r(114) = -0.35, p  <0.000). Total SCQ scores were significantly correlated with infant 
birth weight (r(114) = -0.20, p  = 0.03) and maternal age at delivery (r(114) = -0.28, p  =0.003). 
 
7.3 Results 
7.3.1 Sex differences in maternal and cord blood steroid hormones and in placental 
aromatase and RORA expression 
Overall and within the control group, there were no sex differences in maternal or cord 
blood sex steroid levels.  
Among women with hypertension and/or PCOS, those carrying a female fetus had higher 
circulating testosterone in the 2nd trimester than those carrying a male fetus (t(56) = -2.70, p = 
0.01). No other sex differences in sex steroid levels were observed. 
Sex differences in placental aromatase and RORA expression were not found in either of 
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the two study groups. 
 
7.3.2 Differences in maternal and cord blood sex steroids and in placental aromatase and 
RORA expression by study group 
Collapsing across both sexes, there were no group differences in maternal testosterone, 
maternal estradiol, cord blood testosterone, cord blood estradiol, placental aromatase expression, 
or placental RORA expression. At the p <1.0 threshold, maternal testosterone was higher in 
women with hypertension and/or PCOS compared to those in the control group (t(114) = -1.7, p 
= 0.09). We stratified our analysis by the infant’s sex and found that in female-carrying 
pregnancies, maternal testosterone in the second trimester of pregnancy was significantly higher 
in women with hypertension and/or PCOS among women carrying a female fetus (t(50) = -2.69, 
p = 0.01) (Figure 7.2). At the p < 1.0 threshold, male-carrying pregnancies affected by maternal 
hypertension and/or PCOS were found to have lower RORA expression in the placenta (t(33) = 
1.76, p = 0.09), higher cord blood testosterone (t(62) = -1.76, p = 0.08), and higher cord blood 
estradiol (t(62) = -1.90, p = 0.06). 
 
7.3.3 Differences in child neurobehavioral outcomes between cases and controls 
We performed independent samples t-tests to determine whether scores on any of the 
neurobehavioral outcomes differed between children exposed to maternal hypertension and/or 
PCOS and their matched controls (Table 7.1). Compared to healthy controls, children born to 
mothers with hypertension and/or PCOS had significantly higher total SCQ scores (t(114) = -
2.82, p =0.01), lower total EQ-C scores (t(96) = 2.03, p = 0.05), and higher T-scores on the 
Hyperactivity scale of the BASC-3 (t(110) = -2.14, p =0.04) in childhood (Figure 7.3). The 
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effect of maternal hypertension and/or PCOS on total SCQ and EQ-C scores was only observed 
in females, whereas the effect of maternal hypertension and/or PCOS on Hyperactivity T-scores 
was only observed in males (Figure 7.3). 
 
 
Figure 7.2 Maternal testosterone by study group and sex of the infant 
Maternal testosterone is higher in women with hypertension and/or PCOS carrying a 
female fetus. HTD/PCOS: maternal hypertensive disorder and/or PCOS. Error bars 
represent SEM. # significance at p <0.1; * significance at p > 0.05; ** significance at p < 
0.01, *** significance at p < 0.001, **** significance at p < 0.0001. 
 
 
Table 7.1 Independent samples t-tests comparing cases and controls across neurodevelopmental measures 
 Hypertension/PCOS Controls    
 M SD M SD df t p 
SCQ 2.29 0.88 1.82 0.91 114 -2.82 0.01 
EQ-C 37.11 10.34 41.08 9.25 96 2.03 0.05 
Hyperactivity 50.47 8.73 47.52 6.17 110 -2.14 0.04 
Developmental Social 
Disorders 
47.20 7.37 45.48 6.44 110 -1.31 0.19 







Figure 7.3 Effect of maternal hypertension/PCOS on neurodevelopmental 
outcome measures 
(A) Overall and in females, total SCQ scores are higher in children born to women with 
HTD/PCOS. (B) Overall and in females, total EQ-C scores are lower in children born to 
women with HTD/PCOS. (C) Overall and in males, Hyperactivity t-scores are higher in 
children born to women with HTD/PCOS. (D) There was no effect of maternal 
HTD/PCOS on Developmental Social Disorders t-scores. (E) There was no effect of 
maternal HTD/PCOS on Clinical Probability t-scores. HTD/PCOS: maternal 
hypertensive disorder and/or PCOS. Error bars represent SEM. # significance at p <0.1; * 
significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 0.001, **** 






An unadjusted linear regression further supported a significant association between 
maternal hypertension and/or PCOS and total SCQ scores. Using a stepwise linear regression 
analysis that included maternal age, infant birth weight, and infant gestational age at birth as pre-
determined covariates that were associated with either the independent and dependent variables, 
maternal hypertension and/or PCOS remained a robust predictor of total SCQ scores (Table 7.2).  
 
Table 7.2 Stepwise linear regression model for maternal hypertensive disorder/PCOS and total SCQ scores 
  B SE B  t p 
Model 1 Gestational age at birth (days) -0.10 0.31 -0.04 -0.34 0.74 
 Maternal age at birth (years) -0.04 0.02 -0.26 -2.85 0.01 
 Infant birth weight (grams) 0.00 0.00 -0.12 -1.05 0.31 
 Maternal HTD/PCOS 0.43 0.16 0.24 2.67 0.01 
       
Model 2 Gestational age at birth (days) -0.09 0.31 -0.03 -0.27 0.79 
 Maternal age at birth (years) -0.04 0.02 -0.22 -2.27 0.03 
 Infant birth weight (grams) 0.00 0.00 -0.12 -1.02 0.31 
 Maternal testosterone (ng/ml) 0.39 0.32 0.12 1.22 0.28 
 Maternal HTD/PCOS 4.02 0.16 0.22 2.45 0.02 
Covariates in Model 1 were associated with either the dependent or independent variables 
Maternal HTD/PCOS: maternal hypertensive disorder and/or polycystic ovary syndrome 
 
An unadjusted linear regression further supported a significant association between 
maternal hypertension and/or PCOS and total EQ-C scores. Using a stepwise linear regression 
analysis that included neonatal head circumference and infant gestational age at birth as pre-
determined covariates that were associated with either the independent and dependent variables, 
maternal hypertension and/or PCOS remained a moderate predictor of total EQ-C scores, though 
it did not reach significance at the p < 0.05 threshold (Table 7.3).  
An unadjusted linear regression further supported a significant association between 
maternal hypertension and/or PCOS and T-scores on the Hyperactivity scale of the BASC-3. 
Using a stepwise linear regression analysis that included infant gestational age at birth as a pre-
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determined covariate that was associated with either the independent and dependent variables, 
maternal hypertension and/or PCOS remained a significant predictor of T-scores on the 
Hyperactivity scale (Table 7.4).  
 
Table 7.3 Stepwise linear regression model for maternal hypertensive disorder/PCOS and total EQ-C scores 
  B SE B  t p 
Model 1 Gestational age at birth (days) 0.43 2.97 0.02 0.15 0.89 
 Infant head circumference (cm) -1.69 0.74 -0.25 -2.29 0.03 
 Maternal HTD/PCOS -3.49 2.02 -0.18 -1.72 0.09 
       
Model 2 Gestational age at birth (days) 0.45 2.99 0.02 0.15 0.88 
 Infant head circumference (cm) -1.71 0.76 -0.25 -2.24 0.03 
 Maternal testosterone (ng/ml) -0.34 3.72 -0.01 -0.09 0.93 
 Maternal HTD/PCOS -3.47 2.05 -0.18 -1.69 0.09 
Covariates in Model 1 were associated with either the dependent or independent variables 
Maternal HTD/PCOS: maternal hypertensive disorder and/or polycystic ovary syndrome 
 
 
Table 7.4 Stepwise linear regression model for maternal hypertensive disorder/PCOS and Hyperactivity 
T-scores 
  B SE B  t p 
Model 1 Gestational age at birth (days) -0.16 2.15 -0.01 -0.07 0.94 
 Maternal HTD/PCOS 3.04 1.46 0.21 2.08 0.04 
       
Model 2 Gestational age at birth (days) -0.15 2.16 -0.01 -0.07 0.94 
 Maternal testosterone (ng/ml) 0.18 2.72 0.01 0.07 0.95 
 Maternal HTD/PCOS 3.02 1.48 0.21 2.04 0.04 
Covariates in Model 1 were associated with either the dependent or independent variables 
Maternal HTD/PCOS: maternal hypertensive disorder and/or polycystic ovary syndrome 
 
7.4 Discussion 
This was the first study to report sex-specific effects of pregnancy-related hypertension 
and PCOS on second trimester maternal hormone concentrations in a sample of nulliparous 
women. Due to methodological and ethical constraints, the majority of studies that have 
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measured steroidogenesis in women with these conditions have been limited to the third 
trimester, usually at the time of delivery. The few studies that have evaluated maternal 
testosterone in these clinical populations earlier in pregnancy have found sex- and time-specific 
effects. At 17 week’s gestation, mothers who carried a male or female fetus and who had been 
diagnosed with pregnancy-related hypertension had elevated circulating testosterone (Sven 
Magnus Carlsen et al., 2005). However, by 33 weeks’ gestation, elevated testosterone was only 
observed among mothers who carried a male fetus. In another study, maternal testosterone was 
higher during the second trimester in female-carrying pregnancies, but no differences were 
detected by the second trimester regardless of fetal sex (Tuutti et al., 2011). The first study 
intentionally excluded primipara pregnancies, while the second study did not mentioned parity as 
a variable of interest. Since primiparity is the one of the greatest risk factors for preeclampsia, 
our finding is of particular importance as it may provide a secondary marker of increased risk 
among first-time mothers (Luo et al., 2007). 
Contrary to our hypothesis that placental aromatase would be altered in pregnancies 
complicated by hypertension or PCOS in a sex-dependent manner, we did not find a difference in 
placental aromatase expression. Previous studies have provided inconsistent results regarding the 
effects of hypertension and PCOS on placental aromatase. Two studies reported increased 
aromatase in placentas from preeclamptic pregnancies (Sathishkumar et al., 2012a; Shin et al., 
2018). Sathishkumar et al. (2013) found an interaction effect such that placental aromatase was 
higher in preeclamptic pregnancies if the fetus was female, whereas aromatase was lower if the 
fetus was male. On the contrary, two studies reported that women with preeclampsia had lower 
placental aromatase as measured by both gas chromatography/mass spectrometry and RT-qPCR 
techniques (Berkane et al., 2018; Perez-Sepulveda et al., 2015b). This finding was further 
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supported by a rabbit model for preeclampsia such that partial ligation of the uterine spiral 
arteries induced a reduction in placental aromatase activity (Perez-Sepulveda et al., 2015a). 
Additionally, a specific aromatase defect had been detected in placentas from preeclamptic 
pregnancies at 24-29 weeks’ gestation (Berkane et al., 2018). Similarly, aromatase activity was 
lower in placentas if the mother was diagnosed with PCOS compared to healthy controls 
(Maliqueo et al., 2013).  
Our results support the previously reported association between maternal hypertension 
and PCOS and poorer child neurobehavioral outcomes. Specifically, we found that children born 
to mothers with hypertension and/or PCOS had higher total SCQ scores, higher Hypertension T-
scores on the BASC-3, and lower total EQ-C scores. The relationship between maternal 
hypertension/PCOS and SCQ and EQ-C scores were statistically more robust in females, 
whereas scores on the Hyperactivity scale were more impacted in males.  
There are several potential limitations to this study that should be considered. For one, 
the study consists of a convenience sample, and therefore study subjects may not be 
representative of the population as a whole. We have also considered the possibility of a 
confounding effect between preeclampsia and pre-term or early term birth. Preeclampsia resolves 
following pregnancy, and so treatment of preeclampsia typically involves delivery of the infant 
at 37 weeks, or earlier if severe features develop. The possibility of pre-term birth as a 
confounding variable will need to be further elucidated. Another limitation to consider is 
identification of children at risk for autism through the SCQ questionnaire. While children may 
meet the “at-risk” questionnaire cut-off, they may be exhibiting subclinical behaviors that would 
not ultimately meet criteria for autism when evaluated by a medical provider. Lastly, diagnosis 
of PCOS for women in the study was largely self-reported. With self-reporting there is a concern 
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that not all women self-identifying PCOS meet full criteria for the condition, as diagnosed by a 
medical provider.  
The association between elevated maternal testosterone during the 2nd trimester in 
mothers and risk for autistic features in their children has important implications for early 
diagnosis and management of autism. Maternal testosterone, which is collected as a simple blood 
draw during the 2nd trimester, could be considered as an early noninvasive biomarker to identify 
children who are at risk for developing autism. If implemented into clinical practice, these 
children could be followed closely for development of autistic features. This would ultimately 
allow for earlier diagnosis, and thus earlier intervention that would improve these children’s 
















Chapter 8: General discussion and future directions 
 
8.1 General discussion 
Scientific investigations of the effects of prenatal hormones on neurodevelopment have 
relied on the assumption that the placenta aromatizes maternal testosterone into estradiol, 
limiting the transfer of maternal testosterone to the developing fetus. This hypothesis has 
widespread implications for mental health and has had a particularly strong influence on the 
research associating prenatal testosterone exposure with increased risk for ASD. Here, we 
present the results of in vivo and in vitro studies that were conducted to directly evaluate this 
hypothesis.  
 Several avenues of research have converged to support the hypothesis that fetuses that are 
exposed to higher levels of testosterone during the prenatal period are at greater risk for 
displaying ASD-like behaviors during childhood. Baron-Cohen pioneered this supposition with 
his extreme male brain theory of ASD. This theory described ASD as a disorder characterized by 
male-typical behaviors and interests. In more recent empirical evaluations of this theory, his 
team has found positive associations between prenatal testosterone in amniotic fluid during the 
second trimester and autistic traits in childhood and adulthood. The testosterone in the amniotic 
fluid was considered to be representative of the level of testosterone being produced by the fetus 
because it could not be attributed to the mother if the placental barrier was intact and able to 
aromatize the mother’s testosterone.  
 The premise that the placenta serves as a fetal barrier against maternal testosterone also 
assumes that the permeability of the barrier is consistent across individuals. However, we now 
have evidence that suggests that aromatase expression may vary widely, especially among 
individuals with pre-existing clinical conditions. In the case of ASD, aromatase and its 
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transcriptional regulator, RORA, are both reduced in the prefrontal cortex. Placentas from 
preeclamptic pregnancies also express reduced aromatase mRNA. As previously discussed, 
preeclampsia is associated with elevated maternal testosterone and higher risk for ASD in the 
child. Thus, there are at least two clinical conditions that provide evidence that aromatase 
expression is variable - in the brain and in the placenta - and that this variability is associated 
with increased risk for ASD. 
 Here, our analyses of maternal and infant hormone levels and placental expression of 
aromatase and RORA also revealed a wide range of hormonal and genetic profiles, which further 
supports the notion of individual differences in hormone regulation and metabolism. In contrast 
to previous investigations of variability in fetal hormone exposure that relied on invasive 
procedures like amniocentesis, our measures were collected using non-invasive methods. 
Therefore, studying the relationship between maternal and infant testosterone and estradiol and 
placental regulation of the sex hormones may offer a highly tractable method for identifying 
individual differences in exposure.  
 Moving forward, it will be very important to further understand how reduced aromatase 
in the placenta may contribute to the etiology of ASD. We hypothesized that fetal exposure to 
testosterone would be greatest under conditions where maternal testosterone was high and 
placental aromatase was low because high levels of maternal testosterone would cross the 
placenta, reaching the fetal circulation. Our findings, presented in Chapter 4 and Chapter 7, 
support our hypotheses that high maternal testosterone is associated with high cord blood 
testosterone at birth and greater autism-related behaviors in childhood. While there were no main 
effects of placental aromatase, the greatest increase in cord blood testosterone and autism-related 
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behaviors was observed in children who had mothers with high testosterone and placentas with 
low aromatase expression. 
 It was recently reported that estradiol concentrations were elevated in amniotic fluid 
samples from children diagnosed with autism compared to neurotypical controls (Simon Baron-
Cohen et al., 2019). Estradiol measured in amniotic fluid could be the result of several 
steroidogenic processes including 1) endogenous placental synthesis of estradiol, 2) fetal 
synthesis of estradiol, placental aromatization of maternal and/or fetal testosterone, and 3) fetal 
aromatization of maternal or fetal testosterone. We found that maternal testosterone collected at 
the same gestational time point as amniocentesis was associated with greater autism-related 
behaviors in childhood. Therefore, it is plausible that the elevated estradiol measured during 
mid-gestation via amniocentesis reflects efficient aromatization of high maternal testosterone. 
Given that we did not observe an associated between maternal estradiol in the 2nd trimester or 
cord blood estradiol at birth and neurodevelopmental outcome, it is possible that the effect of 
prenatal estradiol is dependent on the timing and source of the exposure. Estradiol - via the 
aromatization of testosterone - is responsible for masculinizing the brain and behavior. When 
estradiol is blocked, a profound demasculinization of sexual behavior and feminization of the 
brain regions that regulate sexually dimorphic behaviors has been observed. Similarly, 
administration of estradiol can induce the masculinization of behaviors. Therefore, elevated 
estradiol during prenatal development, as a result of reduced aromatase or RORA expression, 
may explain the masculinization of behaviors and interests that has been observed in individuals 
with ASD. Further, this model is also consistent with the female protective effect in ASD. Since 
boys are four times more likely than girls to be diagnosed with ASD, females may be protected 
to some extent. Alpha-fetoprotein, as discussed earlier, binds to estradiol and prevents it from 
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activating estrogen receptors in the brain. If elevated estradiol is contributing to altered 
neurodevelopment, the higher alpha-fetoprotein in females may protect them from the adverse 
estrogenic effects.  
 
8.2 Future directions 
The field of developmental psychobiology has historically relied on twin studies to 
dissociate the effects of genetic influences from those of environmental influences. In one 
framework, it has been suggested that in-utero, maternal effects should be considered a shared 
environmental factor for both twins, whereas placental factors should be considered non-shared 
(Sakai et al., 1991). This conceptualization reflects the lack of consideration of chorionicity and 
amnionicity in twins. For the more common dichorionic/diamniotic twins, it is true that maternal 
influences are shared, but the effects of those influences may differ depending on non-shared 
factors of each twin’s placenta (e.g. expression of regulatory genes, perfusion, location in the 
uterus). However, for monochorionic/monoamniotic twins, who share a fused placenta and 
gestation within the same amniotic sac, the effects of a shared maternal influence may be quite 
similar. Moreover, little is known about differences in non-genomic factors in 
monochorionic/monoamniotic placentas, such as epigenetic regulation, variation in gene 
transcription and translation, and homogeneity in placental permeability. Studying not only 
zygosity, but also chorionicity and amnionicity may further elucidate the relationship between 
genetic and environmental influences on fetal brain development.  
It would also be valuable to study the regulatory mechanisms of the placenta at different 
gestational time points. A cross-sectional approach could help us identify critical periods during 
which exposure to aberrant levels of testosterone or estradiol may have the greatest effects on 
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brain development. For the present analyses, we sampled placentas at term age (>37 weeks 
gestational age), but the genetic profile of the placenta and the hormonal environment in utero 
may change drastically across gestation. Most of the studies that have linked prenatal 
testosterone to risk for ASD have sampled amniotic fluid during the second trimester via 
amniocentesis. Amniocentesis has become increasingly less popular among clinicians with the 
development of non-invasive prenatal screening tools like cell-free DNA (cfDNA) testing. 
Clinicians are now able to extract fetal DNA from a maternal blood sample during pregnancy to 
test for common chromosomal abnormalities, such as trisomy 18 and trisomy 21. During 
pregnancy, placenta cells slough off and are taken up by the mother’s blood. While the 
technology is still being developed, it is possible that soon we will be able to extract cell-free 
DNA to identify fetuses with known genetic variants related to hormone regulation or cell-free 
RNA (cfRNA) to measure placental aromatase expression using a simple, minimally invasive 
blood draw from the mother. Maternal blood is routinely collected throughout the pregnancy, so 
this would allow us to sample the placenta and maternal testosterone across several gestational 
periods.  
 Another conceivable way to study the placenta across development is to repeat our 
methodology in a cohort of preterm infants. A cross-sectional study design that enrolled infants 
born between 25-36 weeks gestational age would allow researchers to study the relationship 
between placental aromatase and RORA expression and the regulation of fetal hormone exposure 
throughout the mid-to-late prenatal period. 
Overall, preterm birth confers a wide range of adverse physical and neurodevelopmental 
outcomes, including risk for ASD (Limperopoulos et al., 2008). Of course, several perinatal 
factors that are common to preterm birth, such as intrauterine infection, would need to be taken 
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into consideration as they have the potential to alter the placenta. Indeed, placental abnormalities 
like trophoblast inclusions - histologically visible placental abnormalities in which an outer ring 
of cytotrophoblasts surrounds a cluster of syncytiotrophoblasts - are associated with higher risk 
for ASD and are substantially more common in preterm placentas compared to full-term 
placentas (Firestein, Myers, Stark, Grieve, & Welch, n.d.). Analyses using preterm placentas 
should therefore strive to account for placental alterations that may be linked to the cause of the 
preterm delivery and researchers should exercise caution when generalizing the findings to full-
term pregnancies. 
Moving forward, ex vivo placental perfusion protocols will be important for empirically 
studying regulatory mechanisms of the placenta across gestation (Ala-Kokko, Myllynen, & 
Vähäkangas, 2000; Pemathilaka, Reynolds, & Hashemi, 2019). In ex vivo perfusion studies, a 
maternal and fetal circuit is created and maintained in order to study how three compartments 
interact in the context of a synthetic intrauterine environment. This method has been widely used 
to study toxicity of drugs, placental permeability, and analyses of basic placental functioning 
(e.g. oxygenation) (Pemathilaka et al., 2019). Similarly, the “placenta-on-a-chip” model has 
gained traction in recent years as it provides a large amount of data very quickly and requires a 
minimal amount of tissue. This model uses microfluidic devices to replicate and alter the 
structure, physiology, and functioning of multiple cell types, cell layers, and subcellular 
influences of the placenta (Pemathilaka et al., 2019). As this technology develops, more nuanced 
processes will be able to be studied across all gestational time points and could be used as part of 
a precision medicine approach. 
 Although there is no known cure for ASD, early diagnosis and early intervention are 
critical determinants of outcome (Eldevik, Hastings, Jahr, & Hughes, 2012; Nadel & Poss, 
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2007). Unfortunately, intervention is often delayed because early behavioral markers are 
overlooked, ignored, or simply unknown. Presently, the earliest reliable behavioral marker of 
ASD is a decline in attention to eyes between 2-6 months of age. If our hypothesis is correct - 
that specific genetic alterations in the placenta degrade the protective fetal barrier against 
maternal hormones, resulting in atypical neurodevelopment - further research into this topic may 
pave the way for a biologically based screening tool for ASD that could be applied during the 
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Appendix A: List of abbreviations 
 
Genes/Proteins and Molecules 
ACTH    Adrenocorticotropic hormone 
AFP    Alpha-fetoprotein 
cDNA    Complimentary DNA 
CYP19A1   Aromatase 
DHEA-S   Dehydroepiandrosterone 
DNA    Deoxyribonuclease 
hCG    Human chorionic gonadotropin 
mRNA    Messenger RNA 
RNA    Ribonucleic acid 
RORA    Retinoic acid-related orphan receptor-alpha 
SHBG    Sex hormone binding globulin 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein zeta 
 
 
Health and Behavior 
ADHD    Attention-deficit/hyperactivity disorder 
ASD    Autism spectrum disorder 
CAH    Congenital adrenal hyperplasia 
GA    Gestational age 
mPOA    Medial preoptic area  
PCOS    Polycystic ovary syndrome 
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PEC    Preeclampsia 
HTD    Hypertensive disease/disorder 
PFC    Prefrontal cortex 
SNB    Spinal nucleus of the bulbocavernosus 
 
Assessments and Measurements 
ADI-R    Autism Diagnostic Interview Revised 
ANOVA   Analysis of Variance 
BASC-3   Behavioral Assessment System for Children, Third Edition 
CV    Coefficient of variations  
EQ    Empathizing Quotient 
EQ-C    Children’s Empathizing Quotient 
LLD    Lower limits of detectability  
SCQ    Social Communication Questionnaire 
SQ    Children’s Systemizing Quotient 
PCA    Principal component analysis 
PCR    Polymerase chain reaction 
 
nuMoM2b   Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to- 










Appendix B: Chapter 3 Supplemental Results 
 
11.1 Effects of demographic and pregnancy-related variables on sex hormone levels in 
maternal and umbilical cord plasma 
Maternal testosterone levels were negatively correlated with maternal age at delivery 
(r(23) = -0.409, p = 0.04) (Supplemental Figure S3.1). Conversely, maternal testosterone was 
positively correlated infant gestational age at birth (r(23) = 0.476, p = 0.01) (Supplemental 
Figure S3.1).  Maternal estradiol levels were not associated with maternal age at delivery 
(Supplemental Figure S3.1), but were positively correlated with infant gestational age a birth 
(r(23) = 0.452, p = 0.02) (Supplemental Figure S3.1). Neither maternal testosterone nor 
maternal estradiol levels were associated with infant birth weight (Supplemental Figure S3.1). 
Umbilical cord blood testosterone levels were not associated with maternal age delivery, 
gestational age at delivery, or infant birth weight. In contrast, cord estradiol was negatively 
associated with maternal age at delivery (r(23) = -0.528, p = 0.006) and positively associated 
with infant gestational age at birth (r(23) = 0.498, p = 0.01) (Supplemental Figure S3.2). 
 
11.2 Effects of demographic and pregnancy-related variables on placental aromatase and 
RORA expression 
Expression of CYP19A1 and RORA mRNA was not associated with maternal age at 
delivery or infant gestational age at birth. Expression of both CYP19A1 and RORA was 
positively associated with infant birth weight, such that infants weighing more grams at birth had 





Supplemental Figure S3.1 Relationship between maternal sex hormones 
and maternal age, gestational age, and birthweight 
(A) Maternal testosterone is negatively associated with maternal age. (B) Maternal 
testosterone is positively associated with gestational age. (C) No relationship between 
maternal testosterone and birthweight. (D) No relationship between maternal estradiol 
and maternal age. (E) Maternal estradiol is positively associated with gestational age. (F) 
No relationship between maternal estradiol and birthweight. The solid black line 
represents the regression line. The gray shading represents the 95% confidence bands of 





Supplemental Figure S3.2 Relationship between cord blood sex hormones 
and maternal age, gestational age, and birthweight 
(A) No association between cord blood testosterone (after square root transformation) 
and maternal age. (B) No association between cord blood testosterone and gestational 
age. (C) No association between cord blood testosterone and birthweight. (D) Cord blood 
estradiol is negatively correlated with maternal age. (E) Cord blood estradiol is positively 
correlated with gestational age. (F) No relationship between cord blood estradiol and 
birthweight. The solid black line represents the regression line. The gray shading 
represents the 95% confidence bands of the best-fit line. 
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Appendix C: Chapter 4 Supplemental Results 
 
12.1 Main effects of infant sex on demographic, hormonal, and placental variables 
 We performed Welch’s two sample t-tests to identify sex differences across demographic, 
hormonal, and placental variables. On average, birth weight and head circumference were higher 
among male infants (p = 0.027 and p < 0.001, respectively). No sex differences in maternal 
testosterone, maternal estradiol, umbilical cord testosterone, umbilical cord estradiol, aromatase 
mRNA expression, RORA mRNA expression, or gestational age at birth were observed. 
 
12.2 Main effects of labor on demographic, hormonal, and placental variables 
 We performed Welch’s two sample t-tests to determine whether labor onset was 
associated with differences in demographic, hormonal, and placental variables. Compared to 
non-laboring deliveries, labor was associated with increased gestational age at birth (p = 0.01), 
younger maternal age at the time of delivery (p <0.0001), and younger paternal age at the time of 
delivery (p = 0.003) (Supplemental Figure S4.1). Maternal testosterone and estradiol were 
significantly high in laboring deliveries (p <0.0001 and p =0.03, respectively). Cord blood 
testosterone and estradiol were also higher following a laboring delivery (p <0.0001 and , p 
<0.0001 respectively) (Supplemental Figure S4.2). Placental aromatase and RORA expression 
did not differ between laboring and non-laboring deliveries. 
 
12.3 Main effects of mode of delivery on demographic, hormonal, and placental variables 
 We performed Welch’s two sample t-tests to determine whether mode of delivery 
(vaginal versus C-section) contributed to differences in demographic, hormonal, and placental 
variables (Supplemental Figure S4.3). Maternal age at the time of delivery and paternal age at 
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the time of delivery were lower in vaginal deliveries (p <0.000 and p = 0.013, respectively). 
Maternal testosterone and estradiol were higher in women who delivered vaginally (p = 0.02 and 
p = 0.01, respectively). Infants born by vaginal delivery had significantly higher cord blood 
estradiol (p <0.0001), though mode of delivery did not affect cord blood testosterone levels. 
Mode of delivery did not impact placental aromatase or RORA mRNA expression, gestational 
age, or infant birth weight. 
 
 
Supplemental Figure S4.1 Effect of labor on demographic variables. (A) 
Infant gestational age at birth is significantly higher in laboring deliveries 
(A) Infant gestational age at birth is significantly higher in laboring deliveries. (B) 
Maternal age is significantly higher among women who did not labor. (C) Paternal age is 
significantly higher in non-laboring deliveries. Horizontal lines represent the mean. # 
significance at p <0.1; * significance at p > 0.05; ** significance at p < 0.01, *** 






Supplemental Figure S4.2 Effect of labor on hormonal and placental 
variables 
(A) Maternal testosterone (square-root transformed) is significantly higher in laboring 
deliveries. (B) Maternal estradiol is significantly higher in laboring deliveries (C) Cord 
blood testosterone (square-root transformed) is significantly higher in laboring deliveries. 
(D) Cord blood estradiol is significantly higher in laboring deliveries. Horizontal lines 
represent the mean. # significance at p <0.1; * significance at p > 0.05; ** significance at 






Supplemental Figure S4.3 Effect of mode of delivery on demographic, 
hormonal, and placental variables 
(A) Maternal testosterone (square root transformed) is significantly higher in vaginal 
deliveries. (B) Maternal estradiol is significantly higher in vaginal deliveries. (C) Cord 
blood estradiol is significantly higher in vaginal deliveries. (D) Cord blood testosterone 
is not affected by mode of delivery. Horizontal lines represent the mean. # significance at 
p <0.1; * significance at p > 0.05; ** significance at p < 0.01, *** significance at p < 
0.001, **** significance at p < 0.0001. 
 
 
12.4 Relationships between sex hormone levels in maternal and umbilical cord plasma and 
covariates 
We conducted bivariate correlation analyses to determine whether maternal or cord blood 
hormone levels were associated with any of the potential covariates. We found significant 
negative correlations between maternal testosterone and neonatal head circumference (r(626) = -
0.098, p = 0.014), maternal age at delivery (r(653) = -0.33, p < 0.001), and paternal age at 
delivery (r(627) = -0.19, p < 0.001) (Supplemental Figure S4.4). Cord blood testosterone was 
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very weakly negatively correlated with 1-minute Apgar scores (r(657) = -0.09, p = 0.02). 
Maternal measures of estradiol were weakly negatively correlated with maternal age (r(638) = -
0.21, p < 0.001) and paternal age (r(613) = -0.16, p < 0.001) at delivery (Supplemental Figure 
S4.5). Similarly, estradiol measured in cord blood was weakly negatively correlated with 
maternal age (r(655) = -0.21, p < 0.001) and paternal age (r(628) = -0.10, p = 0.02) at delivery 




Supplemental Figure S4.4 Relationship between maternal testosterone after 
square root transformation and potential covariates 
(A) Maternal testosterone is negatively correlated with neonatal head circumference. (B) 
Maternal testosterone is negatively correlated with maternal age at delivery. (C) Maternal 
testosterone is negatively correlated with paternal age at delivery. The solid black lines 
represents the regression line. The dashed black lines represent the 95% confidence 






Supplemental Figure S4.5 Relationship between maternal estradiol and 
parental age at delivery. (A) Maternal estradiol is negatively correlated 
with maternal age 
(A) Maternal estradiol is negatively correlated with maternal age. (B) Maternal estradiol 
is negatively correlated with paternal age. The solid black line represents the regression 





Supplemental Figure S4.6 Relationship between cord blood estradiol and 
parental age at delivery 
(A) Cord blood estradiol is negatively correlated with maternal age. (B) Cord blood 
estradiol is negatively correlated with paternal age. The solid black line represents the 








12.5 Relationships between placental aromatase and RORA mRNA expression and 
potential covariates 
 Aromatase mRNA expression was weakly positively correlated with paternal age at 
delivery (r(342) = 0.12, p = 0.03) (Supplemental Figure S4.7). RORA mRNA expression was 
not associated with any of the potential covariates that had been identified a priori. 
 
 
Supplemental Figure S4.7 Relationship between placental aromatase 
expression and paternal age at delivery 
Placental aromatase expression is positively correlated with paternal age. The solid black 
line represents the regression line. The dashed black lines represent the 95% confidence 
bands of the best-fit line. 
 
